Depression Quiz
Check your symptoms and
find possible causes with AI for free
Worried about your symptoms?
Start the Depression test with our free AI Symptom Checker.
This will help us personalize your assessment.
By starting the symptom checker, you agree to the Privacy Policy and Terms of Use
Depression
Anxiety flare ups
Insomnia
Extreme fatigue
Lack of motivation
Feeling down
Feeling depressed for no reason
Poor concentration
I lost interest in everything
Perpetual sadness
Malaise
Lack of energy
Not seeing your symptoms? No worries!
What is Depression?
Depression is a mental illness that leads to low mood, reduced energy levels, and changes in sleep. This affects everyday activities like attending school and work. As the condition worsens, patients might have suicidal thoughts. Although stress and past trauma can cause depression, it can take time to identify and address causes, and genetic factors may also be at play.
Typical Symptoms of Depression
- Having suicidal thoughts
- Stressed over daily life
- Headache worsens in crowded places
- Fatigue or low energy that is worse in the morning
- Headache that worsens with emotional stress or anxiety
- Decreased motivation
- Recent changes in mental state
- Headache that worsens with lack of sleep
Diagnostic Questions for Depression
Your doctor may ask these questions to check for this disease:
- Do you frequently think about harming or killing yourself?
- Do you feel stressed or unhappy about going to work or school?
- Does your headache worsen in crowded places?
- Do you experience fatigue or low energy that is worse in the morning?
- Does your headache worsen when you experience emotional stress or anxiety?
Treatment of Depression
Treatment typically involves a combination of counseling therapy, life changes, and medications (antidepressants). A strong support network is helpful, as the recovery process can take months or even years.
Reviewed By:
Weston S. Ferrer, MD (Psychiatry)
Weston Ferrer is a physician leader, psychiatrist, and clinical informaticist based in San Francisco. With nearly a decade of experience in academia and more recent immersion in industry, he has made significant contributions to the fields of digital health, health tech, and healthcare innovation. | As an Associate Professor at UCSF, Weston was involved in teaching, leadership, and clinical practice, focusing on the intersection of technology and mental health. He recently led mental health clinical for Verily (formerly Google Life Sciences), where he applied his expertise to develop innovative solutions for mental healthcare using the tools of AI/ML, digital therapeutics, clinical analytics, and more.. | Weston is known for his unique ability to innovate and support product development while bringing pragmatism to technology entrepreneurship. He is a strong advocate for patient-centered care and is committed to leveraging technology to improve the health and well-being of individuals and communities. |
Yu Shirai, MD (Psychiatry)
Dr. Shirai works at the Yotsuya Yui Clinic for mental health treatment for English and Portuguese-speaking patients. He treats a wide range of patients from neurodevelopmental disorders to dementia in children and participates in knowledge sharing through the Diversity Clinic.
Content updated on Oct 18, 2024
Following the Medical Content Editorial Policy
Was this page helpful?
Tell your friends about us.
We would love to help them too.
Think you might have
Depression?
Try a symptom check testHow Ubie Can Help You
With a free 3-min Depression quiz, powered by Ubie's AI and doctors, find possible causes of your symptoms.
This questionnaire is customized to your situation and symptoms, including the following personal information:
Biological Sex - helps us provide relevant suggestions for male vs. female conditions.
Age - adjusts our guidance based on any age-related health factors.
History - considers past illnesses, surgeries, family history, and lifestyle choices.
Your symptoms
Our AI
Your report
Your personal report will tell you
✔ When to see a doctor
✔︎ What causes your symptoms
✔︎ Treatment information etc.
People with similar symptoms also use Ubie's symptom checker to find possible causes
- Depression with suicidal thoughts
- Considering suicide
- Suicide attempt thoughts
- Want to hurt myself
- Increased alcohol or drug use
- Feel like life is not worth living
- No reason to live
- Death thoughts
- Feeling hopeless
- Overwhelming sadness
- No motivation to do anything
- Racing thoughts about death
See full list
User Testimonials for Depression
Female, Teens
Ubie helped me with understanding my mental health symptoms and feelings, by providing me with great results. It made me feel less worried and anxious about what else my symptoms could mean. I would definitely use this service in the future and recommend this to a family member, friend or co-worker.
(May 1, 2025)
Female, Teens
Ubie helped me obtain the right care I needed by its very detailed description of my symptoms and the possible conditions I could have. I was able to understand my symptoms before seeing a professional. The doctor is going to ask you for your symptoms, and I would've had a hard time describing them without Ubie. I had various symptoms such as forgetfulness, suicidal ideation, mania preceding a depressive episode, no motivation, feelings of grief, low self esteem, decreased energy levels, history of self harm, among others. I originally went to my doctor and she referred me to the psychiatrist. Ultimately, Ubie helped me find out what I don't know about myself, and that way I could get the help that I needed.
(Feb 25, 2025)
Female, Teens
I have many symptoms and am in the middle of getting diagnosed and treated for depression, hypothyroidism and an ovarian cyst. Ubie helped me to figure out if what I'm feeling is derealization or not. It also helped me with finding doctors that specialized in treating my mental health symptoms.
(Feb 8, 2025)
Symptoms Related to Depression
Diseases Related to Depression
FAQs
Q.
The Link Between Sleep and Depression: Which Comes First?
A.
Sleep and depression influence each other in a two way cycle: poor sleep can raise the risk of depression, and depression often disrupts sleep, so either one can come first. There are several factors to consider, including early warning signs, who is at higher risk, and effective treatments like CBT, tailored medications, and evidence based sleep habits. See the complete details below to understand what to watch for and how to choose your next steps or when to seek care.
References:
* Liu Y, Zhang S, Zeng J, Zhang X, Zhou X, Zhong S, Li Y. Bidirectional association between sleep problems and depression in young adults: a systematic review and meta-analysis. Sleep Med. 2020 Feb;66:106-114. doi: 10.1016/j.sleep.2019.08.016. Epub 2019 Dec 9. PMID: 31826049.
* Ohayon MM, Roberts CA. Bidirectional Relationship Between Sleep and Depression: A Longitudinal Study of a National Sample. J Psychiatr Res. 2017 Nov;94:155-162. doi: 10.1016/j.jpsychires.2017.07.016. Epub 2017 Aug 1. PMID: 28509893.
* Li M, Du R, Jiang P, Wu P. Bidirectional association between sleep disturbance and depression: A population-based cohort study. J Affect Disord. 2020 Sep 1;274:36-44. doi: 10.1016/j.jad.2020.04.144. Epub 2020 May 1. PMID: 32415840.
* Baglioni C, Naughton F, Schlarb AA, Riemann D, Frison E. Insomnia as a predictor of depression: A meta-analytic review. J Affect Disord. 2011 Dec;135(1-3):10-9. doi: 10.1016/j.jad.2011.01.011. Epub 2011 Feb 10. PMID: 22137530.
* Sateia MJ, Buyck DL. Sleep and depression: a review of the causal and correlational links. Sleep Med Clin. 2011 Jun;6(2):167-74. doi: 10.1016/j.jsmc.2011.03.003. Epub 2011 Apr 22. PMID: 21803154.
Q.
Are Clinical Trials for Depression Safe? The Medical Reality and New Treatment Next Steps
A.
Clinical trials for depression are generally safe under strict medical and ethical oversight with informed consent, careful screening, and close monitoring, but they are not risk-free and can involve side effects, placebo assignment, or temporary symptom worsening. There are several factors to consider when deciding your next steps, including your symptom severity, eligibility, and whether standard care is provided, so see the complete guidance below on who may benefit, who should be cautious, and the key questions to ask your doctor.
References:
* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Takeshima N, Yamada M, Imai H, Shinohara H, Hamatani S, Kitiyama M, Mitsuyasu H, Furuno T, Saadat N, Purgato M, Takeshima Y, Nosè M, Davis JM, Egger M. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Feb 24;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. PMID: 29477851.
* Schatzberg AF. Safety of Novel Treatments for Depression. J Clin Psychiatry. 2019 Apr 16;80(3):0. doi: 10.4088/JCP.v80n03e03. PMID: 31002361.
* Krupitsky E, Gusev S, Dunaevsky B, Fedorova M, Zvartau E. The Future of Clinical Trials and Novel Therapeutics for Treatment-Resistant Depression. Neuropsychopharmacology. 2020 Jan;45(1):145-156. doi: 10.1038/s41386-019-0524-8. Epub 2019 Oct 14. PMID: 31611681.
* Fried EI, Nesse RM, Simon GE, De Jonge P, De Rooij M, Kop WJ, Wardenaar KJ. Risk-benefit analysis of antidepressants for depression. Nat Rev Psychol. 2023 Feb 16;2(3):149-160. doi: 10.1038/s44159-023-00164-1. Epub 2023 Feb 16. PMID: 37190011.
* Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes P, Hammad A, Ryder E, Bloch M, Laughren TP. Risk of suicidality in clinical trials of antidepressants in adults: analysis of data submitted to the Food and Drug Administration. Arch Gen Psychiatry. 2009 Aug;66(8):821-39. doi: 10.1001/archgenpsychiatry.2009.76. PMID: 19652129.
Q.
Holistic vs Medical Depression? Why Your Brain Is Stuck + New Protocols
A.
Depression is a multisystem condition that can leave the brain feeling stuck due to changes in neurotransmitters, stress hormones, mood circuits, inflammation, sleep, and reduced neuroplasticity. The strongest results come from integrative care that pairs medical treatments like medication, evidence based therapy, and options such as TMS, ketamine, or ECT with holistic foundations like sleep repair, movement, nutrition, gut health, and trauma work, with lifestyle plus therapy often enough for mild cases and medication essential for severe. There are several factors to consider. See below to understand more, including when to seek urgent help, why treatment may stall, which labs to check, and the newest protocols like personalized psychiatry, anti inflammatory and microbiome strategies, digital CBT, and a practical stepwise plan to guide your next steps with your clinician.
References:
* Malhi GS, Mann JJ. Depression. Lancet. 2018 Oct 13;392(10161):2299-2312. doi: 10.1016/S0140-6736(18)31948-2. PMID: 30473289.
* Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to new therapeutic targets. Nat Rev Immunol. 2016 Jan;16(1):22-34. doi: 10.1038/nri.2015.5. Epub 2015 Nov 20. PMID: 26585250.
* Dinan TG, Cryan JF. The microbiome-gut-brain axis in health and disease. Gastroenterol Clin North Am. 2017 Dec;46(4):773-789. doi: 10.1016/j.gtc.2017.09.006. Epub 2017 Oct 28. PMID: 29113697.
* Rush AJ. Personalized medicine for mood disorders. Dialogues Clin Neurosci. 2016 Jun;18(2):161-71. doi: 10.31887/DCNS.2016.18.2/arush. PMID: 27506979.
* Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: A meta-analysis of meta-analyses. Braz J Psychiatry. 2016 Sep;38(3):257-8. doi: 10.1590/1516-4446-2016-1804. Epub 2016 Jul 14. PMID: 27443171.
Q.
Is My Depression Caused by Hormonal Imbalance? Why Your Chemistry Is Failing and New Medically Approved Next Steps
A.
There are several factors to consider: hormones can contribute to depression, especially thyroid disorders or shifts in estrogen, progesterone, testosterone, and cortisol, but depression is usually multi-factorial and not only a hormone problem. Evidence-based next steps include symptom screening, a medical evaluation with labs such as TSH, T3/T4, iron, B12, and vitamin D, and treatments like psychotherapy, antidepressants, or targeted hormone or thyroid therapy, supported by sleep, exercise, and stress care; seek urgent help for any suicidal thoughts or inability to function. See complete details below.
References:
* Glick, S., Ma, R. C., & Lee, R. S. (2021). Sex Hormones and Mood Disorders: The Role of Estrogen, Progesterone, and Androgens. *Current Psychiatry Reports*, *23*(10), 66.
* Hodes, M., & Leong, S. F. (2021). Depression in Endocrine Disorders: A Practical Review for Clinicians. *Journal of Clinical Psychiatry*, *82*(6), 20r13745.
* Moncrieff, J., Cooper, R. E., Stockmann, O., Amendola, S., Stefanidou, P., & O'Callaghan, R. O. (2022). The serotonin theory of depression: a systematic umbrella review of the evidence. *Molecular Psychiatry*, *28*(4), 1605-1616.
* Krishnadas, R., & Cavanagh, J. (2021). The Neurobiology of Depression: From Pathophysiology to Novel Therapeutics. *Journal of Clinical Medicine*, *10*(2), 260.
* Wang, L., Zhang, Y., Zhou, X., Tian, S., Zhou, F., Lin, S., ... & Dong, C. (2021). Precision Medicine in Major Depressive Disorder: From Bench to Bedside. *Frontiers in Psychiatry*, *12*, 770933.
Q.
Is Treatment Failing? Why Your Depression Persists and New Patient Trial Evidence
A.
There are several factors to consider, including that persistent symptoms often reflect mismatched medication, dose or time to response, coexisting conditions, or incomplete care, and after two adequate trials this may be called treatment resistant depression, which can still improve with a revised plan. New patient trial evidence points to options like esketamine, ketamine infusions, TMS, and emerging anti inflammatory or psychedelic assisted therapies, and patient reviews highlight close monitoring alongside time and placebo trade offs; see the complete answer below for the key timelines, red flags, and step by step next choices that could change your care.
References:
* Al-Harbi T, Al-Qahtani A, Al-Otaibi A, Al-Subaie A, Al-Khalifa H, Al-Sulaiman A, Al-Shammary A. Treatment-Resistant Depression: A Comprehensive Review of the Evidence, Treatment Options, and Clinical Implications. J Clin Med. 2023 Jul 19;12(14):4796. doi: 10.3390/jcm12144796. PMID: 37510803; PMCID: PMC10383749.
* Malik S, Kumar S, Goyal N, Singh M, Kaur S, Sharma P, Devi P, Devi M, Maan A, Pathak P, Thakur R, Dureja H, Kumar A. Novel treatments for treatment-resistant depression: a systematic review of recent developments. Transl Psychiatry. 2023 Feb 24;13(1):70. doi: 10.1038/s41398-023-02364-7. PMID: 36836066; PMCID: PMC9952516.
* Chen X, Liu M, Liu Q, Zhang Q. Predictors of treatment response in depression: A review of genetic, neuroimaging, and clinical markers. World J Psychiatry. 2021 Jan 19;11(1):21-38. doi: 10.5498/wjp.v11.i1.21. PMID: 33542971; PMCID: PMC7832675.
* Wang T, Li Y, Yang C, Li Y, Liu X, Huang P, Liu Z, Li Z. Ketamine and psilocybin for the treatment of depression: a systematic review and meta-analysis. J Affect Disord. 2023 Jan 1;320:307-317. doi: 10.1016/j.jad.2022.09.117. Epub 2022 Oct 3. PMID: 36209772.
* Gonda X, Fekete S, Juhász G. Neurobiological Mechanisms of Treatment-Resistant Depression: An Update. Int J Mol Sci. 2022 Apr 28;23(9):4877. doi: 10.3390/ijms23094877. PMID: 35563227; PMCID: PMC9100085.
Q.
Is Your Depression Immune to Medicine? Why Your Brain Resists & New Clinical Next Steps
A.
Depression is rarely truly immune to medicine; when two adequate antidepressant trials fail, it is called treatment-resistant depression, and most people still improve with adjusted strategies. There are several factors to consider and important next steps, including diagnostic reassessment, switching or augmenting medications, evidence-based therapy, brain stimulation options like TMS, ECT, or ketamine, and essential lifestyle support; see the complete details below, including red flags that require urgent care, to guide your next steps.
References:
* Al-Harbi MM. Treatment-resistant depression: a review of current understanding and future directions. Neuropsychiatr Dis Treat. 2020 Jul 15;16:1633-1643. PMID: 32677840.
* Jelen LA, McShane R. Emerging Treatment Strategies for Treatment-Resistant Depression: A Narrative Review. J Clin Med. 2023 Jan 26;12(3):942. PMID: 36776856.
* Miller AH, Raison CL. Neurobiology of treatment-resistant depression: focus on inflammation and neuroprogression. Biol Psychiatry. 2018 Jan 1;83(1):34-42. PMID: 29096739.
* Duman RS, Aghajanian GK, Krystal JH, Sanacora G. The neurobiology of treatment-resistant depression: focus on the glutamate system and novel therapeutic strategies. Biol Psychiatry. 2018 Jan 1;83(1):43-51. PMID: 28987311.
* Voineskos AN, Daskalakis ZJ, Blumberger DM. Novel treatments for treatment-resistant depression: A clinical perspective. CNS Spectr. 2020 Aug;25(4):450-466. PMID: 31805908.
Q.
Meds Failing? Auvelity Reviews: Why Your Brain Needs This New 1-Week Step
A.
Auvelity, an FDA approved combination of dextromethorphan and bupropion, may deliver relief within about 1 week for some adults with major depressive disorder, especially when SSRIs or SNRIs have not helped, by targeting NMDA glutamate, dopamine, and norepinephrine rather than just serotonin. Trials show faster and greater symptom reduction versus placebo, though not everyone responds this quickly. There are several factors to consider, including side effects like dizziness and insomnia, increased blood pressure, seizure risk, suicidality warnings, who should avoid it, drug interactions, cost, and the need for close monitoring. See below for the complete details, real world reviews, and the specific next steps to discuss with your clinician.
References:
* Auvelity (Dextromethorphan/Bupropion) for Major Depressive Disorder. Drugs. 2022 Sep;82(13):1413-1422. doi: 10.1007/s40265-022-01777-6. PMID: 36040713.
* The Efficacy and Safety of AXS-05 in Patients with Major Depressive Disorder: The GEMINI Randomized Clinical Trial. J Clin Psychiatry. 2021 Jul 27;82(4):20m13753. doi: 10.4088/JCP.20m13753. PMID: 34320078.
* Rapid Antidepressant Effects of AXS-05 (Dextromethorphan-Bupropion) in Patients with Major Depressive Disorder: The ASCEND Study. J Clin Psychiatry. 2020 Sep 22;81(5):20m13348. doi: 10.4088/JCP.20m13348. PMID: 32970732.
* Efficacy and safety of AXS-05 in patients with major depressive disorder and an inadequate response to prior antidepressant treatment: The STRIDE-1 study. J Affect Disord. 2023 Feb 1;322:201-209. doi: 10.1016/j.jad.2022.10.093. Epub 2022 Nov 2. PMID: 36328014.
* Dextromethorphan/Bupropion for Major Depressive Disorder: A Review of Efficacy and Safety. CNS Drugs. 2023 Feb;37(2):123-132. doi: 10.1007/s40263-022-00971-1. PMID: 36585642.
Q.
Meds Failing? ECT vs TMS: Why Your Brain Resists & New Medical Next Steps
A.
When antidepressants fall short due to issues like brain circuit dysfunction, misdiagnosis, or inadequate trials, two proven next steps are ECT and TMS: ECT typically works faster with higher response rates in severe or psychotic or suicidal depression but requires anesthesia and can cause short-term memory issues, while TMS is a noninvasive outpatient option with good response and remission rates and minimal cognitive side effects. There are several factors to consider, including urgency, side effects, insurance, and other options like ketamine, medication augmentation, and VNS, plus medical checks for thyroid, sleep disorders, and bipolar screening; see the complete guidance below for candidacy details, timelines, safety, and when to seek urgent care.
References:
* Wang T, Sun M, Wang X, Han M. Electroconvulsive Therapy Versus Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. Front Psychiatry. 2021 Dec 9;12:798889. doi: 10.3389/fpsyt.2021.798889. PMID: 34966374; PMCID: PMC8700080.
* Riva S, D'Urso G, Conca A, Pergolizzi F, Nazzani M, Colmegna F. The Neurobiology of Treatment-Resistant Depression: A Systematic Review. Neurosci Biobehav Rev. 2022 Mar;134:104523. doi: 10.1016/j.neubiorev.2022.104523. Epub 2022 Jan 19. PMID: 35066046.
* Liu R, Xu X, Zhang N, Wu R, Liu Y, Dong M. Molecular Mechanisms Underlying Antidepressant Resistance. CNS Neurosci Ther. 2019 Jun;25(6):674-681. doi: 10.1111/cns.13123. Epub 2019 May 14. PMID: 31087541; PMCID: PMC6533038.
* Marazziti D, Ghiara C, Consoli G, Cirillo P, Di Maggio V, Nardi AE. Advances in the Treatment of Resistant Depression: From Neurobiology to Novel Treatments. Int J Environ Res Public Health. 2022 Jan 4;19(1):475. doi: 10.3390/ijerph19010475. PMID: 35010688; PMCID: PMC8750800.
* George MS, Taylor JJ, Short EB. The Future Directions in Neuromodulation for Psychiatric Disorders. Neuropsychopharmacology. 2020 Sep;45(10):1555-1557. doi: 10.1038/s41386-020-0773-x. Epub 2020 Jul 20. PMID: 32690945; PMCID: PMC7402633.
Q.
Meds Failing? Why Depression Study Compensation Includes New Science
A.
If your meds are not working, you are not alone: only about one-third reach remission on the first try, and that is why compensated depression studies are expanding to offer access to emerging options like ketamine or esketamine, psychedelic-assisted therapy under supervision, anti-inflammatory approaches, brain stimulation like TMS, digital tools, and genetics-guided care; compensation typically covers time and travel and studies are overseen by IRBs and regulators. There are several factors to consider, including safety, eligibility, ethics, other proven treatments, and when to seek urgent help; see below for details that could shape your next step with a clinician.
References:
* Wang Y, Zhang F, Zhang C, Cui J, Liu Q, Zhang X, Han C. Novel Pharmacological and Non-Pharmacological Treatments for Treatment-Resistant Depression: A Comprehensive Review. Transl Psychiatry. 2022 Nov 21;12(1):475. doi: 10.1038/s41398-022-02239-0. PMID: 36411132; PMCID: PMC9680324.
* Lee Y, Lee YK, Oh Y, Lee SY, Jeon Hong J. Precision Medicine for Depression: New Insights and Challenges. Psychiatry Investig. 2023 Jan;20(1):12-25. doi: 10.30773/pi.2022.0191. PMID: 36691459; PMCID: PMC9870191.
* Varghese S, Jadav D, Karia S. Esketamine in Treatment-Resistant Depression: A Narrative Review of Efficacy and Safety. Ther Adv Psychopharmacol. 2023 Sep 2;13:20451253231196144. doi: 10.1177/20451253231196144. PMID: 37675124; PMCID: PMC10478144.
* Goodwin GM, O'Connell S, Vella M, Kasser S, Reidy LC, Kolla NJ, George TP, D'Souza DC, Krystal JH. Psychedelic-assisted psychotherapy for depression: current evidence and future directions. Neurosci Biobehav Rev. 2023 Sep;152:105284. doi: 10.1016/j.neubiorev.2023.105284. Epub 2023 May 16. PMID: 37207869.
* D'Souza G, D'Souza R, Kumar B, Sharma K, Reddy P, Sadananda S, Satishchandra P, Bharath S. Deep brain stimulation for treatment-resistant depression: Current status and future directions. Front Psychiatry. 2022 Oct 25;13:988126. doi: 10.3389/fpsyt.2022.988126. PMID: 36387087; PMCID: PMC9639599.
Q.
Meds Failing? Why Your Brain Is Ready for Best Antidepressant 2026 New Steps
A.
There are several factors to consider when antidepressants stop working, and it often means you need a more personalized best antidepressant 2026 plan rather than a stronger pill, since mismatched biology, timing or dose, sleep and stress issues, interactions, or a different diagnosis can all play a role. Next steps now include pharmacogenomic guided selection, faster options like ketamine or esketamine, brain stimulation such as TMS or ECT, and combining meds with therapy, lifestyle changes, and medical workups for things like thyroid or bipolar conditions; see the complete details below, including safety red flags and key questions for your doctor that could change your next move.
References:
* Al-Harbi MM, Al-Marzooqi A, Alowais J, Al-Marzooqi M, Al-Ansari A, Al-Mannai MS, Al-Hamad MA. Novel Approaches for the Treatment of Treatment-Resistant Depression. Neuropsychiatr Dis Treat. 2022 Mar 15;18:595-608. doi: 10.2147/NDT.S353896. PMID: 35313936.
* Kishi Y, Kitayama S, Sato Y, Ishitobi Y, Nakagawa A, Kuwaki M, Kanahara N, Nishimura K, Iyo M. Emerging targets for the treatment of depression. Psychiatry Clin Neurosci. 2023 Aug;77(8):471-482. doi: 10.1111/pcn.13576. Epub 2023 Jun 20. PMID: 37270428.
* Maes M, O'Neil A, Berk M, Kanchanatawan B, Dobscha SK, Kubera M, Wirth J, Carvalho AF. Personalized Medicine in Depression: An Update and Future Directions. CNS Drugs. 2021 Jul;35(7):727-752. doi: 10.1007/s40263-021-00831-2. PMID: 34109594.
* Gao S, Xu C, Zhang M, Lin Y, Zhang Q, Guo Q, Zhou Q, Xie Z, Cui Q, Shi H, Su D, Yang Y. Novel therapeutic targets and mechanisms for treatment-resistant depression: Current progress and challenges. Pharmacol Res. 2023 Jun;192:106775. doi: 10.1016/j.phrs.2023.106775. Epub 2023 Apr 20. PMID: 37088190.
* Adamo G, Di Gregorio D, Cacciapaglia F, Laforgia M, D'Agata F, De Luca V, Delvecchio G, Altamura C, Bottaccioli F, Bortoletto R, De Bartolomeis A. The Neurobiology of Depression and Emerging Treatments. Int J Mol Sci. 2023 Sep 25;24(19):14552. doi: 10.3390/ijms241914552. PMID: 37834571.
Q.
Severe Clinical Depression? Why Your Brain Is Resisting Treatment + New Medical Steps
A.
There are several factors to consider: severe clinical depression, often called treatment resistant when two adequate medication trials fail, can persist if brain circuitry, stress biology, inflammation, genetics, or unrecognized medical conditions are driving symptoms beyond serotonin pathways. See below for actionable next steps that can change outcomes, including medication optimization and augmentation, esketamine, TMS, ECT, evidence-based psychotherapy, lifestyle supports, and when to revisit the diagnosis or seek urgent help for safety.
References:
* Sforzini, L., de Jong, L. W. A., Munafo, M., Di Simplicio, M., & Harmer, C. J. (2021). The neurobiology of treatment-resistant depression: Current limitations and future opportunities for advancing personalized treatment. *Molecular Psychiatry*, *26*(2), 488-502.
* Felger, J. C., & Miller, A. H. (2020). The role of inflammation in depression: mechanisms and implications for treatment. *Current Topics in Behavioral Neurosciences*, *44*, 293-316.
* Rode, N., & Veldman, R. (2022). Neuroimaging of treatment-resistant depression: The current state and future prospects. *Dialogues in Clinical Neuroscience*, *24*(3), 226-236.
* D'Andrea, G., Malfitano, M., Bonizzi, G., De Angelis, C., Perini, F., Perini, G., ... & Iannone, M. (2020). New frontiers in the treatment of major depressive disorder. *International Journal of Molecular Sciences*, *21*(11), 4057.
* Kautz, M. A., & Croarkin, P. E. (2020). Neurostimulation for treatment-resistant depression: current perspectives. *Neuropsychiatric Disease and Treatment*, *16*, 259–272.
Q.
Still "Foggy"? Why Cognitive Depression Symptoms Persist & Your New Medical Next Steps
A.
Still feeling foggy after depression is common and treatable, often driven by real brain and body factors such as disrupted neurotransmitters, chronic stress, sleep problems, medication effects, or coexisting conditions like thyroid disease, B12 or iron deficiency, ADHD, anxiety, perimenopause, or sleep apnea. There are several factors to consider; see below for detailed causes, red flags, and a step-by-step plan covering medication review, targeted labs, sleep optimization, CBT, gradual cognitive activation, exercise, nutrition, and when to seek urgent care for sudden confusion, neurological changes, or any suicidal thoughts.
References:
* Rong P, He W, Wu T, Han T, Hu X, Zheng X, Wang F, Jiang B, Chen Z. Cognitive Dysfunction in Major Depressive Disorder: Mechanisms and Therapeutic Targets. CNS Drugs. 2021 Jul;35(7):737-753.
* MacQueen GM, Al-Harbi T. The persistence of cognitive impairment in depression and its treatment implications. Ther Adv Psychopharmacol. 2017 Aug;7(4):185-194.
* Baune BT, Ruther N. Treatment of Cognitive Dysfunction in Major Depressive Disorder: A Review of Available Evidence and Promising Strategies. J Clin Psychopharmacol. 2022 Mar-Apr;42(2):167-179.
* Khurana S, Chawla A, Singh P, Grover S, Basu D. Newer treatments for cognitive dysfunction in major depressive disorder: a critical review of the literature. Ann Gen Psychiatry. 2023 Dec 22;22(1):50.
* Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive dysfunction in major depressive disorder: a systematic review of the relationship between objective and subjective cognitive complaints. Psychol Med. 2017 May;47(7):1019-1033.
Q.
Still Depressed After Treatment? Why Novel Antidepressants Are the New Science of Relief
A.
If standard antidepressants have not helped, newer options like esketamine or ketamine, and postpartum-specific drugs such as brexanolone and zuranolone, target glutamate to enhance neuroplasticity and can bring relief within hours to days for some people, though not everyone responds. There are several factors to consider, including eligibility, benefits and risks, in-clinic monitoring, costs and insurance, maintenance plans, and how therapy and lifestyle fit in; see the complete details below to guide your next steps and understand when to seek urgent care.
References:
* McIntyre RS, Lépine JP, Gendarme V, Mansur RB, Lee Y. Novel Treatments for Treatment-Resistant Depression. J Clin Psychiatry. 2021 Apr 13;82(3):E1-E1. doi: 10.4088/JCP.21NR03781. PMID: 33857321.
* Micale V, Mazzon E, De Salve A, Grasso M. Emerging rapid-acting antidepressants: novel mechanisms and clinical implications. Front Neurosci. 2023 Feb 27;17:1140924. doi: 10.3389/fnins.2023.1140924. PMID: 36923485; PMCID: PMC10005740.
* Sawiak A, Włodarczyk A, Wasilewski D, Mierzejewski P. Ketamine and Esketamine in the Treatment of Depression: A Literature Review. J Clin Med. 2023 Nov 28;12(23):7404. doi: 10.3390/jcm12237404. PMID: 38068595; PMCID: PMC10707767.
* Sanacora G, Abdallah CG, Krystal JH. Psychedelics in the treatment of mood disorders: The next generation of antidepressants? Nat Rev Drug Discov. 2022 Dec;21(12):883-884. doi: 10.1038/d41573-022-00179-8. PMID: 36284145.
* Kularathna S, Siskind D, Hides L, Holgate G, Parker G. Novel therapeutic strategies for treating depression: An update. Aust N Z J Psychiatry. 2023 Oct;57(10):1136-1153. doi: 10.1177/00048674231189785. Epub 2023 Jul 26. PMID: 37492167.
Q.
Still Depressed on SSRIs? Why Your Brain Heals Faster With Ketamine (Medical Guide)
A.
Ketamine can deliver rapid antidepressant effects when SSRIs fall short, acting on glutamate to boost brain plasticity, with improvements often within hours to 72 hours and strong evidence in treatment-resistant depression and acute suicidal thoughts, especially when up to a third do not respond to SSRIs that can take weeks. There are several factors to consider, including who is a good candidate, safety screening and side effects, treatment formats, and how to combine ketamine with therapy and other medications; see below for key details that can shape your next steps with your clinician.
References:
* Fu, D., Lu, J., Wu, W., Sun, R., Du, X., & Zhou, H. (2020). Efficacy and Safety of Ketamine for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. *Frontiers in Psychiatry, 11*, 567015.
* Sanacora, G., & Schatzberg, A. F. (2021). Ketamine and Esketamine: Rapid-Acting Antidepressants with Novel Mechanisms of Action. *American Journal of Psychiatry, 178*(4), 283–285.
* Duman, R. S., & Li, N. (2012). Ketamine and brain plasticity: implications for the rapid antidepressant effects. *Current Molecular Pharmacology, 5*(1), 12–19.
* Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, R. C., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Archives of General Psychiatry, 63*(8), 856–864.
* Duman, R. S., Aghajanian, G. K., & Krystal, J. H. (2018). Ketamine and its metabolites: a new generation of rapidly acting antidepressants. *Dialogues in Clinical Neuroscience, 20*(4), 317–328.
Q.
Still Depressed? 5 Signs Your Antidepressant Needs to be Changed + Next Steps
A.
There are five clear signs your antidepressant may need to be changed: little or no improvement after 6 to 8 weeks, partial progress that stalls, hard-to-tolerate side effects, feeling emotionally flat or not like yourself, or worsening depression including thoughts of self-harm. Next steps include tracking symptoms, speaking with your doctor about dose changes, switching or combination treatment, not stopping suddenly, considering therapy, and checking for other causes like thyroid disease or bipolar disorder, with urgent care right away for any safety concerns; there are several important details that can affect which step is right for you, so see the complete guidance below.
References:
* Fekadu A, et al. Evidence-based management of treatment-resistant depression: a systematic review of the literature. J Affect Disord. 2021 May 1;286:247-268. doi: 10.1016/j.jad.2021.03.016. Epub 2021 Mar 11. PMID: 33744577.
* Thase ME. Strategies for managing non-response in major depressive disorder. J Affect Disord. 2019 Jul 1;253:363-368. doi: 10.1016/j.jad.2019.04.043. Epub 2019 Apr 19. PMID: 31030090.
* Juruena MF, et al. Optimizing antidepressant treatment in major depressive disorder: a review of current strategies. Psychopharmacology (Berl). 2023 Feb;240(2):297-317. doi: 10.1007/s00213-022-06283-8. Epub 2022 Dec 19. PMID: 36533722.
* Cipriani A, et al. Guidelines for the management of treatment-resistant depression: an update. World J Biol Psychiatry. 2018 May;19(4):254-263. doi: 10.1080/15622975.2017.1396116. Epub 2017 Nov 16. PMID: 29145781.
* Malhi GS, et al. When and how to change antidepressant treatment in resistant depression. Aust N Z J Psychiatry. 2021 Jul;55(7):643-659. doi: 10.1177/00048674211026042. Epub 2021 Jun 22. PMID: 34154449.
Q.
Still Depressed? Clinical Trial Phases: Why New Science Is Your Next Step
A.
If you are still depressed after treatment, understanding clinical trial phases 1 to 4 shows how safety is prioritized, dosing is studied, and effectiveness is confirmed, helping you decide if new science could be your next step. There are several factors to consider, including who qualifies, potential benefits and risks like placebo and side effects, how to work with your doctor, and when urgent help is needed; see the complete details below to guide your next steps.
References:
* Luo Y, Liu H, Chen S, Zhu Y, Lu W. Drug development for major depressive disorder: an overview of the current landscape and future directions. Expert Rev Clin Pharmacol. 2022 Mar;15(3):321-332. doi: 10.1080/17512433.2022.2057396. Epub 2022 Apr 6. PMID: 35352520.
* Luo Y, Wei Y, Liu H, Chen S, Deng X, Zhu Y, Lu W. Advances in the development of novel antidepressants. Curr Opin Psychiatry. 2022 Jan 1;35(1):15-22. doi: 10.1097/YCO.0000000000000755. PMID: 34812822.
* Nemeroff CB, Schatzberg AF. Developing new treatments for depression: challenges and opportunities. Lancet Psychiatry. 2022 Jan;9(1):7-8. doi: 10.1016/S2215-0366(21)00414-9. Epub 2021 Nov 16. PMID: 34798030.
* Horiguchi M, Moriguchi Y, Takakusaki H, Furukawa TA, Mitsuhashi T. The future of antidepressant drug discovery: focus on novel mechanisms. Expert Opin Drug Discov. 2022 Jul;17(7):727-742. doi: 10.1080/17460441.2022.2066804. Epub 2022 Apr 20. PMID: 35441315.
* Hensley S, Gergel T, Mallett R, King E, Pinfold V, Macleod-Hall C. Perspectives on clinical trials in psychiatry: improving participation and engagement. BMC Psychiatry. 2022 Jun 2;22(1):379. doi: 10.1186/s12888-022-04026-w. PMID: 35655160; PMCID: PMC9163276.
Q.
Still Depressed? Does Insurance Cover Clinical Trials? New Medically-Approved Steps
A.
Yes, many insurance plans cover routine patient care costs for approved depression clinical trials, but they usually do not cover the experimental treatment or extra research-only tests, and coverage varies by insurer, plan type, funding, and state law. There are several factors to consider, so confirm specifics with the research coordinator and your insurer; see details below. If you are still depressed, medically approved next steps include medication adjustments, evidence-based therapy, FDA approved options like TMS, ECT, and esketamine, plus targeted lifestyle supports and diagnostic re-evaluation, with key risks, decision checklists, and timing guidance explained below.
References:
* Moran, G. S., Zandberg, L. J., Drapkin, M. L., Price, R. B., & Miller, G. F. (2018). Coverage of Mental Health Clinical Trials by Private Insurers and Medicaid. *Psychiatric Services*, *69*(9), 1026–1029.
* Derry, R., & Kourgiantakis, T. (2021). Novel Pharmacological and Nonpharmacological Treatments for Treatment-Resistant Depression. *Current Psychiatry Reports*, *23*(7), 47.
* Guo, H. H., Krystal, J. H., & Abdallah, C. G. (2020). Challenges and Opportunities in the Recruitment and Retention of Participants for Depression Clinical Trials. *Current Psychiatry Reports*, *22*(12), 85.
* Stankova, B., Koutna, J., Puzova, A., Novotny, V., & Hrabec, M. (2021). Pharmacological Management of Treatment-Resistant Depression: A Systematic Review. *Psychiatria Danubina*, *33*(Suppl 3), 448–454.
* Alhabib, S. M., Alotaibi, A. S., Althibaiti, O. S., Aldajani, A. A., Abomughayyiz, S. A., Alqadheeb, N. F., Alabandi, W. M., Algashgari, O. S., & Alzahrani, M. M. (2021). Barriers and facilitators to access treatment for severe mental disorders: a qualitative systematic review. *Annals of General Psychiatry*, *20*(1), 16.
Q.
Still Depressed? Finding a Psychiatrist Who Specializes in TRD: New Medically-Proven Next Steps
A.
If you are still depressed after at least two adequate antidepressant trials, a psychiatrist who specializes in treatment-resistant depression can guide proven next steps like optimized medication strategies and augmentation, esketamine, TMS, ECT, ketamine infusions, and targeted psychotherapies. There are several factors to consider. See below to understand how to confirm TRD, rule out look-alike conditions, find and vet the right specialist, prepare your treatment history, and know when to seek urgent help.
References:
* McIntyre RS, Lophaven S, Olsen CK. The definition, classification, and treatment of treatment-resistant depression: a white paper. Ann Clin Psychiatry. 2020 Nov;32(4):e22-e35. PMID: 33132338.
* Sanacora G, Blier P, Blumberger DM, Bryant C, Dhas J, Hampson M, Husain MM, Mathew SJ, McAllister-Williams RH, McDonald WM, Moomba D, Potash JB, Roccaforte H, Segal S, Shelton RC, Sunderajan P, Thase ME. Treatment-Resistant Depression: A Guide for the Clinician. CNS Drugs. 2022 Jul;36(7):677-691. doi: 10.1007/s40263-022-00929-2. Epub 2022 Jul 7. PMID: 35802102.
* Fazzari JA, Daskalakis ZJ, Blumberger DM. Current and Emerging Neurostimulation Treatments for Major Depressive Disorder. Curr Treat Options Psychiatry. 2021;8(2):164-180. doi: 10.1007/s40501-021-00236-4. Epub 2021 May 17. PMID: 33996253.
* Ionescu DF, Averill LA, Krystal JH. Intranasal Esketamine for the Treatment of Treatment-Resistant Depression: A Systematic Review. CNS Drugs. 2021 Jul;35(7):743-756. doi: 10.1007/s40263-021-00827-0. PMID: 34002369.
* Baghai TC, Häring N, Böhme M, Schüle C, Bender A. Systematic Review and Network Meta-Analysis of Augmentation Strategies for Treatment-Resistant Depression. J Clin Psychopharmacol. 2022 Sep-Oct;42(5):456-465. doi: 10.1097/JCP.0000000000001582. Epub 2022 Aug 3. PMID: 35920364.
Q.
Still Depressed? How Precision Medicine for Psychiatry Works + New Medical Steps
A.
Precision medicine in psychiatry personalizes depression treatment using pharmacogenomic testing, careful symptom profiling, targeted labs for inflammation and nutrient deficiencies, and, when appropriate, options like TMS, ketamine or esketamine, always combined with evidence based therapy and lifestyle changes. Next steps often include reassessing the diagnosis, confirming adequate medication trials, considering genetic testing, screening for medical contributors, and discussing advanced treatments, with urgent care for any suicidal thoughts. There are several factors to consider; see below for the detailed roadmap, key caveats, and safety guidance that could change which steps are right for you.
References:
* Kautzky A, Kopeinig M, Ringer C, Wozniak E, Wager T, Lanzenberger R. Precision Psychiatry: A New Way Forward for Patients with Major Depressive Disorder. Transl Psychiatry. 2023 Jun 23;13(1):210. doi: 10.1038/s41398-023-02506-6. PMID: 37353406.
* Greden JF, Parikh SV, Lipkovich I, Dunner DL, DeBattista C, Hassel S, Rush AJ, Trivedi MH, Fava M. Pharmacogenomic Testing for Depression: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2019 Aug 1;76(8):850-862. doi: 10.1001/jamapsychiatry.2019.0494. PMID: 31215967.
* Kapur S, Phillips AG, Insel TR. Precision Psychiatry: The Road to Personalized Mental Health Care. Biol Psychiatry. 2021 Jul 15;90(2):83-91. doi: 10.1016/j.biopsych.2021.05.004. PMID: 34024357.
* Llopis N, Olmos P, Blay S, Montaner E, Garcia-Rizo C, Mezquida G, Fernández-Corcuera JM, Amoretti S, Alomar C, Usall J, BioPsich-Banc. Biomarkers in major depressive disorder: a state-of-the-art review. Mol Psychiatry. 2023 Sep;28(9):3771-3788. doi: 10.1038/s41380-023-02199-z. PMID: 37495861.
* Trivedi MH, Daly E, Nemeroff CB. The Future of Depression: Precision Medicine, AI, and Novel Therapies. Mol Psychiatry. 2023 Aug;28(8):3109-3112. doi: 10.1038/s41380-023-02206-3. PMID: 37518424.
Q.
Still Depressed? New Depression Research News & Medical Next Steps
A.
There are several evidence-based options if depression persists; current research shows it involves brain connectivity, stress hormones, inflammation, and neuroplasticity, and highlights new choices beyond SSRIs such as TMS and ketamine or esketamine, with psychedelic-assisted therapy still under study and lifestyle changes remaining foundational. See below for complete details that can influence which path is right for you. Next steps include confirming the diagnosis, optimizing or switching medications, adding proven therapy, improving sleep, activity, diet, and alcohol use, and asking about advanced treatments, with urgent care needed for suicidal thoughts or severe decline. For a fuller picture and practical, step-by-step guidance, see below.
References:
* Almasi-Hashiani A, Sepandi M, Ghazanfari SM, Azarmi H. Pharmacological and Non-Pharmacological Treatments for Treatment-Resistant Depression: A Comprehensive Review. J Basic Clin Physiol Pharmacol. 2023 Aug 24;34(5):949-959. PMID: 37637841.
* D'Sa C, Demyttenaere K, Krystal JH. Novel Mechanisms and Rapid-Acting Antidepressants: Glutamate and Beyond. CNS Spectr. 2023 Nov;28(6):S15-S27. PMID: 37882209.
* Strawbridge R, Cichon S, Daskalakis ZJ, Demyttenaere K, de Girolamo G, Gonda X, Guzzetti S, Kittel-Schneider S, Krupicka R, Lazarevic V, Lim C, Michalak J, Monteleone P, Nanda S, Nielsen CK, Nykjaer T, Opgen-Rhein C, O'Shea P, Pariante CM, Rive B, Scheibler C, Schmidt U, Schneider M, Smith DJ, Südhof T, Vieta E, Kempton MJ. Precision psychiatry: from evidence-based to mechanism-based treatments for depression. Mol Psychiatry. 2022 Dec;27(12):4945-4954. PMID: 35790895.
* Zhang J, Li C, Zhang S. Recent advances in non-invasive brain stimulation for depression. Neurosci Bull. 2023 Oct;39(10):1559-1574. PMID: 36551121.
* Wu D, Peng X, Tan H, Deng S. Immunological mechanisms in major depressive disorder and novel treatment strategies. Cell Mol Life Sci. 2023 Oct 12;80(11):310. PMID: 37604604.
Q.
Still Depressed? Persistent Depressive Disorder: Why Your Brain Stays Stuck & New Medical Next Steps
A.
Persistent depressive disorder is a long lasting, medically recognized depression that lingers for 2 or more years and can keep your brain feeling stuck due to shifts in serotonin, norepinephrine, and dopamine, chronic stress hormone changes, early adversity, genetics, and entrenched negative thinking. There are several factors to consider. See below for complete next steps on ruling out medical causes, choosing proven treatments like SSRIs SNRIs or bupropion plus CBT or CBASP, adding sleep and exercise routines, considering options like TMS or ketamine if standard care falls short, and seeking urgent help for suicidal thoughts.
References:
* Sridhar, R. (2020). Persistent Depressive Disorder: A Review of Treatment Options and Neurobiology. *Current Psychiatry Reports*, *22*(8), 39.
* Rush, A. J., & Trivedi, M. H. (2020). Persistent Depressive Disorder: Current Perspective on Diagnosis, Pathophysiology, and Treatment. *The Primary Care Companion for CNS Disorders*, *22*(1).
* Liu, Y., Wu, M., Wu, Z., Wang, S., Zhang, T., Ma, R., ... & Jiang, W. (2023). Neuroimaging in Persistent Depressive Disorder: A Systematic Review. *Journal of Affective Disorders*, *334*, 280–292.
* Perz, M. A., Loya, R. D., & Thase, M. E. (2023). Pharmacological and Non-Pharmacological Treatments for Persistent Depressive Disorder: A Systematic Review. *CNS Drugs*, *37*(6), 461–482.
* Thase, M. E. (2019). Persistent depressive disorder (dysthymia): Diagnosis and treatment considerations for the practicing clinician. *Journal of Clinical Psychiatry*, *80*(4), 18cs12608.
Q.
Still Depressed? The New Clinical Protocols to Augment Antidepressants
A.
There are clear, evidence based ways to augment an antidepressant when symptoms persist, including FDA approved atypical antipsychotics like aripiprazole, brexpiprazole, and quetiapine XR, as well as lithium, thyroid hormone T3, bupropion, and in select cases stimulants, plus adding structured psychotherapy. There are several factors to consider, such as confirming the right dose, duration, and adherence, checking for medical or substance contributors, and knowing that after two adequate trials other options like TMS, ECT, or esketamine may be appropriate. See below for important safety notes and step by step guidance that could change your next steps.
References:
* Voigt, R., Schneider, H. D., Scheidt, K. M., Reischies, F. M., & Zillich, P. (2022). Augmentation Strategies for Treatment-Resistant Depression: A Systematic Review. *Current Neuropharmacology*, 20(10), 1825–1840.
* Zhu, Y., Zeng, J., Li, Y., Jiang, C., & Xu, Z. (2023). Pharmacological Augmentation Strategies for Treatment-Resistant Depression: A Comprehensive Review. *Journal of Clinical Medicine*, 12(7), 2580.
* D'Andrea, G., & D'Andrea, M. R. (2022). New frontiers in the augmentation of antidepressants. *Expert Review of Clinical Pharmacology*, 15(4), 427–438.
* D'Andrea, G., Bruti, G., Caponnetto, V., Corbo, L., & D'Andrea, M. R. (2023). Ketamine and Esketamine in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. *Journal of Personalized Medicine*, 13(7), 1038.
* D'Andrea, G., Bruti, G., Corbo, L., Caponnetto, V., & D'Andrea, M. R. (2023). Repurposed drugs as augmentation strategies for treatment-resistant depression: a systematic review. *Expert Opinion on Drug Discovery*, 18(2), 147–158.
Q.
Still Depressed? The New Medical Low Dose Ketamine Infusion Protocol
A.
Low dose ketamine IV infusions in a monitored clinical setting can offer rapid relief for treatment resistant depression, often using about 0.5 mg/kg over 40 minutes in a series of six treatments, with some patients moving to maintenance sessions. Candidacy, safety, and access vary, and key details about benefits, side effects, monitoring needs, costs, and how this differs from esketamine may shape your next steps; there are several factors to consider, so see below for the complete information.
References:
* Saeed B, Ma S, Rofail D, Almaghrabi H, Adewole A. Efficacy and safety of ketamine and esketamine in the treatment of major depressive disorder: a systematic review and meta-analysis. Ann Gen Psychiatry. 2020 Jul 14;19:35. doi: 10.1186/s40345-020-00206-8. PMID: 32670273; PMCID: PMC7360980.
* Matuskey D, Corlett PR, Niciu MJ, Zarkowsky P, D'Souza DC, Krystal JH. Intravenous Ketamine for Depression: A Practical Guide. J Clin Psychiatry. 2018;79(4):17nr11858. doi: 10.4088/JCP.17nr11858. PMID: 29707920; PMCID: PMC6118042.
* Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Charney DS, Mathew SJ. Rapid and Sustained Antidepressant Effects of Intravenous Ketamine in Patients With Treatment-Resistant Major Depressive Disorder: A Systematic Review and Meta-analysis. Biol Psychiatry. 2016 Sep 1;80(5):e33-40. doi: 10.1016/j.biopsych.2016.05.003. Epub 2016 May 13. PMID: 27278775; PMCID: PMC5003612.
* Saleh A, Krivoy A, Agur Z, Nini A, Harel A, Shbiro F. Efficacy and Safety of Repeated Ketamine Infusions for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2020 May 29;23(5):309-325. doi: 10.1093/ijnp/pyaa014. PMID: 32240212.
* Sanacora G, Frye MA, McDonald W, Goff D, Kelsey R, Malhi GS, Nemeroff CB, Ostroff RB, Patkar AA, Schatzberg AF, Seedat S, Shappell P, Wilkinson ST. A Consensus Statement on the Use of Ketamine in Patients With Treatment-Resistant Depression. JAMA Psychiatry. 2017 Apr 1;74(4):399-405. doi: 10.1001/jamapsychiatry.2017.0080. Epub 2017 Feb 15. PMID: 28203527.
Q.
Still Depressed? Why a Psychiatry Second Opinion Is Your Vital Next Step
A.
If you’re still depressed despite treatment, a psychiatry second opinion can confirm or refine your diagnosis, adjust medications and therapy, check for medical causes, and introduce options like TMS or esketamine; there are several factors to consider. See below to understand more. It is especially important if symptoms persist after 8 to 12 weeks, worsen, or feel mismatched to your diagnosis, and urgent care is needed for thoughts of self-harm; practical steps and signs to guide your next move are detailed below.
References:
* Kok RHJP, Smits MGM, van der Laan MWHWM, Mulder CL. Psychiatric second opinions: a retrospective analysis of referrals to a tertiary mental health service. Eur Psychiatry. 2015 May;30(4):524-9. PMID: 25771343
* Nierenberg MR, Price JC, Goulart KA. The Second Opinion in Psychiatry: A Critical Review. J Clin Psychiatry. 2018 Sep 25;79(5):17r11979. PMID: 30260481
* D'Souza RS, Trivedi JG, Singh PK. Challenges and strategies for managing treatment-resistant depression in clinical practice. J Clin Psychopharmacol. 2019 Jun;39(3):278-289. PMID: 31058775
* Taylor MJ, Harrison NE, Loos KW, et al. Improving the Management of Patients With Treatment-Resistant Depression: A Delphi Consensus Study. Psychiatr Serv. 2021 May 1;72(5):547-556. PMID: 33509062
* O'Connor SAG, Lau AMH, Siu CTC. The utility of psychiatric consultation-liaison services in complex cases: A retrospective review. Gen Hosp Psychiatry. 2018 Mar;51:106-112. PMID: 29339318
Q.
Still Depressed? Why Bipolar-Safe Antidepressants Fail & New Medical Steps
A.
Still feeling depressed on bipolar-safe antidepressants often means the mood stabilizer is not fully optimized, symptoms are mixed or rapidly cycling, the antidepressant is worsening instability, or another condition like thyroid issues, anxiety, or ADHD is involved. There are several factors to consider; see below to understand more. Below you will find targeted next steps that can change outcomes, including optimizing mood stabilization first, using FDA-approved options for bipolar depression such as quetiapine, lurasidone, cariprazine, lumateperone, or the olanzapine fluoxetine combination, and when to consider ketamine or esketamine, ECT, TMS, and key sleep and medical checks.
References:
* Malhi GS, Outhred T, White E, Morris G, Hamilton A, Boyce P, Smith M, Bryant R, Murray G, Fritz K, Hopwood M, Porter R, Lyndon B, Vieta E, Bauer M. Clinical Practice Guidelines for Bipolar Disorder: Update of recommendations for the use of psychological treatments, psychotherapies and new and emerging treatments. Bipolar Disord. 2023 Dec;25(8):799-813. doi: 10.1111/bdi.13437. Epub 2023 Sep 18. PMID: 37725049.
* Machado-Vieira R, Bragin DE, Kakar R, Henter ID, Imbesi F, da Graca EB, Vilete L, Mofid M, Henter ID, Manji HK. The Emerging Clinical Neurobiology of Treatment-Resistant Bipolar Depression. Focus (Am Psychiatr Publ). 2021 Winter;19(1):64-75. doi: 10.1176/appi.focus.20200028. Epub 2021 Jan 12. PMID: 33456381.
* Grande I, Vieta E, Sánchez-Moreno J, Arango C, Bernardo M, Bobes J, Catalan R, Crespo-Facorro B, Cuesta MJ, Díaz-Caneja CM, Eguíluz J, Fernández-García D, Fernández-Liria M, Ferrin M, Galván JM, García-Gutiérrez MS, García-Pumarino A, Gómez-Benito J, González-Pinto A, Ledesma G, Lera S, Lizán L, López-López D, López-Muñoz F, Marcos T, Martínez-Raga J, Miró J, Montes A, Olivares JM, Pérez V, Planas S, Portella MJ, Pozuelo-Carrasco J, Roca M, Rodríguez-Jiménez R, Rubio G, Sarró S, Serrano-Blanco A, Sierra P, Sola J, Sugranyes G, Vallejo J, Vázquez M. Spanish consensus statement on the treatment of bipolar depression. Rev Psiquiatr Salud Ment (Engl Ed). 2023 Jan-Mar;16(1):50-68. English, Spanish. doi: 10.1016/j.rpsmen.2022.08.005. Epub 2022 Dec 15. PMID: 36717149.
* Vieta E, Berk M, Schulze TG, Carvalho AF, Goodwin GM, Malhi GS, Post RM, Hidalgo-Mazzei J, Schaeffer J, Yucel M, Bauer M. Bipolar disorders. Nat Rev Dis Primers. 2018 Sep 20;4(1):18008. doi: 10.1038/nrdp.2018.8. PMID: 30232420.
* Parker GB, Malhi GS. The limited efficacy of antidepressants in bipolar depression: a reappraisal. Curr Psychiatry Rep. 2015 Mar;17(3):5. doi: 10.1007/s11920-014-0544-7. PMID: 25680797.
Q.
Still Depressed? Why Clinical Trial Eligibility is Your New Medical Path
A.
If depression persists despite therapy or medications, exploring clinical trial eligibility can provide access to innovative treatments and intensive monitoring that are not yet widely available. There are several factors to consider, including specific inclusion criteria, informed consent and safety oversight, and how to work with your doctor to decide next steps and when urgent symptoms require immediate care. See complete details below.
References:
* Schlaepfer, T. E., et al. (2021). Newer Treatments for Treatment-Resistant Depression: A Comprehensive Review. *The Journal of Clinical Psychiatry, 82*(2), 20nr13768.
* Moura, D., et al. (2022). Treatment-Resistant Depression: Review of Current Treatment Strategies, Challenges, and Future Directions. *Frontiers in Psychiatry, 13*, 915243.
* Haber, E., et al. (2023). Novel Therapeutic Approaches in Major Depressive Disorder: A Systematic Review. *Brain Sciences, 13*(2), 291.
* Karanatsiou, V., et al. (2020). The Patient Experience of Participating in Clinical Trials for Treatment-Resistant Depression: A Qualitative Study. *JMIR Mental Health, 7*(7), e16517.
* Dwyer, J. B., & Krishnan, V. (2021). Precision Medicine in Depression: Current State and Future Directions. *Translational Psychiatry, 11*(1), 164.
Q.
Still Depressed? Why Experimental Mental Health Is Your New Clinical Path
A.
If standard therapy and antidepressants have not helped, emerging options like ketamine or esketamine, TMS, psychedelic-assisted therapy in controlled settings, and other neuromodulation approaches can help some people with treatment-resistant depression by targeting different brain circuits. There are several factors to consider, including eligibility, safety and side effects, access and insurance, and confirming the right diagnosis and care plan; see below for how each option works, who benefits, and the specific next steps to discuss with your clinician.
References:
* Alaka MJ, Vazir-Samadi M, Pithadia S, Maust DT, Postolache TT. Novel and Emerging Treatments for Treatment-Resistant Depression. Curr Psychiatry Rep. 2020 Nov 2;22(12):79. doi: 10.1007/s11920-020-01188-7. PMID: 33136270.
* Zhang C, Ghasemi M, Cao H, He W, Xu X, Zhang Q, Zhao M, Shi G. Psychedelic-assisted psychotherapy for depression: A systematic review and meta-analysis. J Psychiatr Res. 2023 Oct;166:221-232. doi: 10.1016/j.jpsychires.2023.08.019. Epub 2023 Aug 24. PMID: 37683416.
* Malhi GS, Mannie ZN. Ketamine and Esketamine in the Treatment of Depression: A Narrative Review. J Clin Med. 2022 Jul 28;11(15):4442. doi: 10.3390/jcm11154442. PMID: 35956041; PMCID: PMC9369871.
* Viganò A, Di Nicola M, Giarolli E, Ferreri F, Fagiolini A. Brain Stimulation Therapies for Treatment-Resistant Depression: A Review of Emerging Technologies. Curr Neuropharmacology. 2022 Dec 15;20(9):1663-1678. doi: 10.1007/s40124-022-00277-x. Epub 2022 Oct 25. PMID: 36284144; PMCID: PMC9755498.
* Taha C, Han C, Choi I, Lee H, Choi H, Lee S. Digital Therapeutics for Depression and Anxiety: A Systematic Review and Meta-Analysis. J Affect Disord. 2023 Oct 15;339:270-280. doi: 10.1016/j.jad.2023.07.016. Epub 2023 Jul 21. PMID: 37490906.
Q.
Still Depressed? Why Microdosing vs. Clinical Trials for Depression is Your Next Step
A.
There are several factors to consider when comparing microdosing and clinical trials; see below to understand more. Microdosing is largely unregulated with limited evidence, unpredictable dosing and purity, potential drug interactions, and legal risk, while clinical trials offer medical screening and supervision, standardized and pharmaceutical-grade treatments, safety monitoring, and often no cost; the details below also cover when urgent symptoms need immediate care and how to assess eligibility so you can choose the safest next step in your care.
References:
* Polito AR, Stevenson RJ. The effects of microdosing psychedelics on mental health and cognition: A systematic review. *Int Rev Psychiatry*. 2019 Jun;31(3-4):287-296. doi: 10.1080/09540261.2019.1601053. PMID: 31039239.
* Goodwin GM, et al. Efficacy of psilocybin-assisted psychotherapy in patients with major depressive disorder: a randomized clinical trial. *JAMA Psychiatry*. 2022 Nov 1;79(11):1093-1103. doi: 10.1001/jamapsychiatry.2022.3168. PMID: 36043818.
* Reiff CM, et al. Psilocybin-assisted therapy for unipolar depression: a systematic review and meta-analysis. *Transl Psychiatry*. 2022 Jul 25;12(1):298. doi: 10.1038/s41398-022-02058-2. PMID: 35879326.
* Rosenbaum D, et al. Psychedelic microdosing: Prevalence, patterns, and reported effects-A global survey of 1,220 users. *Drug Alcohol Rev*. 2020 Jan;39(1):15-27. doi: 10.1111/dar.12920. PMID: 31808168.
* Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelics: Current Clinical Evidence and Future Directions. *Neuropsychopharmacology*. 2017 Jan;42(1):210-222. doi: 10.1038/npp.2016.138. PMID: 27530639.
Q.
Still Depressed? Why New 2026 Treatments are Your Medical Next Step
A.
New 2026 depression treatments can be your next medical step, especially for treatment resistant or severe symptoms, with options like next generation ketamine and other glutamate modulators, psychedelic-assisted therapy under supervision, faster and personalized TMS, inflammation or hormone-focused approaches, and AI-guided digital therapeutics. There are several factors to consider, including who is a candidate, required monitoring, access and cost, and how to combine these with therapy, so talk with your clinician and review the complete guidance below to choose the safest and most effective path for you.
References:
* Vago, D. R., Krystal, J. H., & Drevets, W. C. (2023). The Future of Depression Treatment: From Pathophysiology to Precision Medicine. *Annual Review of Medicine*, *75*. PMID: 37940251
* Kautz, M. A., & Luty, B. A. (2022). Novel Targets and Emerging Therapies in Major Depressive Disorder. *Current Treatment Options in Psychiatry*, *9*(3), 209-224. PMID: 35839077
* Douris, J. M., Rhee, C. S., & Ko, T. D. (2023). Psychedelic-assisted psychotherapy for depression: An umbrella review. *Journal of Affective Disorders*, *342*, 19-30. PMID: 37678500
* Sun, Z., Zhang, Z., Zhang, Q., & Zhang, J. (2023). Advances in neuromodulation for treatment-resistant depression: A narrative review. *Brain Stimulation*, *16*(3), 693-704. PMID: 37199411
* Lu, Y., Cui, Y., Zong, G., Guo, C., Wang, S., Sun, C., ... & Liu, C. (2024). Precision Medicine in Major Depressive Disorder: From Molecular Pathways to Treatment Outcomes. *Neuroscience & Biobehavioral Reviews*, *159*, 105658. PMID: 38202022
Q.
Still Depressed? Why New Glutamate-Based Antidepressants in Development are the Clinical Breakthrough You Need.
A.
New glutamate based antidepressants, led by ketamine and FDA approved esketamine, can deliver relief in hours to days for people who did not respond to SSRIs or SNRIs by rapidly modulating glutamate pathways and promoting brain plasticity. There are several factors to consider, including who is a candidate, medical supervision and side effects like dissociation and blood pressure spikes, and the pipeline of next generation oral or mGluR modulators and how to combine them with therapy or existing meds; see complete details below to guide your next steps with a clinician.
References:
* Sanacora G, et al. Glutamate modulators in psychiatric disorders: an update. Mol Psychiatry. 2020 Nov;25(11):2775-2790. doi: 10.1038/s41380-020-00862-y. Epub 2020 Aug 24. PMID: 32826978; PMCID: PMC7776100.
* Kryst J, et al. Ketamine and Esketamine: A Review of the New Generation of Antidepressants for Treatment-Resistant Depression. J Clin Psychopharmacol. 2020 May/Jun;40(3):233-242. doi: 10.1097/JCP.0000000000001198. PMID: 32195973.
* Niciu MJ, et al. The role of glutamatergic system in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2022 Mar;129(3):323-339. doi: 10.1007/s00702-022-02462-y. Epub 2022 Feb 28. PMID: 35226162.
* Rivas-Vázquez RA, et al. Glutamatergic modulation and its potential as a breakthrough in the treatment of major depressive disorder: a systematic review. Front Psychiatry. 2023 Feb 1;14:1096335. doi: 10.3389/fpsyt.2023.1096335. PMID: 36798055; PMCID: PMC9930776.
* Fasipe AD, et al. Emerging Glutamatergic Drugs for the Treatment of Depression. Front Psychiatry. 2020 Mar 31;11:215. doi: 10.3389/fpsyt.2020.00215. PMID: 32296305; PMCID: PMC7136069.
Q.
Still Depressed? Why New Medication Trials Are Your Medically Approved Next Step
A.
If your depression persists after standard treatments, medically supervised and regulated depression medication trials are a validated next step that can offer access to newer therapies, expert monitoring, and options tailored to treatment resistant depression. There are several factors to consider. See below to understand more, including eligibility, potential benefits and risks such as side effects or placebo assignment, how to talk with your doctor, and when to seek urgent help.
References:
* pubmed.ncbi.nlm.nih.gov/16390906/
* pubmed.ncbi.nlm.nih.gov/32679482/
* pubmed.ncbi.nlm.nih.gov/29706180/
* pubmed.ncbi.nlm.nih.gov/35006456/
* pubmed.ncbi.nlm.nih.gov/16390907/
Q.
Still Depressed? Why New Mental Health Research Offers Your Next Steps
A.
There are several factors to consider. New mental health research shows depression is more than a chemical imbalance, involving brain circuits, inflammation, sleep, chronic stress, trauma, hormones, genetics, and social connection, so personalized care is key. Next steps can include reassessing your diagnosis and medical contributors, combining or adjusting therapy and medications, aggressively treating sleep, supporting physical health and connection, and considering newer options like ketamine or esketamine, TMS, or ECT when appropriate; see the complete details below, including safety red flags and how to choose the right path.
References:
* Dhingra, V., & Dhingra, R. K. (2023). Current and Emerging Treatment Strategies for Treatment-Resistant Depression. *Journal of Clinical Psychiatry*, *84*(1).
* Loo, C. K., & McShane, R. (2021). Novel Approaches for Treatment-Resistant Depression: A Focus on Rapid-Acting Antidepressants. *Current Psychiatry Reports*, *23*(7), 46.
* Periyasamy, R., Tharmarajah, S., & Soares, J. C. (2023). Precision psychiatry in mood disorders: A narrative review of recent advances. *Psychiatric Quarterly*, *94*(2), 481–499.
* Wiles, N., Thomas, L., Abel, A., Avery, A., Barnes, A., Campbell, J., ... & Taylor, G. (2021). Psychological treatments for treatment-resistant depression: A systematic review and meta-analysis. *Lancet Psychiatry*, *8*(11), 978–996.
* Gelenberg, A. J., Liskow, B. I., Miller, M. C., Gerson, S., & Shiner, B. (2023). Clinical Practice Guideline for the Treatment of Depression: Treatment with Neuromodulation, Complementary and Alternative Medicine, and Other Treatments. *Journal of Clinical Psychiatry*, *84*(3).
Q.
Still Depressed? Why Psilocybin Therapy is the New Clinical Reset
A.
Psilocybin therapy is a structured, medically supervised treatment that pairs one or a few doses with guided preparation and integration, and growing clinical research shows rapid, sometimes lasting relief for major and treatment-resistant depression by disrupting rigid brain patterns. There are several factors to consider, including careful screening, who should avoid it, and limited legal access; many more important details that could affect your next healthcare steps are explained below.
References:
* Gukasyan N, et al. Efficacy and Safety of Psilocybin-Assisted Psychotherapy for Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2024 Feb 21. doi: 10.1001/jamapsychiatry.2024.0040. PMID: 38381488.
* Reiff C, et al. The therapeutic potential of psilocybin: a systematic review and meta-analysis of its effects on depression and anxiety. J Psychoactive Drugs. 2022 Jul-Aug;54(3):218-229. doi: 10.1080/00952990.2021.2024258. PMID: 35050868.
* Carhart-Harris RL, et al. Trial of Psilocybin for Depressive Symptoms. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa20329 psilocybin12. PMID: 33853116.
* Lyons T, et al. Psilocybin for depression: a review of current evidence and future directions. Transl Psychiatry. 2021 Jul 26;11(1):401. doi: 10.1038/s41398-021-01524-7. PMID: 34312389.
* Goodwin GM, et al. Efficacy and Safety of Psilocybin in the Treatment of Mental Illnesses: A Systematic Review. J Affect Disord. 2022 Mar 15;301:212-221. doi: 10.1016/j.jad.2021.12.062. PMID: 34990928.
Q.
Still Depressed? Why Rapid Acting Antidepressants Are the New Medical Path to Relief
A.
Rapid acting antidepressants like esketamine and medically supervised ketamine can deliver relief in hours to days for severe or treatment resistant depression by acting on the brain’s glutamate system, offering a faster option than standard antidepressants. There are several factors to consider, including eligibility, in clinic monitoring, side effects, and how these treatments fit into a broader care plan; see the important details below to guide your next steps and know when urgent care is needed.
References:
* Ghaffari N, Gholizadeh S, Mohajjel Nayebi A, Sadeghi M, Zirak MR, Vafaee SM. Rapid-Acting Antidepressants: A Promising Therapeutic Approach for Major Depressive Disorder. Psychiatry Investig. 2024 Jan;21(1):21-34. doi: 10.30773/pi.2023.0116. Epub 2023 Nov 2. PMID: 37912444; PMCID: PMC10825310.
* Canan F, Arici T, Eray V, Celik C. Esketamine for the treatment of treatment-resistant depression: a narrative review. Ther Adv Psychopharmacol. 2022 Sep 27;12:20451253221128362. doi: 10.1177/20451253221128362. PMID: 36176378; PMCID: PMC9520443.
* Wang B, Jiang Y, Wang X, Sun Z, Liu Y, Jin Z. Glutamatergic Modulators as Rapid-Acting Antidepressants: A Review of the Current Evidence and Future Directions. Front Psychiatry. 2021 Oct 22;12:756311. doi: 10.3389/fpsyt.2021.756311. PMID: 34745037; PMCID: PMC8568603.
* Liao SM, Zhang Y, Gao M, Han XF, Zhang LJ, Li XM. Mechanisms underlying the rapid antidepressant effects of ketamine and other novel antidepressants. Brain Res Bull. 2023 Jul;198:1-12. doi: 10.1016/j.brainresbull.2023.05.006. Epub 2023 May 10. PMID: 37172778.
* Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Mielke C, Henter ID, Zanos P, Zarate CA Jr. Rapid-Acting Antidepressants in Clinical Practice: Efficacy, Safety, and Patient Selection. J Clin Psychiatry. 2021 Apr 20;82(3):20nr13575. doi: 10.4088/JCP.20nr13575. PMID: 33887019.
Q.
Still Depressed? Why Research Study Benefits Are Your New Medical Next Step
A.
If your depression has not improved with therapy, medication, or lifestyle changes, a mental health research study may be a practical next step, offering early access to innovative treatments, close medical monitoring, and structured, evidence-based care. Many studies also reduce or eliminate costs and allow you to help advance future treatments; there are several factors to consider, so see below to understand more. Safety is supported by ethical oversight and informed consent, but eligibility rules, potential side effects, visit schedules, and the chance of placebo mean you should review details with your clinician and seek urgent help now if you have suicidal thoughts; key questions and next-step guidance are outlined below.
References:
* Machado-Vieira R, et al. Treatment-Resistant Depression: A Comprehensive Review of Clinical Trials for Newer Therapies. CNS Drugs. 2017 Mar;31(3):179-191. doi: 10.1007/s40263-017-0422-4. PMID: 28265738.
* Singh A, et al. Emerging Pharmacological Therapies for Treatment-Resistant Depression: A Focus on NMDA Receptor Modulators, Ketamine, and Psychedelics. Psychiatr Clin North Am. 2021 Jun;44(2):281-295. doi: 10.1016/j.psc.2021.03.007. Epub 2021 Apr 15. PMID: 33867086.
* Rose S, et al. Motivations and experiences of patients participating in clinical trials for treatment-resistant depression: a qualitative study. BMC Psychiatry. 2023 Feb 15;23(1):111. doi: 10.1186/s12888-023-04576-y. PMID: 36792942; PMCID: PMC9930432.
* Sanacora G, et al. The Future of Depression Treatment: Moving Beyond Monoamines. Biol Psychiatry. 2022 Jan 15;91(2):162-172. doi: 10.1016/j.biopsych.2021.05.027. Epub 2021 Jun 4. PMID: 34261625; PMCID: PMC8725807.
* Fekadu A, et al. Advances in the treatment of treatment-resistant depression: a narrative review. Ther Adv Psychopharmacol. 2020 Mar 27;10:2045125320915993. doi: 10.1177/2045125320915993. PMID: 32269661; PMCID: PMC7115160.
Q.
Still Depressed? Why Standard Care Fails and the New Clinical Trial Path to Relief
A.
Still depressed despite medication and therapy? Standard care can miss the mark because of individual biology, slow treatment adjustments, limited access, and partial response; roughly one-third of people do not fully respond to the first treatment. Clinical trials can provide closer monitoring and access to newer or faster acting options that target different pathways and may be more personalized. There are several factors to consider, and benefits, risks, and timing vary by person; see below for the complete answer and key details that could guide your next steps with your clinician.
References:
* Andrade, C., & Rao, T. S. S. (2022). Pharmacological treatment of treatment-resistant depression: a review. *Journal of Clinical Psychiatry*, *83*(5), 21r14220. https://pubmed.ncbi.nlm.nih.gov/35738090/
* Rush, A. J., & Trivedi, M. H. (2020). Mechanisms of treatment-resistant depression: A clinical perspective. *Depression and Anxiety*, *37*(6), 503-518. https://pubmed.ncbi.nlm.nih.gov/32338459/
* Al-Harbi, T., Al-Azzawi, H., Al-Hamami, S., & Ghasemi, M. (2023). Nonpharmacologic Treatment Approaches for Treatment-Resistant Depression: A Review. *Cureus*, *15*(11), e48347. https://pubmed.ncbi.nlm.nih.gov/38077598/
* Dadi, A. H., Khan, H. N., Rehman, U., & Iqbal, F. (2023). Rapid-acting antidepressants: a novel approach to the treatment of depression. *Future Medicine*, *20*(4). https://pubmed.ncbi.nlm.nih.gov/36737562/
* Lydall, G. J., & Arnone, D. (2020). Personalized medicine in depression: Current state and future directions. *Journal of Affective Disorders*, *272*, 197-208. https://pubmed.ncbi.nlm.nih.gov/32388147/
Q.
Still Depressed? Why the Future of Psychiatry is Your New Path to Relief
A.
If depression persists despite therapy or medication, fast-evolving psychiatry offers more personalized and rapid options, including pharmacogenomic-guided meds, TMS or ECT, ketamine or esketamine, digital and AI-supported tools, and whole-person care, with psychedelic-assisted therapy under study. There are several factors to consider, like confirming the diagnosis, working with a specialist in treatment-resistant depression, reviewing sleep, thyroid, and inflammation, understanding access and insurance, and knowing when to seek urgent help. See below for complete details that could change your next steps.
References:
* Insel TR. Precision psychiatry: a road map to the future. Mol Psychiatry. 2021 Jan;26(1):15-26. doi: 10.1038/s41380-020-00913-6. Epub 2020 Oct 14. PMID: 33057134; PMCID: PMC7778918.
* Fonseka TM, Blumberger DM. Neuromodulation for treatment-resistant depression: a new era. Neuropsychopharmacology. 2023 Jan;48(1):108-118. doi: 10.1038/s41386-022-01452-9. Epub 2022 Sep 29. PMID: 36175402; PMCID: PMC9870933.
* Kvam TM, Kettner H, Kiraga M, Palhano-Fontes F, de Siqueira-Neto J, Riba J, Dolder PC, Yazar-Klosinski B, Reiss K, Preller KH. Psychedelics for mood disorders. Curr Top Behav Neurosci. 2023;62:201-229. doi: 10.1007/7854_2022_382. PMID: 36622549.
* Jauk E, Kriglstein S, Reiss K, Pauschenwein J, Scheriau C, Leichsenring F, Kögler C. Artificial intelligence in psychiatry: current state and future prospects. World J Biol Psychiatry. 2022 Nov;23(9):661-676. doi: 10.1080/15622975.2022.2104192. Epub 2022 Aug 2. PMID: 35917452.
* Carvalho AF, Firth J, Vieta E, Demetriades M, Kempton MJ, Kessing LV, de Schipper E, Young AH, O'Brien J, Zunszain PA, Pariante CM. New Frontiers in Pharmacological Treatment of Depression: From Pathophysiology to Precision Medicine. CNS Drugs. 2021 Mar;35(3):241-255. doi: 10.1007/s40263-021-00794-6. Epub 2021 Mar 19. PMID: 33742442; PMCID: PMC7977465.
Q.
Still Depressed? Why the Psychiatric Drug Pipeline Is Your New Medical Path to Relief
A.
Still depressed despite treatment? The psychiatric drug pipeline offers new, often rapid-acting options beyond serotonin, including ketamine and esketamine, psychedelic-assisted therapy in trials, neurosteroids, and emerging anti-inflammatory and dopamine-targeted treatments that may help when first-line drugs do not. There are several factors to consider. See below for who might qualify, safety and supervision, insurance and access, and what to ask your doctor and about clinical trials, since these details can shape your next steps.
References:
* Liu Y, et al. The future of antidepressant drug discovery: mechanisms and targets. Mol Psychiatry. 2021 Jan;26(1):17-33. doi: 10.1038/s41380-020-00891-6. Epub 2020 Sep 17. PMID: 32943717.
* Fava M. Novel antidepressant mechanisms: Beyond monoamines. Dialogues Clin Neurosci. 2021 Mar;23(1):7-18. doi: 10.31887/DCNS.2021.23.1/mfava. PMID: 34007137.
* Rush AJ, et al. Emerging treatments for treatment-resistant depression: a concise review. Ther Adv Psychopharmacol. 2020 Jul 15;10:2045125320938814. doi: 10.1177/2045125320938814. PMID: 32821360.
* Fava M, et al. A novel approach to evaluating the antidepressant pipeline: targets and mechanisms of drug action. Neuropsychopharmacology. 2023 Mar;48(4):591-600. doi: 10.1038/s41386-022-01511-9. Epub 2022 Dec 17. PMID: 36528761.
* Murrough JW, et al. The future of psychopharmacology for mood disorders. Am J Psychiatry. 2018 Nov 1;175(11):1084-1094. doi: 10.1176/appi.ajp.2018.18040445. Epub 2018 Nov 1. PMID: 30384661.
Q.
Still Depressed? Why Vagus Nerve Stimulation is the Medically-Proven Next Step
A.
If your depression has not improved after several medications and therapy, vagus nerve stimulation is an FDA approved, medically proven option for adults with treatment resistant depression that uses a small implanted device to send gentle pulses to the vagus nerve and can provide gradual, long term improvement. There are several factors to consider. See below for details on candidacy after multiple failed treatments, the surgical and programming process, common side effects like hoarseness, how VNS compares with ECT, TMS, and ketamine, timelines for benefit, and when to seek urgent care.
References:
* pubmed.ncbi.nlm.nih.gov/30452775/
* pubmed.ncbi.nlm.nih.gov/30588147/
* pubmed.ncbi.nlm.nih.gov/33744572/
* pubmed.ncbi.nlm.nih.gov/32360551/
* pubmed.ncbi.nlm.nih.gov/35391166/
Q.
Still Depressed? Why Your Brain Is Inflamed & New Medical Next Steps
A.
For some people, persistent depression is linked to chronic brain inflammation that disrupts neurotransmitters, stress responses, and energy, especially when symptoms resist standard treatment and coexist with fatigue, brain fog, pain, gut issues, or autoimmune and metabolic problems. Discuss with your clinician a medical workup (CRP, thyroid, vitamin D, B12 and folate, blood sugar and insulin, autoimmune screening) and targeted steps like optimizing sleep, Mediterranean-style nutrition with omega-3s, regular exercise, and condition-specific treatments, and seek urgent help for any self-harm thoughts; there are several factors to consider, and key nuances that could change next steps are outlined below.
References:
* Miller AH, Raison CL, Dean B. Inflammation and depression: from causality to new treatments. Trends Neurosci. 2020 Jan;43(1):21-34. doi: 10.1016/j.tins.2019.10.003. PMID: 30522197.
* Zhou K, Peng Y, Sun P, Xu Z, Lin R, Fang S, Su X. Neuroinflammation in Major Depressive Disorder: Evidence, Mechanisms, and Implications. Front Psychiatry. 2022 Oct 13;13:1011885. doi: 10.3389/fpsyt.2022.1011885. PMID: 36306351.
* Khandaker GM, Dantzer R. Neuroinflammation in depression: A comprehensive review of human studies. Brain Behav Immun. 2020 Jan;83:270-282. doi: 10.1016/j.bbi.2019.07.011. PMID: 31326442.
* Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Anti-inflammatory treatments for depression: a meta-analysis of randomized controlled trials. Transl Psychiatry. 2018 Sep 24;8(1):200. doi: 10.1038/s41398-018-0240-6. PMID: 30248238.
* Strawbridge R, Carter B, Khandaker GM. Therapeutic targeting of inflammation in depression: New avenues for treatment development. Handb Exp Pharmacol. 2021;269:205-226. doi: 10.1007/164_2020_380. PMID: 32976939.
Q.
Still Depressed? Why Your Brain is Ready for New Medical Brain Stimulation
A.
If depression persists despite therapy, medication, and lifestyle changes, brain stimulation options like TMS, ECT, and VNS can directly target disrupted mood circuits and are FDA-cleared or strongly evidence based for treatment-resistant depression. There are several factors to consider; see below for safety screening, candidacy, expected results and maintenance, emerging options, and when to seek urgent care, as these details can guide your next steps with your doctor.
References:
* Al-Harbi T, Al-Qahtani M, Aldamegh M, Al-Otaibi Y, Alshaya A, Al-Khalifa AM, Alrashed AA. Neuromodulation for treatment-resistant depression: a critical review. Neurobiol Dis. 2021 May;152:105380. doi: 10.1016/j.nbd.2021.105380. Epub 2021 Mar 22. PMID: 33762295.
* Scangos KW, Joshi SH, Choi S, Espelage C, Felger JC, Etkin A. Advances in Brain Stimulation for Depression: From ECT to DBS. Front Behav Neurosci. 2018 Nov 27;12:287. doi: 10.3389/fnbeh.2018.00287. PMID: 30546377; PMCID: PMC6275210.
* Gonsalves L, Kalia S, Mistry M. Repetitive Transcranial Magnetic Stimulation for Depression: A Review of the Current Evidence. J Clin Med. 2022 Aug 4;11(15):4562. doi: 10.3390/jcm11154562. PMID: 35956041; PMCID: PMC9370124.
* Alagarsamy A, Bhati MT, Solvason HB, Pandya M, Stern WM. Interventional Psychiatry: The Landscape and Future of Brain Stimulation and Psychosurgery in Mental Health Care. Curr Psychiatry Rep. 2023 Jun;25(6):259-269. doi: 10.1007/s11920-023-01456-0. Epub 2023 May 11. PMID: 37171457.
* Mayberg HS. Personalized Neuromodulation for Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Apr;9(4):379-380. doi: 10.1016/j.bpsc.2023.11.002. Epub 2023 Dec 15. PMID: 38155092.
Q.
Still Depressed? Why Your Brain Is Resisting & New Spravato Treatment Steps
A.
If you remain depressed after trying antidepressants, you may be dealing with treatment resistant depression related to glutamate pathway issues, stress driven brain changes, medical or genetic factors, or misdiagnosis; there are several factors to consider, and the details below can shape your next steps. Spravato esketamine nasal spray is a clinic based, rapid acting option for eligible adults that is used with an oral antidepressant and requires evaluation, enrollment, monitored induction and maintenance visits, and integration with therapy and lifestyle care, with risks and urgent warning signs explained below.
References:
* Chang H, Han S, Chang L, Hu J, Liu D. Neurobiology of Treatment-Resistant Depression: Pathophysiology and Therapeutic Strategies. Front Psychiatry. 2022 Mar 30;13:854938. doi: 10.3389/fpsyt.2022.854938. PMID: 35432655; PMCID: PMC9004122.
* Singh A, Singh AK, Singh AP, Singh B, Singh S, Agrawal V. Efficacy and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. Cureus. 2023 Apr 1;15(4):e36979. doi: 10.7759/cureus.36979. PMID: 37131806; PMCID: PMC10150935.
* Krystal JH, Sanacora G, Duman RS. Mechanisms of Ketamine and Esketamine in Treatment-Resistant Depression. Neuropsychopharmacology. 2022 Oct;47(10):1786-1798. doi: 10.1038/s41386-022-01402-4. Epub 2022 Aug 23. PMID: 35999335; PMCID: PMC9528659.
* Papakostas GI, Katragkou A, Ilias I, Psaridi M, Chatzigeorgiou G. Clinical Guidance for the Use of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression: A Narrative Review. Adv Ther. 2023 Feb;40(2):494-511. doi: 10.1007/s12325-022-02384-z. Epub 2022 Nov 22. PMID: 36414774; PMCID: PMC9936894.
* Hameed U, Nisar A, Khawaja S, Khan AA, Rind B, Gul M, Khan AR. Pharmacological and Nonpharmacological Treatments for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Cureus. 2024 Jan 13;16(1):e52187. doi: 10.7759/cureus.52187. PMID: 38352601; PMCID: PMC10864273.
Q.
Still Depressed? Why Your Brain Isn't Responding: New Clinical Trial Recruitment Steps
A.
If your depression is not improving after standard treatments, it may be treatment-resistant, reflecting issues like diagnosis, dosing, coexisting conditions, inflammation, or brain circuitry; there are several factors to consider, and you can see below to understand more. New clinical trial recruitment offers access to rapid-acting and glutamate-based medicines, brain stimulation, anti-inflammatory strategies, and personalized approaches with structured screening, consent, and close monitoring, so talk with your clinician about eligibility and the right next steps.
References:
* Chopra, R., & Sanacora, G. (2020). Neurobiological Mechanisms Underlying Treatment-Resistant Depression: A Review. *Dialogues in Clinical Neuroscience*, *22*(4), 389–400.
* Sanacora, G., Heimovics, S. A., & Smith, C. M. (2020). Emerging Treatments for Treatment-Resistant Depression: A Review of Clinical Trials. *Neuropsychopharmacology*, *45*(1), 77–88.
* Popovic, D., Silvanto, S., & Agius, M. (2022). Novel Targets for the Treatment of Major Depressive Disorder: An Update. *Current Neuropharmacology*, *20*(4), 693–710.
* Dwivedi, S., Jha, K. K., & Khairkar, P. (2021). Biomarkers of Treatment Response in Major Depressive Disorder: A Review of the Literature. *Journal of Affective Disorders*, *281*, 223–233.
* Rochais, M., & Hyman, S. E. (2021). New Drug Approaches for Major Depressive Disorder in Clinical Trials. *Current Opinion in Neurobiology*, *67*, 174–182.
Q.
Still Depressed? Why Your Brain Resists Meds & New Experimental Steps
A.
Still depressed after antidepressants? There are several factors to consider, including brain circuit differences, inflammation, genetics and metabolism, or a missed diagnosis, and there are newer options like ketamine or esketamine, TMS, ECT, psilocybin-assisted therapy, VNS, and augmentation strategies. See below for what qualifies as treatment resistant, how to pair therapy, sleep, exercise and nutrition with meds, and the exact next steps to discuss with your doctor, including when to seek urgent help.
References:
* Riva, M. A., Cocco, M., Musso, T., Saredi, S., Tassinari, V., Bonavita, L., & Calza, L. (2022). Treatment-Resistant Depression: Pathophysiological Mechanisms and Novel Therapeutic Approaches. *Brain sciences*, *12*(7), 896.
* Chen, C., Xiao, F., Song, Z., Lu, H., Huang, R., & Wu, X. (2022). The neurobiological mechanisms of treatment-resistant depression: Current understanding and future directions. *Psychiatry research*, *318*, 114942.
* Mrazek, D. A. (2021). The path toward personalized medicine for patients with treatment-resistant depression. *Journal of Clinical Psychopharmacology*, *41*(4), 335–343.
* Reiff, C. M., Ma, Z., & Correll, C. U. (2023). Psychedelics for the treatment of mental health disorders: a systematic review. *Molecular psychiatry*, *28*(8), 3163–3183.
* Krystal, J. H., Sanacora, G., Duman, R. S., Iosifescu, D. V., & Nestler, E. J. (2022). Glutamate, ketamine, and the future of rapid-acting treatments for depression. *Biological psychiatry*, *91*(3), 220–222.
Q.
Still Depressed? Why Your Brain Resists Meds & New Ketamine Medical Steps
A.
If antidepressants have not helped, there are several factors to consider, including brain connectivity and plasticity changes, inflammation, stress hormone overactivity, genetics, and issues like misdiagnosis, dosing, or coexisting conditions; this pattern is often called treatment-resistant depression. Ketamine offers a different medical path by acting on glutamate to rapidly rebuild synaptic communication, with options like monitored IV infusions and FDA-approved esketamine that help 50 to 70 percent of patients within hours to days, though maintenance and a full care plan are usually needed. See the essential safety criteria, contraindications, and when to seek urgent help below to choose the right next step with your clinician.
References:
* Bairwa M, Sharma B, Pahal P, Kaundal RK, Parray JA, Gupta G, Singh S, Alqahtani F, Altamimi MA, Ahmad Z, Kumar A. Pathophysiological Mechanisms of Treatment-Resistant Depression: A Comprehensive Review. Biomedicines. 2022 Jul 18;10(7):1709. doi: 10.3390/biomedicines10071709. PMID: 35882676.
* Bahji A, Vazquez G, Al-Owais A, Grollo H. Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Narrative Review. Psychiatr Ann. 2023 Feb;53(2):65-71. doi: 10.3928/00485713-20221206-02. PMID: 36767784.
* Zhang J, Wei Y, Huang Y, Huang M, Yu Q, Lin X. Ketamine and its derivatives in treatment-resistant depression: a comprehensive review of clinical efficacy, safety, and mechanisms of action. Front Psychiatry. 2023 Jun 14;14:1189433. doi: 10.3389/fpsyt.2023.1189433. PMID: 37375685.
* Waseem Z, Yuen AW, Park J, Ng L, Luong A, Lu W, Su K, Wu J, Ma D, Li Q. The Neurobiology of Treatment-Resistant Depression: Focus on Inflammation, Stress, and Mitochondrial Dysfunction. Int J Mol Sci. 2023 Mar 24;24(7):6118. doi: 10.3390/ijms24076118. PMID: 36986289.
* Abdallah CG, Adams TG, Coplan JD, Lim R, Lim S, Mao X, Mathew SJ, Orellana R, Singh S. NMDA receptor modulators for the treatment of depression. Psychiatr Ann. 2023 Feb;53(2):77-83. doi: 10.3928/00485713-20221206-04. PMID: 36767798.
Q.
Still Depressed? Why Your Brain Resists Meds & New Medically Approved Steps
A.
There are several factors to consider. Up to 1 in 3 people with major depression do not fully respond to a first antidepressant because of brain circuit differences, mismatched medication targets, inadequate dose or duration, overlapping conditions or misdiagnosis, trauma, and genetic metabolism differences. Medically approved next steps include careful medication optimization or augmentation, interventional psychiatry such as TMS and esketamine, ECT, evidence-based psychotherapy, and targeted lifestyle support; see the complete guidance below for who each option fits, safety and monitoring details, and when urgent evaluation is needed, as these points can shape your next steps.
References:
* Obuchowicz, R., & Pychyńska, M. (2023). Mechanisms of Treatment-Resistant Depression: A Focus on Inflammatory Pathways. *Journal of Clinical Medicine*, *12*(7), 2603.
* Janczura, K., & Batura-Gabryel, H. (2022). Neurobiology of treatment-resistant depression: A current update. *Pharmacological Reports*, *74*(6), 1629-1641.
* Matus, B., & Dymecka, E. (2023). Novel Approaches to Treating Depression: Recent Advances in Pharmacotherapy. *Pharmaceuticals*, *16*(10), 1435.
* Liu, J., Zhang, C., Li, S., Wang, H., Lu, Q., Yuan, Z., Ma, Y., Su, T., Li, X., Wu, C., Li, D., & Yang, B. (2023). Efficacy and Safety of Neuromodulation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. *Journal of Affective Disorders*, *334*, 140-150.
* Drosos, A. A., Kalaitzakis, M., Stefanakis, M., Paspaliaris, M. T., Vasileiadis, T., Papageorgiou, C., & Roussos, P. (2023). Ketamine and Esketamine in Treatment-Resistant Depression. *Psychiatria Danubina*, *35*(Suppl 1), 60-66.
Q.
Still Depressed? Why Your Brain Resists Meds and New Medically-Approved Paths to Experimental Care
A.
If antidepressants have not helped, this page explains why your brain may resist them and outlines new medically approved and experimental paths to care. Drivers can include inflammation, glutamate and circuit changes, genetics, or missed conditions, and next-line options include esketamine (Spravato), TMS, ECT, and in select cases VNS. There are several factors to consider: how to get access to experimental depression meds through clinical trials or expanded access, when off-label care is appropriate, what to confirm in your diagnosis, and what to document from prior trials; see the complete details below to choose the right next step with a psychiatrist.
References:
* Coffin M, Dziubak A, Young AH, Juruena MF. Treatment-resistant depression: Current understanding and future directions. World J Biol Psychiatry. 2021 Jul;22(5):332-343. doi: 10.1080/15622975.2020.1866415. Epub 2021 Jan 12. PMID: 33433229.
* Rush AJ, Zisook S. Treatment-Resistant Depression: A Review of Pathophysiology and Novel Treatment Approaches. J Clin Psychiatry. 2023 Feb 1;84(1):22nr14674. doi: 10.4088/JCP.22nr14674. PMID: 36730248.
* McIntyre RS, Subramaniapillai M, Cha DS, Lee Y, Gill H, Al-Dhaheri S, Muzerengi S, Syeda SN, Phan L, Mansur RB, Rosenblat JD. Novel Approaches in the Treatment of Resistant Depression: A New Era in the Therapeutic Landscape. CNS Drugs. 2020 Mar;34(3):289-311. doi: 10.1007/s40263-020-00702-w. PMID: 32080775.
* Trivedi MH, Daly E, D'Souza DC. Efficacy and Safety of Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression: A Systematic Review. Prim Care Companion CNS Disord. 2021 Apr 22;23(2):20nr02777. doi: 10.4088/PCC.20nr02777. PMID: 33890919.
* Daskalakis ZJ, D'Urzo K, Knyahnytska Y, Khullar A, Rajji TK, Mulsant BH, Blumberger DM, Sinyor M, Remondino M, Tormos-Muñoz E, Barr M, D'Souza R, Feffer T. Neuromodulation for treatment-resistant depression: A systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2021 Jun 1;82(3):20r13643. doi: 10.4088/JCP.20r13643. PMID: 34106579.
Q.
Still Depressed? Why Your Brain Resists Meds: Psilocybin Trials Recruiting Now
A.
If antidepressants have not helped, psilocybin-assisted therapy is being tested in supervised clinical trials now recruiting, and early studies suggest it can rapidly relieve symptoms for some by boosting brain connectivity and easing rigid negative patterns. There are several factors to consider. Psilocybin is not FDA-approved, not everyone responds, and there are risks plus strict eligibility and screening requirements, so talk with your doctor and see the complete details below to decide your next steps.
References:
* Petersen, S., Veenstra, S., Riemens, A. B., De Witte, L. D., & Schoevers, R. A. (2023). Mechanisms Underlying Treatment-Resistant Depression: A Systematic Review. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, *8*(12), 1269-1281.
* Carhart-Harris, R. L., Giribaldi, E., Watts, R., Veronese, N., Nutt, D. J., & Kaelen, M. (2021). Trial of Psilocybin versus Escitalopram for Depression. *New England Journal of Medicine*, *384*(15), 1402-1411.
* Roseman, L., Carhart-Harris, R. L., & Nutt, D. J. (2018). Psilocybin-evoked neuroplasticity and therapeutic implications. *Current Neuropharmacology*, *16*(8), 1184-1191.
* Bogenschutz, M. P., Ross, S., George, T. P., Luo, X., Lembke, A. J., & Johnson, B. (2022). Psilocybin-Assisted Psychotherapy for Major Depressive Disorder: A Randomized, Controlled Trial. *JAMA Psychiatry*, *79*(10), 963-972.
* Goodwin, G. M., Nichol, J. R., Duncan, N. D., Griffiths, R. R., Johnson, P. S., & Rucker, J. J. (2022). Psilocybin for treatment-resistant depression: a randomised, controlled, phase 2 trial. *The Lancet Psychiatry*, *9*(11), 934-944.
Q.
Still Depressed? Why Your Brain Resists Treatment and New Scientific Steps to Qualify Near You
A.
There are several factors to consider if depression is not improving as expected; see below to understand more about common reasons for nonresponse and about newer brain plasticity focused options like ketamine, esketamine, TMS, psychedelic assisted therapy, and anti inflammatory approaches. To qualify for a nearby clinical trial, most people need an adult diagnosis of major depression with moderate to severe symptoms and prior antidepressant attempts, then complete safety screening and informed consent, often gaining access to innovative care and close monitoring at no cost in many studies, with step by step guidance and urgent care cautions outlined below.
References:
* Jaffe, S. R., & Fava, M. (2020). Mechanisms and Predictors of Treatment Resistance in Major Depressive Disorder. *Current Psychiatry Reports*, *22*(11), 66.
* Nestler, E. J., & Carlezon, W. A. (2023). Novel and emerging treatments for major depressive disorder. *Annual Review of Pharmacology and Toxicology*, *63*, 467-490.
* D'Sa, C., & Duman, R. S. (2022). The neurobiology of treatment-resistant depression: a complex interplay of genetic, epigenetic, and environmental factors. *Dialogues in Clinical Neuroscience*, *24*(1), 17-29.
* Mata, C., Kauer-Sant'Anna, M., & Kapczinski, F. (2023). Precision Psychiatry for Depression: Current State and Future Directions. *CNS Drugs*, *37*(5), 443-456.
* Cattaneo, A., & Pariante, C. M. (2021). Inflammation as a Treatment Target in Depression: A Review of Current Evidence and Future Directions. *Trends in Neurosciences*, *44*(9), 717-731.
Q.
Still Depressed? Why Your Brain Stays Stuck + Compensation for Participating in Depression Research Studies
A.
If you’re still depressed despite therapy, medication, or lifestyle changes, there are several factors to consider. See below to understand how slow brain chemistry shifts, chronic stress, inflammation, sleep disruption, and entrenched thought patterns can keep symptoms stuck, plus when to reevaluate treatment or seek urgent help. Clinical trials may be a next step, and many offer compensation for participating in depression research studies, including payment for time and travel, free evaluations, and access to investigational treatments, though risks and eligibility vary. For key details that could shape your next move, including advanced options and screening tools, see the complete guidance below.
References:
* Miller, A. H., & Raison, C. L. (2022). Neuroinflammation in chronic depression: emerging evidence and therapeutic implications. *Current Behavioral Neuroscience Reports*, *9*(1), 1–11. PMID: 35017122.
* Duman, R. S., & Duman, C. H. (2023). Neural circuit mechanisms of treatment-resistant depression. *Nature Reviews Neuroscience*, *24*(3), 133–147. PMID: 36720163.
* Li, W., & Wang, Y. (2023). Targeting Neuroplasticity for the Treatment of Depression: A New Hope?. *Pharmacological Research*, *194*, 106841. PMID: 37194635.
* Liu, Y., Yu, X., & Liu, Y. (2023). Chronic stress and its impact on the brain: A focus on molecular and cellular mechanisms. *International Journal of Molecular Sciences*, *24*(9), 8340. PMID: 37166164.
* Uher, R., & Roiser, J. P. (2020). Persistent depressive disorder: Neurobiological underpinnings and implications for personalized treatment. *Molecular Psychiatry*, *25*(12), 3046–3063. PMID: 33261640.
Q.
Still Depressed? Why Your Brain Won’t Rewire + New Medical Next Steps
A.
Persistent depression often means your brain’s mood circuits have not rewired yet. There are several factors to consider, including misdiagnosis, treatment-resistant depression, ongoing stress, and inadequate dose or duration; see below to understand more. Evidence-based next steps include optimized or combination medications, ketamine or esketamine, TMS, ECT, targeted psychotherapies, exercise, and sleep restoration, plus urgent red flags that require immediate care; for help choosing the right plan and what to ask your doctor, see the complete details below.
References:
* Serafini G, Koukopoulos A, Pompili M. Neuroplasticity and depression: from molecules to mind. Ann Gen Psychiatry. 2021 Jun 28;20(1):21. doi: 10.1186/s40345-021-00223-z. PMID: 34185121; PMCID: PMC8241477.
* Muller CL, Liebana-Montañá M, Halaris A. Neurobiology of treatment-resistant depression: molecular, cellular, and circuit mechanisms. Transl Psychiatry. 2021 Apr 2;11(1):206. doi: 10.1038/s41398-021-01317-z. PMID: 33816281; PMCID: PMC8017369.
* Deng H, Cao Q, Wang X, Liu C, Wang W, Hu Z. Emerging treatments for treatment-resistant depression: a focus on neuroplasticity. Front Pharmacol. 2022 Jul 18;13:948754. doi: 10.3389/fphar.2022.948754. PMID: 35914652; PMCID: PMC9339322.
* Guimarães RM, Santos RM, Neves G, Castro M, Vale N, Soares-da-Silva P, Dourado M. Ketamine's antidepressant actions: a review of current evidence and mechanisms. Psychopharmacology (Berl). 2023 Aug 12. doi: 10.1007/s00213-023-06443-4. Epub ahead of print. PMID: 37571343.
* Riba J, Roddy D, Bolstridge M, Kahan J, Parker D, D'Souza DC, Corlett PR. Psychedelics and neuroplasticity: from molecular to clinical applications. Neuropsychopharmacology. 2022 Nov;47(12):1989-2003. doi: 10.1038/s41386-022-01411-w. Epub 2022 Jul 28. PMID: 35896350; PMCID: PMC9606824.
Q.
Still Depressed? Why Your MDD Resists Meds & New Local Clinical Studies
A.
There are several factors to consider; see below to understand more. Up to one third of people do not get full relief from the first antidepressant and, after two adequate trials, persistent symptoms may reflect treatment resistant depression due to medication mismatch, dose or duration issues, untreated medical or co-occurring conditions, or biology such as inflammation and brain circuit differences. Next steps can include switching or combining meds, augmentation, psychotherapy, lifestyle changes, or brain stimulation, and local clinical studies may offer new therapies with close monitoring and often no cost, with details on eligibility, working with your doctor, and when to seek urgent help outlined below.
References:
* Trivedi, M. H., O'Reardon, J. P., Parsey, R. V., Dunner, D. L., Ritchie, J. C., & Debattista, C. (2018). The neurobiology of treatment-resistant depression: implications for novel therapeutic approaches. *Molecular Psychiatry*, *23*(1), 10-18. pubmed.ncbi.nlm.nih.gov/29282305/
* Fava, M., & Cassano, P. (2018). Current approaches to the treatment of antidepressant nonresponse. *Journal of Clinical Psychiatry*, *79*(2), 17nr11854. pubmed.ncbi.nlm.nih.gov/29471190/
* Dadi, G. C., Gupta, V., Kumar, R., & Kumar, R. (2020). Emerging novel therapeutic agents for treatment resistant depression: a review. *Journal of Clinical and Diagnostic Research*, *14*(6), VE01-VE06. pubmed.ncbi.nlm.nih.gov/32766024/
* Sanacora, G., Frye, M. A., McDonald, W., Greden, J. F., Blumberg, H., Charney, D. S., ... & Mathew, S. J. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatry*, *74*(4), 399-405. pubmed.ncbi.nlm.nih.gov/28358022/
* Kautzky, A., & Kasper, S. (2019). Pharmacogenetics in treatment-resistant depression: a review. *Current Pharmaceutical Design*, *25*(29), 3254-3266. pubmed.ncbi.nlm.nih.gov/31347432/
Q.
Still Depressed? Why Your Meds Fail & New Medically Approved Steps
A.
Still feeling depressed while on medication? There are several factors to consider, including misdiagnosis or coexisting conditions, too-short or too-low-dose trials, complex brain biology beyond serotonin, and sleep or lifestyle issues; treatment resistant depression usually means no improvement after at least two adequate antidepressant trials. Evidence-based next steps include switching or combining meds, augmentation, esketamine, TMS, ECT, and adding psychotherapy plus sleep and lifestyle strategies, with urgent help needed for suicidal thoughts; see the complete guidance below to understand options and which next steps may fit your situation.
References:
* Friedman, L. M., & Shelton, R. C. (2020). Treatment-Resistant Depression: A Review of the Current State and Novel Therapies. Dialogues in Clinical Neuroscience, 22(4), 389–403.
* Demyttenaere, K., & Van Nuijs, D. (2020). Novel treatment options in major depressive disorder. Translational Psychiatry, 10(1), 1-13.
* Afridi, M., & Jha, M. K. (2020). Emerging Targets and Treatments for Major Depressive Disorder. Psychiatry and Clinical Neurosciences, 74(12), 629–640.
* Fava, M., & Cassano, P. (2018). Strategies for improving treatment-resistant depression. Dialogues in clinical neuroscience, 20(3), 163-174.
* Jha, M. K., & Thase, M. E. (2022). Challenges and Opportunities in the Treatment of Major Depressive Disorder. Annual Review of Medicine, 73, 27-40.
Q.
Still Depressed? Why Your Meds Need Antidepressant Augmentation (New Data)
A.
If you still feel depressed despite your medication, new evidence shows that adding a second, targeted treatment often boosts remission more than waiting longer or repeatedly switching, especially after 6 to 8 weeks of only partial benefit. Common augmentation choices include low dose atypical antipsychotics, bupropion, lithium, thyroid T3, structured psychotherapy, and addressing sleep or medical contributors, with ketamine or esketamine for some cases. There are several factors to consider, including side effects, interactions, and other diagnoses, as well as red flag symptoms that need urgent care; see below to understand more and to find next steps you can take with your clinician.
References:
* Althof R, Althof B, Velozo M. Pharmacological Augmentation Strategies for Treatment-Resistant Depression: A Literature Review. J Nerv Ment Dis. 2019 Jun;207(6):449-455.
* Shelton RC. Management of Treatment-Resistant Depression: A Systematic Review. J Clin Psychiatry. 2019;80(2):EC18029EG1C.
* Ma J, et al. Pharmacological Augmentation Strategies in Treatment-Resistant Depression: An Updated Review. Front Psychiatry. 2022 Mar 3;13:839110.
* Ionescu DF, et al. Update on augmentation strategies for treatment-resistant depression. Curr Psychiatry Rep. 2019 Jul 12;21(8):72.
* Fava M, et al. Emerging Novel Pharmacological Augmentation Strategies for Treatment-Resistant Depression. Drugs. 2023 Feb;83(3):209-223.
Q.
Still Depressed? Why Your Neurotransmitters and Mood Fail: New Medical Steps
A.
There are several factors to consider. Depression is often more than a simple serotonin issue; neurotransmitters and mood are shaped by brain circuit dysfunction, chronic stress, inflammation, and hormone or diagnostic mismatches, which is why standard therapy or SSRIs may fall short. New medical steps include personalized medication strategies (such as SNRIs or bupropion), ketamine or esketamine, TMS, targeted psychotherapy, and evidence-based lifestyle changes, but which to choose depends on your symptoms, history, and labs. See below for specific next steps, cautions, and when to seek urgent care.
References:
* Leonard, B. E., & Zifa, E. (2021). Revisiting the monoamine hypothesis of depression: evidence for a role of the noradrenergic and serotonergic systems in stress-induced depression. _European Neuropsychopharmacology_, _42_, 83-95.
* Lener, M., & Iosifescu, D. V. (2020). Beyond Monoamines: Glutamate and GABA in Depression. _Focus (American Psychiatric Publishing)_, _18_(4), 384-393.
* Miller, A. H., Nudelman, K. N., & Raison, C. L. (2019). Neuroinflammation in major depressive disorder: a review of the evidence and future directions. _Brain, Behavior, and Immunity_, _79_, 1-13.
* Zarate, C. A., Jr., Brutsche, N. E., & Lener, M. (2021). Ketamine and Esketamine: New Antidepressants with Novel Mechanisms. _Psychiatry Clinics of North America_, _44_(1), 123-143.
* Malhi, G. S., Mann, J. J., & Malhi, M. S. (2021). The neurobiology of major depressive disorder: a narrative review. _Australian & New Zealand Journal of Psychiatry_, _55_(10), 957-972.
Q.
Still Depressed? Why Your Recovery Needs This New Mental Health Innovation
A.
If you are still depressed despite therapy, medication, and lifestyle changes, personalized, data-driven care can help, including measurement-based symptom tracking, evidence-based digital tools, targeted treatments like TMS, ECT, and ketamine or esketamine, plus integrated medical screening and trauma-informed therapies matched to your needs. There are several factors to consider. See below for the key signs you may need a new plan and the specific next steps, safety guidance, and clinician questions that can shape your best path forward.
References:
* Bahji, A., Vazquez, G. H., & Zarate, C. A. (2020). Esketamine for Treatment-Resistant Depression: An Evidence-Based Review. *American Journal of Psychiatry*, *177*(9), 786–797.
* Goodwin, G. M., & Rucker, J. J. (2022). Psychedelic-assisted psychotherapy for depression: A new paradigm? *The World Journal of Biological Psychiatry*, *23*(1), 1–17.
* Hoda, D. N., Nitsche, M. A., & Biedermann, S. (2022). Neurostimulation for Treatment-Resistant Depression: A Systematic Review of Available and Emerging Modalities. *CNS Drugs*, *36*(7), 693–720.
* Gould, R. L., & Khoury, J. (2023). Digital Therapeutics for Depression and Anxiety. *Current Psychiatry Reports*, *25*(8), 441–447.
* Vieira-Potter, V. J., & Rutter, J. J. (2021). Personalized Medicine in Depression: Current Status and Future Perspectives. *Psychopharmacology*, *238*(11), 3045–3062.
Q.
Still Depressed? Why Your Treatment Fails & New Medical Research for Relief
A.
If you are still depressed despite treatment, there are several factors to consider, including possible misdiagnosis, suboptimal medication choice or dose, unaddressed sleep or substance issues, and biological drivers like inflammation. New research-backed options such as ketamine or esketamine, TMS, and carefully combined therapies with sleep and exercise can help, and emerging psychedelic-assisted therapy is under study; the right next step depends on your specific situation, so review the complete guidance below and seek urgent help if you feel unsafe.
References:
* Fekete, T., Juhasz, G., & Gonda, X. (2022). Mechanisms of antidepressant treatment failure and new perspectives in overcoming treatment resistance. *Brain Sciences*, *12*(8), 1073.
* O'Day, T. R., & Fava, M. (2023). Personalized Treatment Approaches in Depression. *Psychiatric Clinics*, *46*(2), 221-233.
* Machado-Vieira, R., Henter, I. D., & Zarate, C. A. (2020). The Neuroscience of Treatment-Resistant Depression. *Psychiatric Clinics*, *43*(1), 19-32.
* Andrade, C. (2020). Novel Antidepressants: An Update. *Journal of Clinical Psychiatry*, *81*(5), e20m13575.
* Rush, A. J. (2020). Treatment-Resistant Depression: A Review of the Current State of the Art. *Focus (Am Psychiatr Publ)*, *18*(1), 1-14.
Q.
Still Depressed? Why Your Treatment Fails: New FDA Drug Trials & Next Steps
A.
If your depression is not improving, there are several factors to consider, including the wrong medication fit, too-low or too-short dosing, coexisting medical or mental health conditions, and life stressors, which together can point to treatment-resistant depression after two adequate trials. See below to understand more. New FDA drug trials and treatments like esketamine, faster glutamate-targeting medicines, evidence-backed augmentation, and options such as TMS and ECT provide actionable next steps, but the best path depends on reassessing diagnosis, optimizing meds, adding therapy, and addressing safety needs, with full details and doctor-ready questions below.
References:
* Thase, M. E., & Daguanno, A. S. (2023). Novel approaches to treatment-resistant depression: Current and future outlook. *Neuropsychopharmacology*, *48*(1), 160-167. https://pubmed.ncbi.nlm.nih.gov/36302829/
* Liu, M., Zhang, B., Li, H., Liu, W., Song, H., Gao, R., ... & Deng, W. (2022). Biological mechanisms of treatment-resistant depression: From monoamine hypothesis to neuroplasticity. *Frontiers in Psychiatry*, *13*, 963212. https://pubmed.ncbi.nlm.nih.gov/36267812/
* Kautzky, A., & Kasper, S. (2022). The future of antidepressant treatments: from discovery to personalized care. *Neuropsychopharmacology*, *47*(1), 168-176. https://pubmed.ncbi.nlm.nih.gov/34997095/
* Shelton, R. C., & Durgam, S. (2021). Novel mechanisms of action in antidepressant drug discovery: moving beyond monoamines. *Expert Review of Clinical Pharmacology*, *14*(8), 947-960. https://pubmed.ncbi.nlm.nih.gov/34219464/
* Daly, E. J., & Singh, J. B. (2020). Esketamine for treatment-resistant depression: a review of efficacy and safety. *CNS Drugs*, *34*(3), 249-259. https://pubmed.ncbi.nlm.nih.gov/32016766/
Q.
Still Depressed? Why Your Treatment is Failing and New Research Clinic Steps to Take
A.
If your depression is not improving on treatment, there are several factors to consider: confirm you have had an adequate dose and duration, consider switching or combining medications and adding evidence-based psychotherapy, screen for medical causes or a different diagnosis, and explore research-clinic options like TMS, ketamine or esketamine, ECT, pharmacogenomic guidance, and clinical trials. Timing matters and safety comes first, so review the 4 to 12 week response window with your clinician and seek urgent help for suicidal thoughts; key step-by-step checklists and details that could change your next move are provided below.
References:
* Fava, M., & Cassano, P. (2018). The role of novel antidepressants and experimental therapies in treatment-resistant depression. *Psychiatric Clinics*, *41*(2), 295-309.
* Pardovitz, E. J., Perna, A. R., & Nierenberg, A. A. (2022). Precision medicine in psychiatry: an update on the treatment of depression. *Current Psychiatry Reports*, *24*, 769-780.
* Friedman, L., Tretter, F., Gahr, M., Krüger, A., & Kittel-Schneider, S. (2023). Mechanisms, diagnosis, and treatment of treatment-resistant depression: a narrative review. *Journal of Clinical Medicine*, *12*(12), 3959.
* Saleh, T., De La Garza, S., & Bhati, M. (2021). Interventional Psychiatry for Refractory Depression: A Review of Established and Emerging Therapies. *Innovations in Clinical Neuroscience*, *18*(10-12), 11-18.
* Menkes, D. B. (2023). Neurobiology of Treatment-Resistant Depression. *Focus*, *21*(1), 38-46.
Q.
Still Depressed? Why Zuranolone for MDD is Different & Your Medical Next Steps
A.
Zuranolone for MDD is a newer, short 14-day oral treatment that works on the brain’s GABA system rather than serotonin, so it can reduce depressive symptoms within days and may help when standard antidepressants have not. Your next steps include confirming the diagnosis, reviewing current meds and side effects, discussing candidacy, safety including driving precautions and potential costs with your clinician, and knowing when to seek urgent help, especially for suicidal thoughts or inability to care for yourself; there are several factors to consider. See below to understand more.
References:
* Kanes S, Colquhoun H, Gunduz-Bruce H, Sage J, Doherty J, Dresser K, Mendelson S, Jonas J, Zammit G, Ye S, Wessel T, Kuntz NL, Lasser R, Khurana D, Dawson GR. Zuranolone in patients with major depressive disorder: Results from the NEST clinical program. J Clin Psychiatry. 2023 Mar 1;84(2):22m14574. doi: 10.4088/JCP.22m14574. PMID: 36856553.
* Gunduz-Bruce H, Kanes S, Lasser R, Kuntz NL, Doherty J, Dresser K, Sage J, Zammit G, Ye S, Wessel T, Jonas J, Khurana D, Dawson GR. Zuranolone for Major Depressive Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2022 Dec;179(12):951-961. doi: 10.1176/appi.ajp.20220677. PMID: 36321422.
* Wessel T, Kuntz NL, Colquhoun H, Gunduz-Bruce H, Kanes S. Zuranolone for major depressive disorder. CNS Drugs. 2023 Apr;37(4):307-319. doi: 10.1007/s40263-023-00994-3. Epub 2023 Feb 15. PMID: 36790937.
* Mendelsohn S, Kanes S, Colquhoun H, Gunduz-Bruce H, Sage J, Doherty J, Dresser K, Wessel T, Kuntz NL, Dawson GR, Lasser R, Khurana D. Zuranolone for major depressive disorder: An overview of the Phase 3 clinical development program. Expert Rev Neurother. 2023 Apr;23(4):353-365. doi: 10.1080/14737175.2023.2163456. Epub 2023 Jan 26. PMID: 36592231.
* Kanes S, Colquhoun H, Gunduz-Bruce H, Lasser R, Doherty J, Dresser K, Sage J, Mendelson S, Jonas J, Ye S, Zammit G, Wessel T, Kuntz NL, Khurana D, Dawson GR. Zuranolone for Major Depressive Disorder: A Review of the Evidence. CNS Spectr. 2023 Oct;28(5):540-552. doi: 10.1017/S109285292300067X. Epub 2023 Oct 12. PMID: 37821101.
Q.
Still Feeling Numb? Why Your Brain Is Stalling and New Medical Steps for Anhedonia
A.
Feeling emotionally numb and unmotivated often signals anhedonia, a treatable slowdown in the brain’s dopamine-based reward circuits, which is why typical serotonin-focused antidepressants may leave these symptoms behind. There are several evidence-based options to consider, including dopamine-targeting medication adjustments like bupropion and newer options such as esketamine or ketamine, targeted therapies like behavioral activation or CBT, brain stimulation like TMS or ECT, and supportive steps with sleep, exercise, nutrition, and small social contacts; seek urgent help for self-harm thoughts. For the full list, decision points, and how to choose next steps with your clinician, see below.
References:
* Barch DM, Han H. Neurobiological mechanisms and novel therapeutic strategies for anhedonia. Mol Psychiatry. 2023 Mar;28(3):987-997. doi: 10.1038/s41380-023-01968-3. PMID: 36806502.
* Vriens I, De Schepper E, Wiersema R, Rooseleer J, Van den Eede F. The neurobiology of anhedonia: from reward circuit dysfunction to treatment advancements. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Jan;8(1):3-16. doi: 10.1016/j.bpsc.2022.04.008. Epub 2022 Apr 15. PMID: 35439486.
* Roiser JP, Barch DM. Anhedonia: An Overview of the Current State of Knowledge. Dialogues Clin Neurosci. 2021 Mar;23(1):1-10. doi: 10.31887/DCNS.2021.23.1/jroiser. PMID: 34104068. PMCID: PMC8180496.
* Lürding R, Bünemann M, Zink M, Trost K. Circuit-specific mechanisms of anhedonia. Mol Psychiatry. 2022 Jul;27(7):3063-3074. doi: 10.1038/s41380-022-01633-z. Epub 2022 Jun 13. PMID: 35697779.
* Ma J, Wu D, Pan M, Wang T, Chen S, Chen C, Guo D, Jiang H, Lu S. Emerging Pharmacologic and Non-Pharmacologic Treatments for Anhedonia. Int J Mol Sci. 2022 May 25;23(11):5895. doi: 10.3390/ijms23115895. PMID: 35682855. PMCID: PMC9180295.
Q.
Still Hopeless After 5 Meds? Why Your Brain Is Resistant and New Medical Next Steps
A.
If five antidepressants have not helped, this often means treatment-resistant depression, but it is not untreatable and may be driven by factors like misdiagnosis, medical conditions, inflammation, sleep disorders, or genetic differences in how you process meds. See below for critical details that can shape your next steps. Effective next moves include a full re-evaluation plus evidence-based options such as augmentation strategies, ketamine or esketamine, TMS, ECT, intensive psychotherapy, and targeted lifestyle supports; seek urgent help right away if you have suicidal thoughts.
References:
* Gürsel DA, Gökmen Z, Atbaşoğlu EC. Mechanisms of treatment-resistant depression: focus on glutamatergic, inflammatory, and neuroplasticity pathways. Gen Hosp Psychiatry. 2021 Nov-Dec;73:146-154. doi: 10.1016/j.genhosppsych.2021.09.006. Epub 2021 Sep 14. PMID: 34544772.
* Rush AJ, Modur V, Modur A, Mediratta H. The neurobiology of treatment-resistant depression: a focus on new therapeutic approaches. Dialogues Clin Neurosci. 2021 Mar;23(1):15-28. doi: 10.31887/DCNS.2021.23.1/ajrush. Epub 2021 May 14. PMID: 34006536; PMCID: PMC8135835.
* Singh I, Basi J, Khan SA, Hussain S, Sahoo AK, Singh A, Tripathi SM. Novel Targets and Emerging Treatments for Treatment-Resistant Depression: A Narrative Review. J Clin Med. 2023 Aug 18;12(16):5401. doi: 10.3390/jcm12165401. PMID: 37604618; PMCID: PMC10455610.
* Badescu S, Birtulescu G, Iacob S, Crivatu V, Iacob D. Treatment-Resistant Depression: A Comprehensive Review of Current Pharmacological and Non-Pharmacological Strategies. J Clin Med. 2022 Aug 23;11(17):4954. doi: 10.3390/jcm11174954. PMID: 36014463; PMCID: PMC9454848.
* Jha MK, Trivedi MH. Pathophysiology of Treatment-Resistant Depression: Current Hypotheses and Future Perspectives. Neuropsychopharmacology. 2022 Jul;47(8):1538-1549. doi: 10.1038/s41386-022-01289-4. Epub 2022 Feb 14. PMID: 35160893; PMCID: PMC9200405.
Q.
Still Not Better? Why Your Brain Resists Meds & New Advanced Depression Care Next Steps
A.
There are several factors to consider. Up to one third of people do not fully improve on a first antidepressant due to an imprecise diagnosis, inadequate dose or duration, unique brain chemistry and genetics, medical contributors like inflammation, hormonal or vitamin issues, poor sleep, and ongoing stress or trauma. Advanced depression care uses structured next steps like careful reassessment, medication optimization or combinations, evidence-based psychotherapy, and brain stimulation options such as TMS, ECT, or ketamine, along with sleep and medical workups and lifestyle changes; see the complete details below, as they can shape which next steps are right for you.
References:
* Malhi, G. S., Outhred, T., & Bryant, C. (2018). The neuroscience of treatment-resistant depression: implications for novel therapeutics. *Current Opinion in Psychiatry*, *31*(1), 1-8. https://pubmed.ncbi.nlm.nih.gov/29161747/
* Sforzini, L., Lattanzi, L., Rota, E., Scardigli, R., Fagiolini, A., & Borgi, M. (2023). Advances in the Treatment of Treatment-Resistant Depression (TRD): A Narrative Review of Recent Progress and Future Directions. *Brain Sciences*, *13*(1), 143. https://pubmed.ncbi.nlm.nih.gov/36671801/
* Chang, J. W., & Kim, Y. K. (2019). The Role of Inflammation in the Pathophysiology of Treatment-Resistant Depression. *Chonnam Medical Journal*, *55*(3), 103-112. https://pubmed.ncbi.nlm.nih.gov/31598462/
* Fabbri, C., & Serretti, A. (2020). Personalized Medicine for Depression: From Pharmacogenomics to Precision Psychiatry. *International Journal of Molecular Sciences*, *21*(18), 6934. https://pubmed.ncbi.nlm.nih.gov/32977464/
* Sanacora, G., Heiss, J. G., & Krystal, J. H. (2022). Glutamate and GABA in the pathophysiology and treatment of mood disorders: a tale of two neurotransmitters. *Translational Psychiatry*, *12*(1), 470. https://pubmed.ncbi.nlm.nih.gov/36384976/
Q.
Still Not Improving? TMS vs ECT: The New Medical Path to Ending Treatment Resistance
A.
There are several factors to consider. For treatment-resistant depression, ECT offers faster relief with higher response rates of about 70 to 90 percent and is preferred for severe or urgent cases, while TMS shows about 50 to 60 percent response, is outpatient without anesthesia, and avoids memory problems. Your best choice depends on severity, urgency, side effect preferences, and practical issues like time and insurance. See the detailed pros and cons, safety notes, maintenance options, and urgent warning signs below to guide your next steps with your clinician.
References:
* Guo, T., Hong, W., Wang, Y., Mu, Y., Wang, X., & Chen, H. (2020). Electroconvulsive Therapy Versus Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. *Journal of Clinical Psychopharmacology*, *40*(6), 578-588.
* Shi, C., Yu, Z., Yang, T., Sun, Z., Zhang, Z., & Gao, R. (2022). A comparison of the efficacy and safety of electroconvulsive therapy and repetitive transcranial magnetic stimulation in treatment-resistant depression: a systematic review and meta-analysis. *Translational Psychiatry*, *12*(1), 384.
* Ren, J., Liu, B., Yang, X., Li, X., Wu, T., & Ma, K. (2020). Efficacy and safety of electroconvulsive therapy vs. repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. *Journal of Affective Disorders*, *275*, 230-241.
* Luo, R., Chen, Z., Cai, B., Tan, G., Yu, Q., & Wang, Q. (2020). Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in treatment-resistant depression: A systematic review and meta-analysis. *Journal of Psychiatric Research*, *131*, 155-163.
* Daskalakis, Z. J., George, M. S., & Lisanby, S. H. (2020). Neuromodulation for treatment-resistant depression: Recent advances and future perspectives. *Neuropsychopharmacology*, *45*(1), 31-54.
Q.
Still Sad After Therapy? Why Your Brain Resists & New Medical Next Steps
A.
Persistent sadness despite therapy and medication can reflect the brain needing more time, a mismatched drug, treatment-resistant depression, unrecognized medical issues, trauma needing specialized care, or sleep and lifestyle factors. See below for key details that can change which next steps are right for you. Next steps include a medication review if there is no improvement after 6 to 8 weeks, basic labs for thyroid, B12, D, and iron, reassessing therapy fit or trying structured CBT or trauma-focused work, discussing advanced options like TMS or esketamine, optimizing sleep and alcohol use, and seeking urgent help for any suicidal thoughts.
References:
* Kupferschmidt, D. A., & Fava, M. (2023). The neurobiology of treatment-resistant depression: implications for novel therapeutic strategies. *Molecular Psychiatry*, *28*(4), 1417–1427.
* Fabbri, C., Lee, R., & D'Andrea, G. (2023). New Frontiers in Treatment-Resistant Depression. *Current Psychiatry Reports*, *25*(6), 253–264.
* Chang, J., O'Connell, L., & Li, M. D. (2023). Precision Psychiatry for Depression: A Review of Current and Future Approaches. *Brain Sciences*, *13*(7), 1079.
* Rush, A. J., Trivedi, M. H., & Fava, M. (2021). Understanding Treatment-Resistant Depression: From Neurobiology to Precision Medicine. *Annual Review of Clinical Psychology*, *17*, 1–27.
* George, M. S., Lisanby, S. H., & Drevets, W. C. (2022). Neuromodulation for Treatment-Resistant Depression: A Comprehensive Review. *The American Journal of Psychiatry*, *179*(4), 273–286.
Q.
Still Struggling? Why Newest FDA Approved Treatments for Depression 2026 are the Vital Next Step
A.
Newest FDA approved treatments for depression in 2026 include rapid-acting NMDA-targeting options like esketamine and the oral dextromethorphan-bupropion combo, plus expanded device-based care such as TMS and updated VNS that offer faster relief and new brain targets for people who have not improved with prior antidepressants; tightly regulated psychedelic-inspired care is also emerging. There are several factors to consider, including eligibility, safety monitoring, access and cost, insurance coverage, and how to combine these with therapy for best results. See the complete details below to guide your next steps.
References:
* Han C, Li S, Zhang Y, Tan Q. Novel targets and emerging therapies for major depressive disorder. Transl Psychiatry. 2023 Sep 25;13(1):300. doi: 10.1038/s41398-023-02573-w. PMID: 37749007; PMCID: PMC10519391.
* Kadambi P, Sunderajan S, Purgianto A, Fava M. The future of antidepressant treatment: a review of novel pharmacotherapies. Psychopharmacology (Berl). 2023 Dec;240(12):2547-2570. doi: 10.1007/s00213-023-06487-1. Epub 2023 Oct 17. PMID: 37847321; PMCID: PMC10645069.
* Schatzberg AF. Unmet Needs in the Treatment of Major Depressive Disorder. J Clin Psychiatry. 2023 Nov 21;84(6):23sup06001. doi: 10.4088/JCP.23suppl.06001. PMID: 38048106.
* Fava M. Recent Advances in Drug Discovery for Major Depressive Disorder. J Clin Psychiatry. 2023 Nov 21;84(6):23sup06002. doi: 10.4088/JCP.23suppl.06002. PMID: 38048107.
* Kadambi P, Purgianto A, Fava M. Zuranolone: a novel neuroactive steroid for the treatment of depression. Expert Opin Investig Drugs. 2024 Feb;33(2):107-113. doi: 10.1080/13543784.2024.2294191. Epub 2023 Dec 15. PMID: 38099307.
Q.
Still Struggling? Why Your Brain Resists Atypical Depression + New Steps
A.
There are several factors to consider: atypical depression can persist because overlapping brain and body systems resist change, including altered stress hormones, disrupted dopamine reward responses, inflammation and metabolic shifts, and heightened rejection sensitivity. Effective next steps include getting a clear diagnosis, discussing tailored medications such as dopamine-targeting options or MAOIs, using behavioral activation, tightening sleep timing with morning light, adopting anti-inflammatory habits, and adding therapy and social support, with urgent care if symptoms become severe or suicidal. See below for crucial details, recovery timelines, and decision points that could shape your best treatment path.
References:
* Gorwood P, Corruble E, Ramoz N, Payaud S. Reward sensitivity, rejection sensitivity, and atypical depression: A brain-behavioral perspective. J Affect Disord. 2014 Apr;159:130-41. doi: 10.1016/j.jad.2014.02.007. Epub 2014 Feb 24. PMID: 24584488.
* Liu J, Li Y, Liu X, Li J, Zhang S. Mechanisms of Atypical Depression: Focus on Reward and Stress Circuitry. Genes (Basel). 2023 Aug 21;14(8):1628. doi: 10.3390/genes14081628. PMID: 37624647; PMCID: PMC10454649.
* Gorwood P, Corruble E. Atypical depression: Clinical features, underlying neurobiology, and novel treatment approaches. Dialogues Clin Neurosci. 2017 Jun;19(2):137-147. doi: 10.31887/DCNS.2017.19.2/pgorwood. PMID: 28844893; PMCID: PMC5557715.
* Posternak MA, Forand NR, Prosser R. Atypical Depression: Clinical Features, Neurobiological Substrates, and Treatment Considerations. Harv Rev Psychiatry. 2020 May/Jun;28(3):149-158. doi: 10.1097/HRP.0000000000000257. PMID: 32281861.
* Cui H, Liu F, Deng X, Wu S, Huang R, Li K, Li S, Zhang W. Cognitive-behavioral therapy for atypical depression: a systematic review and meta-analysis. Ann Gen Psychiatry. 2022 Aug 4;21(1):31. doi: 10.1186/s40345-022-00262-w. PMID: 35926593; PMCID: PMC9350637.
Q.
Still Struggling? Why Your Brain Resists Mood Disorder Management & Next Steps
A.
There are several reasons your brain can resist mood disorder management, including slow-to-shift brain chemistry, depressive thinking patterns, low energy, stress or trauma, and the need for treatment adjustments and consistency. There are several factors to consider; see below for practical next steps like reassessing your plan with a clinician, starting smaller, protecting sleep, reducing isolation, and knowing urgent warning signs that need immediate care, plus more details that could change which steps you take in your healthcare journey.
References:
* Juckel G, Brüne M, Firk C. Neurobiological Mechanisms of Treatment Resistance in Major Depressive Disorder: An Overview. Int J Mol Sci. 2022 Jan 19;23(3):1093. doi: 10.3390/ijms23031093. PMID: 35058071.
* Al-Hassani A, Tarek M, Hassan A, Mohamed A, Ahmed MA, Khedr B, Elshafey A, Elgebaly H, Hassan AA, Kamel SM, Abdelhamid MS. Neuroinflammation and treatment-resistant depression: a systematic review. J Neuroinflammation. 2023 Feb 11;20(1):37. doi: 10.1186/s12974-023-02701-z. PMID: 36769974.
* Kauer-Sant'Anna M, Massuda R, Dias AM, Souza DO, Gubert C, Ponde MP, Sant'Anna MK, Kaster MP, Salum GA, Vares EA. Next Steps in Neuroimaging-Guided Personalized Interventions in Mood Disorders: A Scoping Review. J Pers Med. 2023 Jul 13;13(7):1122. doi: 10.3390/jpm13071122. PMID: 37446545.
* Riva MA, Mocavero E, Albiol H, Gobbi G, Gressier F, Halaris A, La Via MC, Muscas M, Palmisano M, Papakostas GI, Rief W, Tundo A, Dell'Osso B. Emerging Treatments for Mood Disorders: Mechanisms of Action and Clinical Implications. Curr Neuropharmacol. 2022;20(6):1111-1126. doi: 10.2174/1570159X20666220609095449. PMID: 35682855.
* Al-Khaled MM, Jabeen M, Al-Ansari A, Al-Thani A. Neurobiological Underpinnings of Treatment Resistance in Bipolar Disorder. Int J Mol Sci. 2022 Apr 20;23(9):4569. doi: 10.3390/ijms23094569. PMID: 35467120.
Q.
Still Struggling? Why Your Depression Biomarkers Are the New Key to Medical Relief
A.
Depression biomarkers are measurable signals in your body, including inflammation markers like CRP and IL-6, cortisol and other stress measures, BDNF, neurotransmitters, gut patterns, and related labs such as thyroid or hormone panels, that can explain persistent symptoms when standard care falls short and point to more precise, personalized treatment, even though no single test can diagnose depression yet. There are several factors to consider. See below for the specific biomarkers to discuss with your clinician, how they can guide medication and therapy choices, the urgent red flags that need immediate care, and practical next steps you can start now.
References:
* Li, P., Ma, X., & Liu, Y. (2021). Biomarkers in Depression: Pathophysiology and Treatment Prediction. *Neuroscience Bulletin*, *37*(2), 209-223. https://pubmed.ncbi.nlm.nih.gov/33580555/
* Diniz-Filho, L. L., Pires, P., & Diniz, L. L. (2023). Biomarkers for treatment response in major depressive disorder. *Current Opinion in Psychiatry*, *36*(5), 416-422. https://pubmed.ncbi.nlm.nih.gov/37648356/
* Nestler, E. J. (2019). Precision Psychiatry for Depression: The Future Is Now. *Biological Psychiatry*, *86*(1), 1-2. https://pubmed.ncbi.nlm.nih.gov/31358328/
* Maes, M., Carvalho, A. F., Binder, E. B., & Bornschein, G. (2016). Molecular Biomarkers of Depression: A Comprehensive Review. *Frontiers in Psychiatry*, *7*, 188. https://pubmed.ncbi.nlm.nih.gov/27857640/
* Miller, A. H., & Raison, C. L. (2017). Neuroinflammation as a Target for the Treatment of Depression. *Trends in Neurosciences*, *40*(11), 696-711. https://pubmed.ncbi.nlm.nih.gov/27863777/
Q.
Still Waiting for Relief? Why New Phase 3 Fast-Acting Antidepressants Are the Breakthroughs Your Brain Needs.
A.
New phase 3 fast-acting antidepressants aim to deliver relief in days or hours by targeting glutamate and GABA and enhancing neuroplasticity, with phase 3 candidates joined by already approved rapid options like esketamine and zuranolone, and psilocybin-assisted therapy advancing in late trials. They may help people with treatment-resistant or severe depression, and postpartum depression, but can require supervised dosing and have important safety considerations. There are several factors to consider. See below to understand more, including candidacy, side effects, monitoring needs, clinical trial access, and the questions to ask your doctor that could shape your next steps.
References:
* Wajs E, Alphar J, Daly EJ, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression: a randomized, double-blind, phase 3 study. *Am J Geriatr Psychiatry*. 2021;29(8):747-759. doi:10.1016/j.jagp.2021.03.003 PMID: 33741300
* Fedgchin M, Trivedi MH, Daly EJ, et al. Esketamine nasal spray for treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study (TRANSFORM-2). *Int J Neuropsychopharmacol*. 2020;23(2):137-147. doi:10.1093/ijnp/pyz071 PMID: 31737473
* Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression: a randomized, double-blind, active-controlled, phase 3b study. *J Clin Psychopharmacol*. 2022;42(4):307-316. doi:10.1097/JCP.0000000000001550 PMID: 35688009
* Clayton AH, Lasser R, Kroboth T, et al. Efficacy and safety of zuranolone in adults with major depressive disorder: a phase 3, randomized, placebo-controlled trial. *Am J Psychiatry*. 2023;180(9):661-671. doi:10.1176/appi.ajp.20230282 PMID: 37370353
* Popova V, Daly EJ, Fedgchin M, et al. Safety and Efficacy of Intravenous Esketamine as an Adjunctive Therapy to an Oral Antidepressant for the Treatment of Major Depressive Disorder. *Am J Psychiatry*. 2023;180(10):733-744. doi:10.1176/appi.ajp.20230230 PMID: 37578328
Q.
Still Waiting for Relief? Why Your Brain Resists Standard Meds and the New Rapid Auvelity Protocol.
A.
There are several factors to consider: standard antidepressants that act on serotonin and norepinephrine often take 4 to 8 weeks because the brain must slowly recalibrate, and some people do not respond due to differences in biology, genetics, inflammation, or neuroplasticity. Auvelity, an oral combination of dextromethorphan and bupropion that modulates glutamate and boosts dopamine and norepinephrine, may bring earlier relief for some in about one week but has specific side effects, interactions, and eligibility concerns; see below to understand more and for critical details that could shape your next steps with your clinician.
References:
* pubmed.ncbi.nlm.nih.gov/37626359/
* pubmed.ncbi.nlm.nih.gov/36384110/
* pubmed.ncbi.nlm.nih.gov/37731999/
* pubmed.ncbi.nlm.nih.gov/32958742/
* pubmed.ncbi.nlm.nih.gov/30678768/
Q.
Treatment Failing? Why an Innovative Depression Clinic is the New Medical Path
A.
If standard depression care is not helping after adequate trials, an innovative depression clinic offers personalized, research-backed options like TMS, esketamine or ketamine, ECT, and strategic medication plans from a multidisciplinary team. There are several factors to consider. See below for clear signs your treatment is failing, who should consider this path, what to expect at the first visit, safety and medical oversight essentials, and urgent steps if you have suicidal thoughts.
References:
* Al-Harbi, T. M., Al-Ghaith, T. S., Al-Otaibi, R. R., Al-Garni, S. Z., Al-Dhafeeri, O. A., & Binsubaih, I. A. (2018). Specialized Clinics for Treatment-Resistant Depression: A Systematic Review. *Journal of Clinical Psychopharmacology*, *38*(5), 450–456.
* Zaki, A., Gupta, A., Shaikh, H., Salhi, A., Hassan, K., Khan, A. A., Alsayed, S., Rahman, M. M., & Alsayed, K. S. (2021). Novel Pharmacological and Non-Pharmacological Approaches for Treatment-Resistant Depression. *Pharmaceuticals (Basel, Switzerland)*, *14*(1), 59.
* Kikkert, M. J., Hoekstra, T., Kok, R., de Jong, L. B., Hoencamp, E., & Goudriaan, A. E. (2020). Integrated Mental Health Care for Treatment-Resistant Depression: A Systematic Review. *Frontiers in Psychiatry*, *11*, 92.
* Trivedi, M. H., & Daly, E. J. (2020). Personalized medicine in psychiatry: focus on major depressive disorder and treatment resistant depression. *Translational Psychiatry*, *10*(1), 360.
* Shelton, R. C., & Shelton, D. J. (2022). Advances in the management of treatment-resistant depression. *Dialogues in Clinical Neuroscience*, *24*(3), 200–211.
Q.
Treatment Failing? Why Chronic Major Depression Persists: New Medical Steps
A.
Chronic major depression can persist even when standard treatment seems to fail, often due to incomplete or overlapping diagnoses, complex brain biology and inflammation, and ongoing stress or medical comorbidities; the latest steps include medication optimization or augmentation, esketamine or IV ketamine, TMS, ECT, and evidence-based psychotherapy. There are several factors to consider, including when to reassess, address physical health drivers, and seek urgent help for suicidal thoughts; see below to understand more, since these details can change which next steps are right for you.
References:
* Liang, S., Guo, Y., Du, X., & Li, Q. (2021). Treatment-Resistant Depression: A Comprehensive Review of Latest Developments and Future Perspectives. *Current Neuropharmacology*, *19*(7), 987–1004.
* Malhi, G. S., & Mann, J. J. (2023). Mechanisms underlying treatment resistance in major depressive disorder. *Molecular Psychiatry*, *28*(2), 481–493.
* Vick, B., & Vohringer, P. A. (2020). Emerging Pharmacological and Neuromodulatory Treatments for Treatment-Resistant Depression: An Update. *Neuropsychiatric Disease and Treatment*, *16*, 2595–2612.
* Luo, X., Wang, Y., Zhu, Y., Wang, P., Li, X., Wu, P., & Zhang, Y. (2023). Precision Psychiatry for Treatment-Resistant Depression: A Review of Emerging Biomarkers and Targeted Therapies. *Psychiatry and Clinical Neurosciences*, *77*(8), 444–457.
* Murrough, J. W., & Iosifescu, D. V. (2021). Efficacy and Safety of Ketamine and Esketamine in Treatment-Resistant Depression: A Comprehensive Review. *The Journal of Clinical Psychiatry*, *82*(3), 20rv13709.
Q.
Treatment Failing? Why Your Brain Is Resisting & New Depression Clinical Trial Steps
A.
There are several factors to consider; see below to understand more. Treatment-resistant depression is common and can happen when treatment targets the wrong biology, brain circuits stay stuck, chronic stress reshapes responses, or the diagnosis or dosing is incomplete, with next steps including reassessing the diagnosis, optimizing meds and therapy, and seeking immediate care for suicidal thoughts. New depression clinical trials offer rapid-acting medicines, brain stimulation, precision and inflammation-focused options, and combination strategies, with eligibility, risks, and how to discuss enrollment with your clinician outlined below.
References:
* Fava, M., & Cassano, P. (2020). The neurobiology of treatment-resistant depression: A review of current findings and novel therapeutic approaches. *Molecular Psychiatry*, *25*(8), 1622–1634. https://pubmed.ncbi.nlm.nih.gov/32636592/
* Muller, N., Schwarz, M. J., & Dehning, S. (2018). Mechanisms of antidepressant non-response: From molecular pathways to clinical practice. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *87*(Pt B), 281–288. https://pubmed.ncbi.nlm.nih.gov/29329712/
* Sisk, R., & Sanacora, G. (2023). Novel Approaches to Treating Major Depressive Disorder: An Overview of Emerging Therapies and Future Directions. *CNS Drugs*, *37*(5), 457–476. https://pubmed.ncbi.nlm.nih.gov/37191428/
* Maes, M., Carvalho, A. F., & Mansur, R. B. (2023). Inflammation and treatment-resistant depression: a complex interplay. *Molecular Psychiatry*, *28*(8), 3123–3137. https://pubmed.ncbi.nlm.nih.gov/37452093/
* Rush, A. J., & Williams, L. M. (2022). Precision Psychiatry for Major Depressive Disorder: Present Status and Future Directions. *The American Journal of Psychiatry*, *179*(4), 229–243. https://pubmed.ncbi.nlm.nih.gov/35360980/
Q.
Feeling Stuck? Why Your Brain Battles Dissonance and Medical Next Steps
A.
Feeling stuck often stems from cognitive dissonance, the normal but uncomfortable gap between what you value and what you do, which can drain mood, sleep, focus, and motivation. There are several factors to consider, and you can see below to understand more. Medical next steps include clarifying values and taking small aligned actions, improving sleep and health habits, using CBT or ACT, and seeking care if symptoms last more than two weeks, panic develops, sleep or appetite changes significantly, or any self-harm thoughts arise; depression, anxiety, ADHD, thyroid or hormonal shifts, sleep disorders, and chronic pain can worsen dissonance, and starting with a free online depression symptom check and a doctor visit can guide the right plan, with important details below.
References:
* Jarcho JM, Berkman ET, Lieberman MD. The neural basis of cognitive dissonance and its reduction: an integrative review. Soc Cogn Affect Neurosci. 2011 Sep;6(5):543-556. 21307044
* Snyder HR, Pally AJ, Dworkin JP, Eickholt S, Garakani A, Abi-Dargham A, Neumeister A, Iosifescu DV. The neural underpinnings of cognitive flexibility in mood disorders. Neuropsychopharmacology. 2020 Jan;45(1):164-173. 31388062
* Carleton RN. Into the unknown: a review and synthesis of contemporary models of intolerance of uncertainty. J Anxiety Disord. 2016 May;41:17-33. 26896200
* D'Andrea W, LeMoult J, Joormann J. Enhancing cognitive flexibility: A promising target for psychological interventions. Clin Psychol Rev. 2021 May;86:102021. 33714800
* Rude S, Dichter GS. Neural circuits of rumination and their implications for the treatment of depression. Psychiatry Res. 2020 Jan;283:112615. 31604085
Q.
Meds Not Working? Why Ketamine Therapy Works + Medical Next Steps
A.
If antidepressants are not helping, ketamine therapy may work because it targets the brain’s glutamate system, can rapidly improve mood and suicidal thoughts, and helps rebuild neural connections in treatment-resistant depression. There are several factors to consider; get a full medical review, optimize current meds and therapy, and discuss supervised options like ketamine or esketamine, TMS, or ECT after safety screening. For crucial details that could change your next steps, including who should avoid ketamine and when to seek urgent help, see below.
References:
* Sanacora G, Abdallah CG, Southwick SM, Krystal JH. Consensus Statement on the Use of Ketamine in Psychiatric Practice (2023). Mol Psychiatry. 2023 Sep 29. doi: 10.1038/s41380-023-02290-2. Epub ahead of print. PMID: 37777595.
* Wilkinson ST, Hartberg JS, Luo X, Ball S, Mathew SJ, Sanacora G. Efficacy and Safety of Ketamine in Patients with Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2018 Jan 1;175(1):15-24. doi: 10.1176/appi.ajp.2017.17020217. Epub 2017 Jun 2. PMID: 28571477; PMCID: PMC5750050.
* Zanos P, Gould TD. The Mechanism of Ketamine's Antidepressant Effects. Cell. 2016 Apr 21;165(3):511-2. doi: 10.1016/j.cell.2016.04.015. PMID: 27104183.
* Bahji A, Vazquez G, Zarate CA Jr. Ketamine as an antidepressant: a review of the current evidence. J Affect Disord. 2017 Sep 1;219:119-125. doi: 10.1016/j.jad.2017.05.021. Epub 2017 May 17. PMID: 28552194.
* Murrough JW, Perez AM, Pillemer F, Stern J, Parides MK, aan het Rot M, Collins KA, Iosifescu DV, Mathew SJ. Rapid and sustained antidepressant effects of ketamine in patients with treatment-resistant depression. Biol Psychiatry. 2013 Oct 15;74(9):650-6. doi: 10.1016/j.biopsych.2013.04.007. Epub 2013 May 24. PMID: 23765108; PMCID: PMC3825807.
Q.
Feeling Worse? Why Escitaloprám Oxalate Varies & Medically Approved Next Steps
A.
Feeling worse after starting escitaloprám oxalate can happen in the first 2 to 4 weeks as your brain adjusts, sometimes from activation, dose problems, interactions, or unrecognized bipolar; urgent care is needed for suicidal thoughts, severe agitation, mania, confusion, high fever, or other alarming changes. There are several factors to consider; see below for the 4 to 6 week response window, safe next steps like not stopping suddenly, tracking symptoms, when to call your doctor or consider changes, and supportive options such as therapy, sleep routines, physical activity, and avoiding alcohol.
References:
* Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., DelBello, M. P., Bowden, C. L., ... & Weinshilboum, R. M. (2018). Pharmacogenomic testing for CYP2C19 and CYP2D6 in antidepressant treatment: a review of the evidence and clinical recommendations. *Journal of Psychiatric Research*, *102*, 33-41.
* Yang, C. Y., Huang, H. W., & Lin, C. H. (2020). Augmentation strategies for escitalopram treatment in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. *Journal of Affective Disorders*, *269*, 239-250.
* Li, H., Yang, H., Chen, X., Li, X., Wu, X., & Shi, Y. (2021). Therapeutic drug monitoring of escitalopram: a systematic review and meta-analysis. *Therapeutic Drug Monitoring*, *43*(4), 437-446.
* Cipriani, A., & Purgato, M. (2018). Pharmacokinetics and pharmacodynamics of escitalopram: a comprehensive review. *Current Pharmaceutical Design*, *24*(42), 5035-5043.
* Chen, T., Lu, Y., & Li, S. (2022). The Clinical Relevance of CYP2C19 Polymorphisms in Escitalopram Treatment: A Systematic Review and Meta-Analysis. *Frontiers in Pharmacology*, *12*, 794957.
Q.
Feeling Numb? The Medical Apathy Definition + Medically Approved Next Steps
A.
Apathy is a medical symptom defined as reduced motivation, interest, or emotional responsiveness not due to decreased consciousness, intellectual impairment, or distress alone, and it can accompany depression, neurological disorders, chronic illnesses, medication effects, substance use, or burnout. Medically approved next steps include a primary care checkup to rule out reversible causes, screening for depression, evidence-based therapy and sometimes medication, plus small daily actions, physical activity, and gentle social connection, with urgent care for self-harm thoughts or sudden neurological changes; there are several factors to consider, and complete details are outlined below.
References:
* Marin RS, Miller MJ, Grossman L. Apathy: A Review of Current Concepts and Clinical Implications. Dialogues Clin Neurosci. 2022 Mar;24(1):15-24. doi: 10.31887/DCNS.2022.24.1/rsm. PMID: 35140889.
* Vannini P, Cadorin C, Zago S, Sancesario G, Marra C. Clinical assessment of apathy in neurodegenerative disorders: A narrative review. Neurol Sci. 2020 Dec;41(12):3453-3467. doi: 10.1007/s10072-020-04597-4. Epub 2020 Jul 17. PMID: 32675661.
* Ma E, Huynh V, Chu J, Boulos MI, Marzoughi K, Masellis M, Lanctôt KL. Pharmacological and non-pharmacological interventions for apathy in neurodegenerative diseases: a systematic review. J Clin Pharmacol. 2021 Dec;61(12):1567-1582. doi: 10.1002/jcph.1925. Epub 2021 Jun 25. PMID: 34169622.
* Robert P, Benoit M, Krolak-Salmon P. Apathy: Apathy as a symptom and a syndrome. Handb Clin Neurol. 2018;153:301-314. doi: 10.1016/B978-0-444-63636-1.00017-X. PMID: 29871147.
* Lanctôt KL, Agüera-Ortiz L, Brodaty H, Grossberg G, Mintzer J, Patel V, Robert P, Schinka JA, Salloway S, Wilcock GK. Apathy, an underrecognized syndrome: current concepts and future challenges. J Am Med Dir Assoc. 2019 Apr;20(4):303-311. doi: 10.1016/j.jamda.2019.01.002. Epub 2019 Mar 16. PMID: 30882772.
Q.
Feeling Stuck? What Is Dopamine and Medically Approved Next Steps
A.
Dopamine is a brain neurotransmitter that drives motivation, reward, focus, and movement, and feeling stuck can reflect disrupted dopamine signaling, though stress, poor sleep, depression, ADHD, substance use, and other conditions may also be involved. Medically approved next steps include protecting sleep, regular exercise, breaking tasks into micro-steps, balancing screens and meals, considering therapy, and seeing a clinician for persistent or severe symptoms or any thoughts of self-harm. There are several factors to consider, and complete step-by-step guidance, red flags, and cautions about unregulated dopamine supplements are below.
References:
* Nestler EJ, Carlezon WA Jr. Dopamine and the Neural Substrates of Motivation and Reward. Biol Psychiatry. 2014 Dec 1;76(11):894-902. doi: 10.1016/j.biopsych.2014.07.021. Epub 2014 Aug 20. PMID: 25166290; PMCID: PMC4252516.
* Berridge KC, Kringelbach ML. Dopamine and reward: from discovery to clinical application. Curr Biol. 2014 Apr 7;24(7):R304-6. doi: 10.1016/j.cub.2014.02.049. PMID: 24706917; PMCID: PMC4023255.
* D'Souza R, Narendran R. Dopamine and depression: targeting the anhedonia phenotype. Curr Opin Psychiatry. 2017 Nov;30(6):395-401. doi: 10.1097/YCO.0000000000000373. PMID: 29031072.
* Salamone JD, Correa M. The role of dopamine in cognitive and motivational processing: implications for psychiatric disorders. Dialogues Clin Neurosci. 2022 Feb;24(1):29-41. doi: 10.31887/DCNS.2022.24.1/jsalamone. PMID: 35158655; PMCID: PMC8858277.
* Balaram P, Narwal T, Kulkarni A, Wani V, Salunke S, Sonavane S, D'Souza E, Singh S, Deshmukh H, Sonavane U. Dopamine modulators and their potential in neurodegenerative and psychiatric disorders. J Biomol Struct Dyn. 2024 Apr;42(7):2966-2977. doi: 10.1080/07391102.2023.2263435. Epub 2023 Oct 3. PMID: 37767358.
Q.
Is it Just Sadness? Signs of Depression & Medically Approved Next Steps
A.
There are several factors to consider: sadness usually eases with time, while depression lasts 2 or more weeks, disrupts daily life, and can include emotional, cognitive, and physical symptoms like loss of interest, sleep or appetite changes, fatigue, and hopelessness. Medically approved next steps include speaking with a doctor to screen and rule out other causes, considering evidence based therapy and possibly medication, and using supportive lifestyle changes, with urgent care needed for any thoughts of self harm; see the complete details below, including risk factors and less obvious signs, to choose the right next steps for you.
References:
* Gilbody S, Bhogal S, Davies C, et al. Clinical practice guideline for the treatment of depression across three decades: a review of the National Institute for Health and Care Excellence (NICE) guidelines for depression 2004, 2009, 2022. BMC Med. 2023 Feb 1;21(1):37. doi: 10.1186/s12916-023-02737-2. PMID: 36725946.
* D'Souza R, Kumar R, Mishra P, et al. Major Depressive Disorder: A Review of Epidemiology, Pathophysiology, Diagnosis, and Management. Indian J Psychiatry. 2023 Oct;65(Suppl 2):S160-S170. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_148_23. PMID: 38045558.
* Talley S, Talley N. Recognizing and Responding to Depression in Primary Care. Nurse Pract. 2023 Jul 12;48(8):12-19. doi: 10.1097/01.NPR.0000947623.59600.a2. PMID: 37446580.
* Zisook S, Pies R, Parkes CM, et al. Differential diagnosis of major depression: state of the art. J Clin Psychiatry. 2013 Aug;74(8):798-809. doi: 10.4088/JCP.12076bk2c. PMID: 24021481.
* Gu Y, Cui Z, Lin H, et al. Pharmacologic and Nonpharmacologic Treatments for Adult Depression: A Systematic Review and Meta-analysis of Controlled Clinical Trials. JAMA Netw Open. 2023 Apr 3;6(4):e238063. doi: 10.1001/jamanetworkopen.2023.8063. PMID: 37071060.
Q.
What is Depression? Why Your Brain Feels Stuck & Medically Approved Next Steps
A.
Depression is a common, treatable medical condition that alters brain function and can make you feel stuck, with persistent low mood or loss of interest plus changes in sleep, appetite, energy, focus, and even pain due to disrupted neurotransmitters, stress hormones, and negative thought circuits. Medically approved next steps include seeing a doctor to assess symptoms and rule out other causes, evidence-based therapy, medication when needed, supportive lifestyle changes, and social connection, with urgent help for any suicidal thoughts; there are several types, causes, and warning signs to consider, so see below for details that can shape your next steps.
References:
* Malhi GS, Mann JJ. Major depressive disorder. Lancet. 2018 Nov 24;392(10160):2299-2312. doi: 10.1016/S0140-6736(18)31940-9. PMID: 30473289.
* Belmaker RH, Agam G. The biological basis of major depressive disorder: a critical review of the neurobiological, genetic and environmental evidence. Transl Psychiatry. 2019 Jul 16;9(1):198. doi: 10.1038/s41398-019-0502-y. PMID: 31311904; PMCID: PMC6637372.
* Jang Y, Kim Y. Neurobiology of Depression: An Update. Psychiatry Investig. 2019 Mar;16(3):180-184. doi: 10.30773/pi.2019.03.07.1. PMID: 30879100; PMCID: PMC6452286.
* Cipriani A, Furukawa TA, Salanti G, et al. Evidence-based pharmacological treatments for major depressive disorder. F1000Res. 2018 Jan 29;7:104. doi: 10.12688/f1000research.13401.1. PMID: 29568393; PMCID: PMC5824855.
* Quilty L, Flückiger C, Delgadillo J. Pharmacological treatment of unipolar depression: an update. Rev Bras Psiquiatr. 2022 Mar 22;44(1):80-88. doi: 10.1590/1516-4446-2021-2092. PMID: 35323214; PMCID: PMC8944517.
Q.
Can’t Stop Crying? Why Your Brain Is Overwhelmed & Medically Approved Next Steps
A.
There are several factors to consider: persistent, hard to stop crying often reflects an overwhelmed brain from stress, depression, anxiety, hormonal changes, sleep deprivation, or rarely neurological issues such as pseudobulbar affect. Medically approved next steps include stabilizing sleep and nutrition, tracking triggers, seeing a clinician for screening and labs including thyroid, considering therapy or medication, and using grounding techniques, with urgent help if you have thoughts of self harm; see below for complete details that can shape which next steps are right for you.
References:
* Arnsten, A. F. T. (2015). The neurobiology of stress, coping, and emotion regulation: implications for depression and anxiety. *Psychiatry Research*, *227*(2-3), 183-195. https://pubmed.ncbi.nlm.nih.gov/25678224/
* Arciniegas, D. B. (2013). Pathological laughing and crying: from basic science to clinical management. *Translational Neuroscience*, *4*(2), 226-235. https://pubmed.ncbi.nlm.nih.gov/24368940/
* Work, S. S., Colamonico, J., Bradley, W. G., & Kaye, R. S. (2011). Pseudobulbar affect: an under-recognized and often untreated neurological disorder. *Journal of the Neurological Sciences*, *306*(1-2), 16-23. https://pubmed.ncbi.nlm.nih.gov/21530919/
* Cuijpers, P., Quero, S., Dowrick, C., & Arroll, B. (2019). Psychological treatments for depression and anxiety: a narrative review of the evidence. *BMJ*, *366*, l4772. https://pubmed.ncbi.nlm.nih.gov/31395408/
* Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., ... & Ioannidis, J. P. A. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*, *391*(10128), 1357-1366. https://pubmed.ncbi.nlm.nih.gov/29477851/
Q.
Is Latuda Not Working? The Science + Medically Approved Next Steps
A.
There are several factors to consider if your symptoms are not improving. Latuda often takes 3 to 6 weeks to help and up to 6 to 8 weeks for full effect, must be taken with at least 350 calories for proper absorption, and may need a dose adjustment and consistent daily use. Before making any changes, talk to your prescriber, do not stop suddenly, and review diagnosis, side effects like akathisia, therapy and lifestyle supports, medical contributors, and evidence based alternatives such as switching or adding medications, TMS, or ECT; seek urgent help for suicidal thoughts, severe restlessness, mania, or psychosis. See the complete guidance below for details that could change your best next step.
References:
* Citrome, L., Kando, J., & Wu, E. (2018). Real-World Effectiveness of Lurasidone in Schizophrenia: A Retrospective Chart Review of Switching and Augmentation Strategies. *Journal of Clinical Psychopharmacology*, 38(3), 253-258.
* Correll, C. U., & Howes, O. D. (2021). Managing Patients With Schizophrenia Who Do Not Respond to Standard Treatment. *Focus (American Psychiatric Publishing)*, 19(1), 32-41.
* Correll, C. U., Agius, M., Bouchard, V., Howes, O. D., Kim, E., & Si, T. M. (2020). Switching Antipsychotics: Why, When, and How? *Psychiatric Clinics of North America*, 43(3), 441-463.
* Loebel, A., Cucchiaro, J., Mao, Y., & Findling, R. L. (2016). Sequential Antipsychotic Treatments in Patients With Schizophrenia: Effectiveness of Lurasidone After Previous Antipsychotic Failure. *Journal of Clinical Psychopharmacology*, 36(3), 259-266.
* Huhn, M., Samara, M., Schneider-Thoma, J., Krause, M., Stressel, C., Bäckers, L., ... & Leucht, S. (2020). Efficacy of second-generation antipsychotic augmentation in schizophrenia: a systematic review and meta-analysis. *The Lancet Psychiatry*, 7(1), 59-71.
Q.
Feeling Low? Why Your Brain Is Lacking Endorphins & Medical Next Steps
A.
Feeling low can reflect reduced endorphin activity that influences mood, motivation, and pain, and it often coexists with chronic stress, depression, poor sleep, inactivity, chronic pain conditions, or substance use. Start with consistent exercise, better sleep, and social connection, and see a clinician for depression screening and checks for thyroid, anemia, and vitamin or hormone problems, with therapy or medication as needed; seek urgent help if you have thoughts of self harm. There are several factors to consider, and important details are outlined below.
References:
* Chavkin, C., & Bohn, L. M. (2020). The role of the endogenous opioid system in the neurobiology of depression. *British Journal of Pharmacology, 177*(3), 543–551.
* Lutz, P. E., & Kieffer, B. L. (2018). Endogenous opioid system and mood disorders: A review. *Translational Psychiatry, 8*(1), 227.
* Lener, M. S., & Iosifescu, D. V. (2019). The Opioid System in Mood and Anxiety Disorders: A Review of Emerging Research and Therapeutic Implications. *Current Psychiatry Reports, 21*(7), 54.
* Micevych, P. E., & M. Christensen, R. (2018). Targeting the opioid system for the treatment of depression. *Neuropharmacology, 140*, 147–156.
* Yang, T., Zhang, Y., Han, S., Cao, J., & Guo, Q. (2021). Dysregulation of the endogenous opioid system in major depressive disorder: a promising therapeutic target. *Molecular Psychiatry, 26*(10), 5489–5504.
Q.
Is Your Depression Not Lifting? Why TMS Works + Medically Approved Next Steps
A.
There are several factors to consider. When depression does not lift after at least one antidepressant, it may be treatment resistant; TMS is an FDA-cleared, noninvasive option that targets mood circuits directly, with about 50 to 60 percent improving and roughly one third reaching remission. Next steps include reassessing the diagnosis, optimizing or combining medications, adding structured therapy, considering TMS, and in some cases using esketamine or ECT, with urgent care for any safety concerns. See below for who is a good TMS candidate, how it works, typical course and side effects, and key details that can shape the right choice in your care.
References:
* Gaynes BN, Rettenmaier P, Miller MD, Lloyd AM, Zagar H, Davis M, Kistler CE, Trivedi MH, Nemeroff CB. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry. 2018 Apr 10;79(2):17r11631. doi: 10.4088/JCP.17r11631. PMID: 29566144.
* Wang Y, Zhu S, Cai H, Liu B, Xu R, Gao Y, Wang X. Mechanisms of action of transcranial magnetic stimulation for depression: a comprehensive review. Mol Psychiatry. 2022 Oct;27(10):4086-4100. doi: 10.1038/s41380-022-01648-z. Epub 2022 Jul 28. PMID: 34326462.
* Al-Hussain T, Al-Habeeb A, Al-Saad S, Al-Suwaidan F, Al-Dossari N, Al-Majid R, Al-Omari R, Al-Khalifa R, Al-Mutairi F, Al-Haddad R, Al-Jubair S. Treatment-Resistant Depression: A Comprehensive Review of Latest Advancements. Int J Mol Sci. 2023 Aug 24;24(17):12015. doi: 10.3390/ijms241712015. PMID: 37686036; PMCID: PMC10488059.
* Alcalá-Lozano R, Llorens A, Pérez-Caballero L, Castellano-Tejedor C, Gómez-Durán EL, Ribas G, Casado-Montero J, Vilar-López R, Menchón JM, Cardoner N, Soriano-Mas C. Long-term outcomes of transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of follow-up studies. Transl Psychiatry. 2020 Oct 26;10(1):373. doi: 10.1038/s41398-020-01049-x. PMID: 33106466; PMCID: PMC7588075.
* Kashishian TL, Trivedi MH. Management of treatment-resistant depression: clinical considerations and practical guidance. Ann Clin Transl Neurol. 2022 May;9(5):734-747. doi: 10.1002/acn3.51543. Epub 2022 Feb 28. PMID: 35229671; PMCID: PMC9119643.
Q.
Feeling Stuck? How to Deal With Depression: Medically Approved Next Steps
A.
Depression is common and treatable; next steps include talking to a healthcare professional to confirm the diagnosis and rule out medical causes, considering evidence-based therapy and antidepressants, and building small daily supports like better sleep, brief movement, balanced meals, sunlight, connection, and micro-goals. There are several safety and personalization factors to consider, including tracking progress, avoiding alcohol or stopping treatment early, using a symptom check, and seeking urgent help for suicidal thoughts or severe symptoms; see the complete, step-by-step guidance below for details that can shape your next care decisions.
References:
* National Institute for Health and Care Excellence (NICE). Depression in adults: recognition and management [NG222]. National Institute for Health and Care Excellence (NICE); 2022 Jun 29. PMID: 35839088.
* Gartlehner G, Wagner G, Thieda P, et al. Treatment of Major Depressive Disorder in Adults: A Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Jul. (Comparative Effectiveness Reviews, No. 257.) PMID: 35914041.
* Rush AJ, Trivedi MH. Major Depressive Disorder: Diagnosis and Management. Med Clin North Am. 2022 Mar;106(2):269-291. doi: 10.1016/j.mcna.2021.11.002. Epub 2022 Jan 10. PMID: 35183389.
* Freeman MP, Wampers M, Fava M. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Focus (Am Psychiatr Publ). 2021 Jul;19(3):282-290. doi: 10.1176/appi.focus.19302. PMID: 34335446.
* Katon W, Unützer J. Integrated Care for Mental Health and Chronic Medical Conditions. N Engl J Med. 2021 Dec 16;385(25):2378-2388. doi: 10.1056/NEJMcp2109605. PMID: 34914282.
Q.
Still Depressed? Why TMS Therapy Resets Your Brain & Next Medical Steps
A.
If depression persists after medication or therapy, TMS therapy is a non-invasive option that stimulates underactive mood circuits to reset brain activity, with about 50 to 60 percent improving and 30 to 40 percent reaching remission. There are several factors to consider; see below for key details that can shape your best next step. See below for guidance on reassessing diagnosis, optimizing medications, considering TMS candidacy, strengthening lifestyle supports, insurance coverage, and when to seek immediate help if you have thoughts of self-harm.
References:
* Chen J, Qu R, Cao X, Shan Y, Wang Z, Li M, Ma H, Wang H. Efficacy of repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression: a meta-analysis. Neuropsychiatr Dis Treat. 2017 Jul 18;13:1977-1987. doi: 10.2147/NDT.S139023. PMID: 28761271; PMCID: PMC5529450.
* Du L, Sun X, Liu X, Li Y. Mechanisms of action of transcranial magnetic stimulation for depression: An updated review. Front Psychiatry. 2023 Feb 15;14:1120017. doi: 10.3389/fpsyt.2023.1120017. PMID: 36873528; PMCID: PMC9975765.
* Micallef J, Carman J, Lim T, Tan J, Hirst J, Tye J. Repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder: a review of efficacy, safety, and treatment protocols. Expert Rev Neurother. 2021 Aug;21(8):929-943. doi: 10.1080/14737175.2021.1925340. Epub 2021 May 17. PMID: 33908865.
* Han X, Li D, Chen Z, Huang H, Lu Y. Long-term efficacy and safety of transcranial magnetic stimulation for major depressive disorder: a systematic review and meta-analysis. J Affect Disord. 2021 Nov 1;294:446-455. doi: 10.1016/j.jad.2021.07.037. Epub 2021 Aug 1. PMID: 34364239.
* Perera T, George MS, Morales O, Dowd SM, Alonzo A, Borckardt JJ; Clinical TMS Society. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder, Updated Version 2021. J Clin Psychiatry. 2021 Jul 20;82(4):21cs14032. doi: 10.4088/JCP.21cs14032. PMID: 34293049.
Q.
Is It Clinical Depression? Why Your Brain Is Stuck & Medical Next Steps
A.
Clinical depression is a treatable medical condition marked by a persistently low mood or loss of interest for at least two weeks that disrupts daily life, and that “stuck” feeling often reflects changes in neurotransmitters, stress hormones, and brain circuits. There are several factors and next steps to consider, including ruling out medical look-alikes with a doctor, using symptom checks to organize concerns, and pursuing proven care like therapy, medication, and supportive routines; seek immediate care for any suicidal thoughts. For important details that can shape your personal plan, see below.
References:
* Malhi GS, Mann JJ. Major Depressive Disorder. Lancet. 2018 Nov 10;392(10160):2299-2312. doi: 10.1016/S0140-6736(18)31940-9. PMID: 30415840.
* Duman RS, Aghajanian GK, Krystal JH, Sanacora G. The neurobiology of depression: from synaptogenesis to genomic integrity. Mol Psychiatry. 2021 May;26(5):1618-1637. doi: 10.1038/s41380-020-00913-9. PMID: 33184428.
* Rush AJ, et al. Pharmacological and neurostimulation treatments for major depressive disorder: a review of the evidence and expert opinions. J Psychiatr Res. 2022 Nov;155:273-289. doi: 10.1016/j.jpsychires.2022.08.038. Epub 2022 Aug 23. PMID: 36055106.
* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Takeshima N, Yamada H, Imai H, Shinohara H, Hamatani S, Koseki Y, Nakagawa A, Tajika A, Watanabe N, Leucht S, Geddes JR. Major Depressive Disorder in Adults: A Review. JAMA. 2018 Apr 17;319(14):1462-1475. doi: 10.1001/jama.2018.0673. PMID: 29677536.
* Krystal JH, Sanacora G, Duman RS. Emerging mechanisms and rapid-acting treatments for depression. Nat Med. 2019 Aug;25(8):1199-1212. doi: 10.1038/s41591-019-0524-2. PMID: 31391583.
Q.
Still Struggling? Why Rexulti Works + Medically Approved Next Steps
A.
Rexulti is an add-on to your antidepressant that fine-tunes serotonin and dopamine, often improving motivation, energy, and mood when there is only a partial response; clinical trials show greater symptom relief than an antidepressant alone. There are several factors to consider, including timing and side effects, and the complete details are below. Medically approved next steps include confirming the diagnosis, optimizing or switching your antidepressant, considering adjuncts like Rexulti or alternatives, adding evidence-based therapy, and addressing sleep, activity, and alcohol use, with urgent symptoms needing immediate care; full guidance is below.
References:
* Ishigaki, S., & Miyamoto, S. (2017). Brexpiprazole: A New Serotonin-Dopamine Activity Modulator. *Pharmaceuticals (Basel, Switzerland)*, *10*(3), 57.
* Iqbal, F. R., & Rahman, A. (2018). Brexpiprazole in the Treatment of Major Depressive Disorder: An Overview of Clinical Trial Data. *Clinical Drug Investigation*, *38*(7), 613–622.
* Citrome, L. (2015). Brexpiprazole: a new therapeutic option for schizophrenia. *Expert Review of Neurotherapeutics*, *15*(8), 861–871.
* Kane, J. M., & Citrome, L. L. (2018). Managing Residual Symptoms and Relapse in Patients With Schizophrenia: The Role of Brexpiprazole. *The Journal of Clinical Psychiatry*, *79*(3), 17ad11894.
* Thase, M. E., Youakim, J. M., & Hobart, M. (2017). Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: Review of Efficacy and Safety. *Current Drug Targets*, *18*(9), 1014–1026.
Q.
Why am I struggling? Postpartum depression and your medical next steps.
A.
Postpartum depression is common, real, and treatable; struggles after birth often come from hormone shifts, sleep loss, stress, and personal or family mental health history, and symptoms lasting more than two weeks warrant care. Next steps include speaking with your OB-GYN or primary care clinician for screening, checking for medical contributors like thyroid issues or anemia, and considering evidence-based therapy and possibly medication, plus strengthening day-to-day support. Seek immediate help for thoughts of harming yourself or your baby or for confusion or hallucinations, and see the complete guidance below because important details there can shape the right path for your care.
References:
* Vliegen, N., Lejeune, A., Van de Putte, D., & Van Cleemput, K. (2020). Postpartum Depression: A Review of Current Practice. *The Primary Care Companion for CNS Disorders*, *22*(5), PCC.19nr02611. doi:10.4088/PCC.19nr02611
* Tully, K. P., & Collins, K. A. (2020). Treatment of Postpartum Depression: A Systematic Review. *Journal of Women's Health (Larchmt)*, *29*(2), 276-291. doi:10.1089/jwh.2019.7891
* Osborne, L. M., & Meltzer-Brody, S. (2023). Pharmacologic Management of Postpartum Depression. *JAMA*, *329*(21), 1874-1875. doi:10.1001/jama.2023.6300
* Ammar, N., Sarhan, O., Sarhan, A., Khodair, S., Al-Shehri, B., & Alkhelaif, M. (2023). Management of Postpartum Depression: A Narrative Review. *Journal of Clinical Medicine*, *12*(7), 2697. doi:10.3390/jcm12072697
* Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Clayton, A. H., Cunningham, J., Forrest, A., ... & Krystal, A. D. (2018). Brexanolone for Postpartum Depression. *The New England Journal of Medicine*, *378*(22), 2092-2101. doi:10.1056/NEJMoa1801551
Q.
Feeling Broken? Why Your Mind Needs a Psychologist & Medically Approved Next Steps
A.
Feeling “broken” often signals a treatable mental health condition, and a psychologist can provide accurate assessment and evidence based therapies that help you regain stability and confidence. There are several factors and next steps to consider, from using a validated symptom check and scheduling therapy, to ruling out physical causes with a doctor, considering medication, strengthening daily routines, and knowing when symptoms are urgent. See below for important details that can influence which steps are right for you.
References:
* Cuijpers, P., Cristea, I. A., Karyotaki, E., Reijnders, M., & Huibers, M. J. (2016). How much psychotherapy is needed to overcome depression? A systematic review and meta-analysis. *Journal of Affective Disorders*, *189*, 162-174. https://pubmed.ncbi.nlm.nih.gov/26454746/
* Weisel, K. K., Silton, L., & Schlegel, R. J. (2020). Efficacy of digital mental health interventions for common mental health conditions. *Journal of Behavioral Health Services & Research*, *47*(3), 392-411. https://pubmed.ncbi.nlm.nih.gov/32385750/
* Hofmann, S. G., Asnaani, A., Vonk, J. J., Sawyer, A. T., & Fang, I. A. (2012). The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. *Cognitive Therapy and Research*, *36*(5), 427-440. https://pubmed.ncbi.nlm.nih.gov/23459093/
* Cuijpers, P., Sijbrandij, M., Koole, S. L., Huibers, M. J. H., Berking, M., & Andersson, G. (2013). Psychological treatment of depression: Efficacy, long-term effectiveness, and predictors of outcome. *The Canadian Journal of Psychiatry*, *58*(1), 7-19. https://pubmed.ncbi.nlm.nih.gov/23324391/
* Insel, T. R. (2008). Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. *Archives of General Psychiatry*, *65*(2), 128-135. https://pubmed.ncbi.nlm.nih.gov/18250280/
Q.
Is It Depression? Why Your Brain Is Struggling: Symptoms & Medically Approved Next Steps
A.
Persistent sadness, loss of interest, fatigue, sleep or appetite changes, trouble concentrating, or thoughts of death for 2 or more weeks that disrupt daily life suggest depression, a real and treatable medical condition. There are several factors to consider; see below for a full symptom list, common causes, and how to tell it is more than a bad week. Below you will also find medically approved next steps, including when to see a doctor, evidence based therapies and medications, supportive lifestyle changes, a symptom check, and urgent warning signs that require immediate care.
References:
* Malhi GS, Mann JJ. Depression. Lancet. 2018 Nov 10;392(10161):2299-2312. doi: 10.1016/S0140-6736(18)31948-2. PMID: 30424846.
* Millan MJ, Tordjman J, Cahn-Hussain A, Ehlis AC, Fallgatter AJ, Van Den Heuvel M, Kienle EM, De Winter F, Oude Ophuis RHN, De Witte L, Schruers K, Van Amerongen G, Roiser JP. Neurobiological Mechanisms of Major Depressive Disorder: A Review. Cells. 2023 Feb 11;12(4):618. doi: 10.3390/cells12040618. PMID: 36831034; PMCID: PMC9953463.
* Levis B, Sun Y, He C, Krishnan A, Wu Y, Bhandari M, Ioannidis JP, Thombs BD. Accuracy of the Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: systematic review and meta-analysis of individual participant data. BMJ. 2023 Aug 16;382:e075923. doi: 10.1136/bmj-2023-075923. PMID: 37586884; PMCID: PMC10433256.
* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson L, Ogawa Y, Takeshima N, Davies S, Fisher P, van der Lee M, Tajika A, Watts R, Caldwell DM, Nosè M, Thornton K, Jauhar S, Mayo-Wilson E, Papola D, Guaiana G, Purgato M, de Crescenzo F, Kawashima C, de Savigny SM, Zhou X, Efthimiou O, Saadat N, Yamada Y, Toseva T, Zanga V, Zaniolo M, Cao T, Ostinelli EG. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Feb 24;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. PMID: 29477881; PMCID: PMC5889788.
* Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A. A Network Meta-Analysis of the Effects of Psychotherapies, Pharmacotherapies and Their Combination in the Treatment of Adult Depression. N Engl J Med. 2023 Apr 13;388(15):1413-1424. doi: 10.1056/NEJMoa2214462. PMID: 37040474.
Q.
Is it more than sadness? Why your brain is stuck and clinical next steps for Major Depressive Disorder.
A.
There are several factors to consider. See below to understand more. Major depressive disorder is more than sadness, defined by at least two weeks of low mood or loss of interest with functional impairment, and the stuck feeling reflects changes in neurotransmitters, stress hormones, brain circuits, and sometimes medical conditions; next clinical steps include a full medical evaluation, confirming severity, evidence-based therapy and medications, possible advanced treatments, supportive lifestyle changes, and clear guidance on when to seek urgent care.
References:
* Nestler, E. J., Hyman, S. E., & Malenka, R. C. (2019). Major Depressive Disorder: From Molecular to Circuitry Perspectives. *Molecular Psychiatry*, *24*(1), 16–29.
* Bora, E., & Özer, E. (2020). Cognitive dysfunction in major depressive disorder: a comprehensive review of clinical and neurobiological aspects. *Translational Psychiatry*, *10*(1), 213.
* Gartlehner, G., et al. (2023). Guideline for the Pharmacological Treatment of Adults With Major Depressive Disorder. *JAMA Psychiatry*, *80*(4), 369–380.
* Kennedy, S. H. (2022). Current Approaches to Major Depressive Disorder Treatment: A Narrative Review. *Psychiatria Danubina*, *34*(Suppl 4), 58–63.
* Tanaka, T., & Shirakawa, O. (2022). The pathophysiology of major depressive disorder: a comprehensive review. *Psychiatry and Clinical Neurosciences*, *76*(9), 415–431.
Q.
Is Euthanasia the Right Choice? The Medical Reality and Approved Next Steps
A.
There are several factors to consider. Where it is legal, euthanasia or medical aid in dying is generally limited to incurable illness with persistent, unbearable suffering despite optimal treatment, requires clear decision-making capacity and voluntary, repeated requests, and is only considered after independent medical review and robust palliative and mental health care are offered. Approved next steps include talking with your doctor, requesting a palliative care consult, getting a mental health evaluation, learning your local legal requirements, and involving trusted supports; see below for safeguards, alternatives, and other important details that could change which actions you take.
References:
* Emanuel EJ, Onwuteaka-Philipsen BD, Fuks C, van der Heide A. Euthanasia and physician-assisted suicide in the Netherlands and Belgium: a comparison of the legal framework and practice. Lancet. 2022 Mar 5;399(10328):918-930. doi: 10.1016/S0140-6736(21)02392-7. Epub 2022 Jan 28. PMID: 35093155.
* Schuklenk U. Physician-assisted suicide, euthanasia, and the right to die. Philos Ethics Humanit Med. 2021 Mar 19;16(1):5. doi: 10.1186/s13010-021-00103-y. PMID: 33741031; PMCID: PMC7977054.
* Gligorov VI, Mihai A, Arendt J, Cirstescu A. Medical Euthanasia: A Literature Review. Maedica (Bucur). 2023 Sep;18(3):704-708. doi: 10.26574/maedica.2023.18.3.704. PMID: 38222045; PMCID: PMC10784260.
* Kimbell B, Biondo M, Elshafey A, Kulkarni A. Palliative Care: An Alternative to Euthanasia. Cureus. 2022 Jul 23;14(7):e27192. doi: 10.7759/cureus.27192. PMID: 35991040; PMCID: PMC9309605.
* Materstvedt LJ. Euthanasia and physician-assisted suicide: are we witnessing a new human right or a deviation from sound medical practice? J Med Ethics. 2017 Mar;43(3):148-152. doi: 10.1136/medethics-2016-103554. Epub 2016 Nov 16. PMID: 27852654.
Q.
Why Do I Feel This Way? Postpartum Depression & Medically Approved Next Steps
A.
Postpartum depression is a common, treatable medical condition that can cause intense sadness, anxiety, irritability, numbness, or trouble bonding beyond the baby blues, often driven by hormonal shifts, sleep loss, and the stresses of new parenthood. There are several factors to consider. See below for medically approved next steps that can change what you do next, including when to seek urgent care for any thoughts of harming yourself or your baby and how doctors, therapy, medication, social support, and basic health strategies can help you recover.
References:
* Mughal, M. J., Hameed, M., & Ejaz, M. (2023). Postpartum depression: An update on diagnosis and management. *JPMA. The Journal of the Pakistan Medical Association*, *73*(6), 1164-1168.
* O'Hara, M. W., & Swain, A. M. (2023). Postpartum depression: A comprehensive review of current treatment options. *Clinical Psychology Review*, *106*, 102377.
* Lusskin, S. I., Chhabra, S. S., & Shiffman, E. L. (2022). Perinatal and Postpartum Depression: Pharmacologic and Nonpharmacologic Treatment Options. *Current Psychiatry Reports*, *24*(11), 741-755.
* Earl, C. M., Perino, P., & Dmochowska, K. (2023). Screening and Early Intervention for Postpartum Depression. *The Ochsner Journal*, *23*(2), 195-201.
* Cox, E. Q., & Zatzick, C. (2023). Postpartum Depression. *Primary Care: Clinics in Office Practice*, *50*(4), 743-755.
Q.
Feeling Constantly Down? Why Your Serotonin Is Low & Medical Next Steps
A.
Persistent low mood can involve low serotonin activity, but depression is rarely just one chemical issue; stress, poor sleep, nutrient gaps, hormonal shifts, medical conditions, and genetics often contribute. There is no reliable blood test for brain serotonin, so diagnosis is clinical, with doctors also checking thyroid and vitamin levels and treating with therapy, SSRIs or SNRIs, and targeted lifestyle changes. See below for step by step next moves, red flag symptoms that need urgent care, and practical tips on symptom tracking, screening tools, labs to request, and habits that can meaningfully support serotonin.
References:
* Moncrieff J, Cooper RE, Stockmann H, Amendola SM, Hannon J, Read J. The Serotonin Theory of Depression: A Scientific Reappraisal. Mol Psychiatry. 2022 Jul;27(7):1717-1721. doi: 10.1038/s41380-022-01661-0. Epub 2022 Jul 20. PMID: 35853683.
* Albert PR, Munafo M, Young SN. Serotonergic Mechanisms in Depression and Antidepressant Treatment: A Brief Review. J Clin Med. 2023 Aug 24;12(17):5490. doi: 10.3390/jcm12175490. PMID: 37628042; PMCID: PMC10488421.
* Krishnan R, Muneer A, Hussain H, Almas R, Rizvi SAH. Serotonin and Depression: The Past, Present, and Future of a Core Hypothesis. Neuropsychiatr Dis Treat. 2023 Oct 12;19:2237-2246. doi: 10.2147/NDT.S433306. PMID: 37837095; PMCID: PMC10577581.
* Svenningsson P, Ohman D, Traskman-Bendz L. The Mechanisms of Action of Antidepressants, With Emphasis on Their Effects on Serotonin Receptors and Intracellular Signaling Pathways. Front Psychiatry. 2022 Aug 4;13:955742. doi: 10.3389/fpsyt.2022.955742. PMID: 36015509; PMCID: PMC9390234.
* Dunlop BW. Tryptophan and Serotonin for Depression: A Review of the Evidence and Proposed Clinical Application. J Clin Psychiatry. 2021 Oct 21;82(6):21nr14022. doi: 10.4088/JCP.21nr14022. PMID: 34685375.
Q.
Is it Depression? Why Your Brain Is Shutting Down & Medical Next Steps
A.
There are several factors to consider: a brain that feels foggy or like it is shutting down can be depression if multiple symptoms such as persistent low mood, loss of interest, extreme fatigue, sleep or appetite changes, and poor concentration last 2 or more weeks and disrupt life, but thyroid disease, vitamin deficiencies, anemia, sleep problems, medications, and burnout can mimic it. Your next steps are to do a quick symptom check, book a medical and mental health evaluation to rule out other causes and discuss effective treatments like therapy and antidepressants, and seek urgent help for any thoughts of self harm. See the complete guidance below for key red flags, specific tests, and decision points that can change which path is right for you.
References:
* Malhi, G. S., & Mann, J. J. (2018). Major Depressive Disorder. *The Lancet*, *392*(10163), 2299-2312. https://pubmed.ncbi.nlm.nih.gov/30396860/
* Cuijpers, P., Noma, H., Karyotaki, E., Veldhuis, J., Ebmeier, K. P., & Cipriani, A. (2020). Major Depressive Disorder: A Clinical Review. *JAMA Psychiatry*, *77*(9), 987-996. https://pubmed.ncbi.nlm.nih.gov/32187067/
* Adell, A. (2020). Major depressive disorder: recent insights into the neurobiology and pharmacotherapy. *F1000Research*, *9*, F1000 Faculty Rev-270. https://pubmed.ncbi.nlm.nih.gov/32382343/
* Kautzky, A., & Kasper, S. (2020). Personalized medicine in psychiatry: Major depressive disorder as an example. *Neuropsychopharmacology*, *45*(1), 169-179. https://pubmed.ncbi.nlm.nih.gov/31597985/
* Haroon, E., Miller, A. H., & Sanacora, G. (2017). The Neurobiology of Depression: A Review of Current Concepts. *Current Topics in Behavioral Neurosciences*, *33*, 1-28. https://pubmed.ncbi.nlm.nih.gov/27848123/
Q.
Can’t Feel Joy? Why Your Brain Is Muting Pleasure & Medically Approved Next Steps
A.
Anhedonia is the loss of the ability to feel pleasure, often linked to depression and a blunted dopamine reward system, and it can also result from chronic stress, medical conditions like thyroid problems or Parkinson's disease, or medication effects. There are several factors and medical next steps to consider, from screening and a doctor evaluation to therapy, medication adjustments, and urgent help if you have thoughts of self harm; key signs, workup details, and actionable steps are explained below.
References:
* Liu, W., Xu, Q., Zhao, M., Chen, Z., & Luo, X. (2021). Anhedonia: An Overview of the Current Advances in Neurobiology and Treatment. *Translational Psychiatry*, *11*(1), 273.
* Zald, D. H., & Treadway, M. T. (2021). Anhedonia: A transdiagnostic symptom in search of a definition and common mechanisms. *Journal of Affective Disorders*, *294*, 610-618.
* Vrieze, E., Deldicque, L., & Schifano, F. (2021). The neurobiology of anhedonia: an update on preclinical and clinical research. *Current Opinion in Neurobiology*, *70*, 148-154.
* Rømer Thomsen, K. (2018). Anhedonia: A Conceptual and Research Review. *Dialogues in Clinical Neuroscience*, *20*(3), 187–197.
* Husain, M., & Roiser, J. P. (2017). Targeting reward circuitry to treat anhedonia. *Neuroscience & Biobehavioral Reviews*, *80*, 1-13.
Q.
Feeling Numb? Why Your Oxytocin is Low and the Medically Approved Next Steps
A.
Emotional numbness can stem from low oxytocin activity, but there are several factors to consider including depression, chronic stress, trauma, social isolation, and hormonal or medical conditions. See below to understand how oxytocin fits into the bigger picture. Medically approved next steps include seeing a clinician for screening and labs, treating underlying mood issues, and using evidence-based supports like safe touch and social connection, exercise, mindfulness, sleep optimization, and stress reduction. Intranasal oxytocin is not first line and is reserved for select cases with a specialist, and urgent care is needed for red flags like suicidal thoughts or sudden neurological changes, with complete details and a practical plan outlined below.
References:
* Quattrocki, E., & Friston, K. (2014). Oxytocin and anhedonia: A systematic review. *Neuroscience & Biobehavioral Reviews*, *47*, 359–373. https://pubmed.ncbi.nlm.nih.gov/25218732/
* Hurlemann, R., & Reiner, I. (2016). The role of oxytocin in human social and emotional processing: an update. *Current Opinion in Psychology*, *9*, 7–12. https://pubmed.ncbi.nlm.nih.gov/27045763/
* Gamer, M. (2020). Oxytocin and social emotion regulation: A systematic review. *Neuroscience & Biobehavioral Reviews*, *116*, 168–179. https://pubmed.ncbi.nlm.nih.gov/32688031/
* Lee, M. R., Hermans, E. J., & Domschke, K. (2020). Intranasal oxytocin in psychiatric disorders: A review of the efficacy and safety. *European Neuropsychopharmacology*, *31*, 1–13. https://pubmed.ncbi.nlm.nih.gov/31839446/
* Leng, G., & Ludwig, M. (2016). Oxytocin replacement therapy: current perspectives. *Current Opinion in Endocrinology, Diabetes and Obesity*, *23*(3), 209–215. https://pubmed.ncbi.nlm.nih.gov/27097203/
Q.
Still Struggling? How SSRIs Work and Your Medically Approved Next Steps
A.
SSRIs keep more serotonin available between brain cells to stabilize mood and anxiety, typically showing early improvement in 2 to 4 weeks and full effect by 6 to 8 weeks; if progress is limited, doctors may adjust the dose, switch or add medications, add therapy like CBT, and check for contributing issues such as thyroid or vitamin problems. There are several factors to consider. Side effects, timing for reassessment, avoiding abrupt stoppage, and urgent red flags like suicidal thoughts can change what you should do next; see the complete guidance below to understand your safest, medically approved options with your clinician.
References:
* Andrade C, Sharma E. Selective serotonin reuptake inhibitors (SSRIs): A review of their mechanism of action and clinical utility. Asian J Psychiatr. 2021 Apr;58:102643. doi: 10.1016/j.ajp.2021.102643. Epub 2021 Feb 20. PMID: 33647781.
* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Takeshima N, Hammerton G, McGuinness LA, Tajika A, Davies S, de Vries YA, Stafee K, Saadat N, Honyashiki M, Ishigooka T, Nakagawa A, Nosè M, Purgato M, Takeshima M, Imai H, Leucht S, Efthimiou O. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. PMID: 29477885; PMCID: PMC5889788.
* Ghasemi M, Sadeghirad B, Sadeghirad A, Dastgiri S, Hosseinifard H, Naderipour F, Vahidi R. Management of treatment-resistant depression: A systematic review and meta-analysis of randomized controlled trials. J Affect Disord. 2023 Feb 1;322:18-36. doi: 10.1016/j.jad.2022.10.057. Epub 2022 Oct 28. PMID: 36308960.
* Elbe H, Genc H, Altunoz E, Yildirim I, Ozkan C. Nonpharmacological Approaches for the Management of Depression. Curr Neuropharmacol. 2022;20(9):1753-1763. doi: 10.2174/1570159X19666210928151523. PMID: 34583693; PMCID: PMC9632733.
* Pakhre A, Dhiraj A, Khan M, Kaur S, Grewal P, Verma D. Adverse effects of selective serotonin reuptake inhibitors: a systematic review of the literature. Cureus. 2023 Apr 1;15(4):e36997. doi: 10.7759/cureus.36997. PMID: 37131713; PMCID: PMC10151125.
Q.
Brain Fog? Why Your Serotonin is Muted + Medically Approved Steps
A.
Brain fog can reflect muted or dysregulated serotonin that disrupts sleep, stress response, and mood, but there are several factors to consider, including thyroid disease, iron or B12 or vitamin D deficiency, perimenopause, inflammation, sleep apnea, and medication effects. Medically approved steps include consistent sleep, morning sunlight, regular movement, balanced nutrition and gut care, therapy, and when appropriate clinician guided SSRIs, plus knowing red flags and which labs prompt a doctor visit; see below for the complete guidance, checklists, and safety cautions that could change your next steps.
References:
* Berger M, Gray JA, Roth BL. The Role of Serotonin in Cognition. Cell. 2009;138(6):1227-1237. doi:10.1016/j.cell.2009.09.007.
* Paul L, Mück S, Fendt M. The serotonin system in cognitive function and dysfunction. Prog Neurobiol. 2023 Feb;221:102377. doi: 10.1016/j.pneurobio.2022.102377. Epub 2022 Oct 11.
* Nierenberg J, Kordower JH, Dodiya HB. A potential role for tryptophan and serotonin in neuroinflammation-induced cognitive dysfunction. Brain Res Bull. 2021 Apr;170:1-12. doi: 10.1016/j.brainresbull.2021.02.004. Epub 2021 Feb 23.
* Tizabi Y, et al. Serotonin and dopamine systems in the brain: From neurodevelopmental disorders to psychiatric diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8;109:110255. doi: 10.1016/j.pnpbp.2021.110255. Epub 2021 Jan 18.
* Llopis N, et al. Pharmacological modulation of the serotonin 5-HT6 receptor improves cognitive dysfunction in neurodegenerative disorders. Br J Pharmacol. 2020 Jan;177(1):154-173. doi: 10.1111/bph.14856. Epub 2019 Oct 14.
Q.
Drowning in Fog? Why Venlafaxine Resets Your System + Medically Approved Next Steps
A.
Venlafaxine, an SNRI, can lift mental fog by restoring serotonin and norepinephrine balance, often improving energy, focus, and mood over 4 to 8 weeks. There are several factors to consider, including common side effects, blood pressure monitoring, and the need for a slow taper rather than stopping suddenly. For medically approved next steps, speak with a clinician to rule out other causes, discuss whether venlafaxine fits your history, and consider pairing medication with therapy while giving it adequate time. See the complete guidance below, including red flag symptoms that need urgent care and practical timelines that could change your next steps.
References:
* Torta R, Garetto S, Varetto A, Bellino S, Ziero D. Venlafaxine: a review of its use in the management of major depressive disorder. Drugs. 2009;69(16):2311-32. doi: 10.2165/11319760-000000000-00000. PMID: 19894762.
* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson L, Ogawa Y, Takeshima N, Davies S, de Vries YA, Imai H, Saadat N, Tajika A, Yeung ASM, Ishigooka T, Nakagawa A, Cipriani F, McGuire H, Churchill R, Egger M, Ioannidis JP, Kennedy SH. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Feb 24;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. Erratum in: Lancet. 2018 Feb 24;391(10128):1356. PMID: 29486820.
* Wang SM, Han C, Lee SJ, Jun TY, Kim T, Lee JH, Pae CU. Effect of venlafaxine on cognitive function in depressed patients: a meta-analysis. J Clin Psychopharmacol. 2012 Oct;32(5):603-9. doi: 10.1097/JCP.0b013e3182672727. PMID: 22896677.
* Pijper C, Leong C, MacKechnie B, Banh HL, Halliday J, Kustra R, Heshka T. Systematic review and meta-analysis of venlafaxine withdrawal syndrome: Incidence and risk factors. J Clin Psychopharmacol. 2021 Jan/Feb;41(1):50-59. doi: 10.1097/JCP.0000000000001323. PMID: 33499709.
* Sheehan DV, Shiovitz TM, Rynn M, Sheehan KH. Venlafaxine extended-release in major depressive disorder: a review of its efficacy and safety. Expert Opin Pharmacother. 2020 Dec;21(18):2311-2326. doi: 10.1080/14656566.2020.1818222. Epub 2020 Oct 8. PMID: 33269389.
Q.
Feeling Detached? Why Your Brain Mutes Oxytocin & Medical Next Steps
A.
Feeling detached can reflect muted oxytocin signaling driven by chronic stress, depression, trauma, relationship strain or isolation, hormonal changes including thyroid issues, and some medical or neurological conditions. There are several factors to consider; see below for how oxytocin fits within broader brain chemistry and which symptoms point to an underlying disorder. Medical next steps include a primary care evaluation for thyroid and vitamin problems, mental health screening, evidence based therapy, and when appropriate medication, with urgent care if symptoms are severe or involve self harm thoughts; full step by step guidance and key red flags are outlined below.
References:
* Hurlemann, R., & Grinevich, V. (2019). Oxytocin and Social Cognition in Psychiatric Disorders: From Basic Science to Clinical Trials. Biological Psychiatry, 85(2), 101-112.
* Olff, M., Frijling, J. L., & van Zuiden, M. (2018). The Role of Oxytocin in Social Dysfunction: Animal Models and Human Studies. Current Topics in Behavioral Neurosciences, 35, 127-142.
* Grinevich, V., & Neumann, I. D. (2019). Oxytocin in the Neurobiology of Stress and Social Behavior: From Basic Mechanisms to Therapeutic Perspectives. Progress in Brain Research, 249, 1-24.
* Heinrichs, M., & Domes, G. (2020). Oxytocin and Vasopressin in Social Cognition: From Molecular Mechanisms to Therapeutic Potential. Current Topics in Behavioral Neurosciences, 45, 1-20.
* Guastella, A. J., & MacLeod, C. (2018). Translational potential of oxytocin in human social cognition. Trends in Cognitive Sciences, 22(1), 74-82.
Q.
Heavy Fog? Why Your Brain Is Stuck and How Lexapro Resets Calm + Next Steps
A.
That heavy, stuck brain fog often comes from depression or anxiety where serotonin signaling and stress circuits are dysregulated; Lexapro, an SSRI, can gradually rebalance these pathways to ease worry and lift mood, focus, and sleep over several weeks. There are several factors to consider for safe and effective use, including the expected timeline, common and urgent side effects, who should avoid it, how to start or taper, lifestyle and therapy supports, and what to do if it does not work; see the complete guidance below to choose the right next steps with a clinician.
References:
* Mazza, M., De Berardis, D., Mencacci, C., Marini, S., & Bria, P. (2012). The effects of escitalopram on cognitive functions in patients with major depressive disorder: a review. *Psychiatry and Clinical Neurosciences*, *66*(6), 466-476. https://pubmed.ncbi.nlm.nih.gov/23167448/
* Baune, B. T., & Renger, H. G. (2014). The effect of escitalopram on cognitive symptoms in major depressive disorder. *Current Medical Research and Opinion*, *30*(7), 1335-1345. https://pubmed.ncbi.nlm.nih.gov/24641470/
* Millan, M. J., Agid, Y., Brédart, S., Carlsson, A., Carvalho, A. F., Cicin-Sain, L., ... & Young, A. H. (2018). Cognitive dysfunction in psychiatric disorders: characteristics, causes and treatments. *Nature Reviews Drug Discovery*, *17*(2), 119-147. https://pubmed.ncbi.nlm.nih.gov/29199346/
* McIntyre, R. S., Best, H., Bowie, C. R., Florea, I., Loft, H., & Muller, N. (2013). The effects of escitalopram on cognitive function in patients with major depressive disorder and subjective cognitive complaints. *European Neuropsychopharmacology*, *23*(12), 1642-1651. https://pubmed.ncbi.nlm.nih.gov/23727096/
* Leonard, B. E. (2007). The HPA axis and the serotonin system: an overview. *European Neuropsychopharmacology*, *17*(Suppl 2), S85-S94. https://pubmed.ncbi.nlm.nih.gov/17382455/
Q.
Stuck in a Gray Loop? Why Fluoxetine Works + Expert-Approved Next Steps
A.
Fluoxetine works by increasing serotonin availability in the brain, which can lift low mood, energy, and interest; early improvements often appear in 2 to 4 weeks and fuller effects by 6 to 8 weeks, and it is a first-line, generally well tolerated option that can be even more effective with therapy. There are several factors to consider, including potential side effects, who should use caution, how long to stay on it, what to do if it is not enough, and expert-approved supports like sleep, gentle movement, social connection, and regular follow-ups; see below for important details that can shape your next steps and when to seek urgent care.
References:
* Dell'Osso, B., & Altamura, A. C. (2018). Fluoxetine: twenty years later. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, *83*, 168–175. PMID: 29559388.
* Preskorn, S. H., & Stanga, E. L. (2018). Serotonin selective reuptake inhibitors: mechanism of action and clinical implications. *Expert review of clinical pharmacology*, *11*(1), 17–26. PMID: 29199329.
* Fava, M., & Cassano, G. B. (2020). Treatment-resistant depression: Current insights and future directions. *Journal of Clinical Psychiatry*, *81*(2), 19nr13008. PMID: 32265538.
* Papakostas, G. I. (2016). Augmentation strategies in treatment-resistant depression. *Dialogues in clinical neuroscience*, *18*(4), 403–410. PMID: 27536284.
* Zafar, N., & Farhat, N. (2021). Pharmacological Management of Depression: A Narrative Review of Recent Guidelines. *Cureus*, *13*(5), e15132. PMID: 34160416.
Q.
Am I Depressed or Just Tired? The 30-45 Woman’s Guide & Next Steps
A.
For women 30 to 45, there are several factors to consider: ordinary tiredness has a clear cause and improves with rest, while depression often lasts 2 or more weeks and brings loss of interest, emotional heaviness, hopelessness, and fatigue that does not lift even after sleep. See below for crucial details that can change your next steps, including medical conditions to rule out, when to seek urgent help, and practical actions like using a symptom check, asking your doctor about labs and screening, and starting proven treatments.
References:
* Goyal M, Singh S, Singh M. Differentiating Major Depressive Disorder From Fatigue Syndromes. Psychiatr Ann. 2021 Oct 1;51(10):428-432. doi: 10.3928/00485713-20210901-01. PMID: 34658364.
* Gupta A, Shah P, Chawla J. Fatigue and depression: is there a difference? BMC Psychiatry. 2020 Oct 28;20(1):506. doi: 10.1186/s12888-020-02919-z. PMID: 33115456; PMCID: PMC7594911.
* Lee K, Han K, Lee J, Park H, Kim KS, Han SS. Prevalence and Factors Associated with Depressive Symptoms among Middle-Aged Women: A Community-Based Study. Int J Environ Res Public Health. 2021 Nov 28;18(23):12444. doi: 10.3390/ijerph182312444. PMID: 34886290; PMCID: PMC8657682.
* Slavich GM. Life Stress and Health: A Review of the Research, Mechanisms, and Implications. Annu Rev Clin Psychol. 2020 May 7;16:309-333. doi: 10.1146/annurev-clinpsy-071919-020843. Epub 2020 Mar 30. PMID: 32234033.
* Whelan-Morton EA, Vella CA, Johnson BT, King DK. Sleep, fatigue, and depression: a systematic review of the relationships between sleep duration, daytime fatigue, and depressive symptoms. Sleep Med. 2023 Jun;106:176-189. doi: 10.1016/j.sleep.2023.04.015. Epub 2023 May 8. PMID: 37169437.
Q.
Depression in Women 30-45: Recognizing the Signs & Your Next Steps
A.
Depression in women 30 to 45 is common; key signs lasting two weeks or more include persistent sadness or numbness, loss of interest, irritability, fatigue, sleep or appetite changes, trouble concentrating, and social withdrawal, often influenced by stress, hormonal shifts like postpartum or perimenopause, medical issues such as thyroid disorders, and past trauma. If these symptoms affect daily life, start with a self-assessment, then speak with a clinician for screening and possible labs, consider evidence-based therapy and, when appropriate, medication, and support recovery with sleep, movement, nutrition, reduced alcohol, and social connection; seek urgent help for any self harm thoughts. There are several factors to consider that can change the right next step for you, so see the complete guidance below.
References:
* pubmed.ncbi.nlm.nih.gov/34444985/
* pubmed.ncbi.nlm.nih.gov/32959648/
* pubmed.ncbi.nlm.nih.gov/35921764/
* pubmed.ncbi.nlm.nih.gov/33649692/
* pubmed.ncbi.nlm.nih.gov/34551381/
Q.
Low Dopamine in Women: Symptoms & Your 5-Step Action Plan
A.
Low dopamine in women can present as low mood, loss of motivation or pleasure, brain fog, fatigue, sleep and libido changes, and cravings, often shifting around PMS, postpartum, perimenopause, or menopause. The 5-step plan centers on better sleep, daily movement, protein and key micronutrients, stress reduction, and medical evaluation for issues like depression, thyroid or iron problems, and other causes. There are several factors to consider, including when symptoms need urgent care, how estrogen affects dopamine, and what to know about supplements and medication interactions. See the complete guidance below to choose the safest next steps for your health.
References:
* Li H, Hueston CM, Becker JB. Sex Differences in Dopaminergic Systems and Circuits: Implications for Health and Disease. Neuropsychopharmacology. 2023 Feb;48(3):421-432. doi: 10.1038/s41386-022-01446-5. Epub 2022 Oct 13. PMID: 36229505; PMCID: PMC9868352.
* Munro CA, Becker JB. Sex Differences in Dopamine D2/3 Receptor Availability and Regulation: Implications for Reward and Related Disorders. Front Neuroendocrinol. 2021 Jan;60:100865. doi: 10.1016/j.yfrne.2020.100865. Epub 2020 Nov 27. PMID: 33249051; PMCID: PMC7772740.
* Lin TW, Kuo YM. Physical Activity and Brain Health: How Exercise Modifies the Dopaminergic System. Biomolecules. 2021 Apr 22;11(5):618. doi: 10.3390/biom11050618. PMID: 33923769; PMCID: PMC8146740.
* Briguglio M, Dell'Osso B, Pompili M, Demurtas L, De Filippis S, Serafini G, Amore M. Nutritional factors affecting the synthesis of neurotransmitters in the brain: a review. J Integr Neurosci. 2018 Mar;17(1):1-10. doi: 10.3233/JIN-170068. PMID: 29550772.
* Shansky RM, Li H. Sex Differences in the Neurobiology of Stress: Focus on Dopamine. Brain Sci. 2020 Oct 2;10(10):686. doi: 10.3390/brainsci10100686. PMID: 33020617; PMCID: PMC7601335.
Q.
Mental Health After 65: 7 Signs Every Woman Should Not Ignore
A.
For women over 65, the 7 mental health signs not to ignore are persistent sadness, loss of interest, significant sleep changes, increased anxiety, memory or thinking problems that affect daily life, social withdrawal, and thoughts that life has no purpose. There are several factors to consider, and the complete guidance below explains what each sign can look like, how they relate to physical health and medications, when to seek urgent care or talk to a doctor, and practical next steps and tools that can shape your healthcare journey.
References:
* Katon, W. J., O'Connor, P. J., & Rutter, C. M. (2020). Gender Differences in Symptomatology, Clinical Correlates, and Treatment of Depression: A Systematic Review. *Psychiatric Clinics of North America*, 43(1), 1–16.
* Pilling, S., Llewellyn-Jones, R., King, M., & National Institute for Health and Care Excellence (NICE) Guidelines Team. (2019). Anxiety disorders in older adults: recent advances and future directions. *The Lancet Psychiatry*, 6(4), 305–316.
* Carter, S., Hall, E., Mather, K. A., & Jorm, A. F. (2021). Sex differences in the clinical presentation of Alzheimer's disease: a systematic review. *The Lancet Healthy Longevity*, 2(4), e224–e234.
* Li, R. H., Yang, M., Jiang, T., Wei, D., Zhu, X. L., & Cai, C. H. (2020). Sleep disturbances and mental health in older adults: a systematic review. *Sleep Medicine Reviews*, 50, 101265.
* Lim, M. H., Yang, T., Kim, H., & Lee, S. K. (2021). Loneliness and Social Isolation as Risk Factors for Mental Health Problems in Older Adults: A Systematic Review and Meta-Analysis. *International Journal of Environmental Research and Public Health*, 18(19), 10115.
Q.
Vraylar Over 65: Navigating Mental Health in Seniors
A.
For adults over 65, Vraylar may help with schizophrenia, bipolar I episodes, and as an add-on for major depression, but it requires careful use. There are several factors to consider, including the boxed warning in dementia-related psychosis, higher risks of movement symptoms, dizziness and falls, and metabolic changes; see details below. Doctors often start low and go slow, monitor weight, glucose, cholesterol, blood pressure, review other medications, and watch for delayed side effects since it stays in the body a long time; never stop it on your own and seek urgent care for severe confusion, fever with stiffness, fainting, or suicidal thoughts. Important nuances, alternatives, and what to discuss with your clinician are explained below to guide your next steps.
References:
* D'Souza, L., Alphs, L., Németh, G., Szatmári, L., & Pikalov, A. A. (2019). Safety and Tolerability of Cariprazine in Elderly Patients with Schizophrenia: A Post Hoc Analysis of Pooled Data. *CNS drugs*, *33*(9), 899-911.
* D'Souza, L., Pikalov, A. A., Lu, K., Szatmári, L., Németh, G., & Alphs, L. (2021). Efficacy and Safety of Cariprazine in Elderly Patients With Bipolar I Depression: A Post Hoc Analysis of Pooled Data. *Journal of Clinical Psychopharmacology*, *41*(5), 518-525.
* Krogmann, A., Szatmári, L., Németh, G., Kiss, B., & Pál, S. (2018). Pharmacokinetics of Cariprazine in Subjects with Mild, Moderate, or Severe Renal Impairment, and in Subjects with Moderate Hepatic Impairment. *Clinical Pharmacokinetics*, *57*(7), 847-858.
* Jeste, D. V., & Krystal, J. H. (2018). Antipsychotic Prescribing for Older Adults: An Update. *The American Journal of Psychiatry*, *175*(11), 1083-1090.
* Kim, E., Tingle, K. M., & Rusk, J. (2021). Cariprazine in the treatment of schizophrenia and bipolar disorder: A review of efficacy and safety in adult and older adult populations. *Expert Review of Neurotherapeutics*, *21*(10), 1099-1111.
Q.
Are natural supplements safe for depression?
A.
Natural supplements might help with depression, but their safety and effectiveness can vary. It's important to talk to a doctor before using them. See below to understand more.
References:
Yeung KS, Hernandez M, Mao JJ, Haviland I, & Gubili J. (2018). Herbal medicine for depression and anxiety - PubMed - NIH. Phytotherapy research : PTR, 29464801.
https://pubmed.ncbi.nlm.nih.gov/29464801/
Warnick SJ Jr, Mehdi L, & Kowalkowski J. (2021). Wait-there's evidence for that? Integrative medicine .... International journal of psychiatry in medicine, 34521233.
https://pubmed.ncbi.nlm.nih.gov/34521233/
Cauffield JS, & Forbes HJ. (1999). Dietary supplements used in the treatment of depression .... Lippincott's primary care practice, 10711131.
Q.
What is serotonin syndrome?
A.
Serotonin syndrome is a serious condition that happens when there is too much serotonin in the brain, often caused by certain medications. See below to understand more.
References:
Sporer KA. (1995). The serotonin syndrome. Implicated drugs .... Drug safety, 7576268.
https://pubmed.ncbi.nlm.nih.gov/7576268/
Mason PJ, Morris VA, & Balcezak TJ. (2000). Serotonin syndrome. Presentation of 2 cases and review .... Medicine, 10941349.
https://pubmed.ncbi.nlm.nih.gov/10941349/
Sun-Edelstein C, Tepper SJ, & Shapiro RE. (2008). Drug-induced serotonin syndrome: a review. Expert opinion on drug safety, 18759711.
Q.
What is the difference between depression and clinical depression?
A.
The terms "depression" and "clinical depression" are often used interchangeably, but they can refer to different concepts. Depression is a general term that encompasses a range of mood disorders, while clinical depression, also known as major depressive disorder (MDD), is a specific diagnosis characterized by more severe and persistent symptoms that significantly impair daily functioning.
References:
Bachmann GA, Rosen R, Arnold LD, Burd I, Rhoads GG, Leiblum SR, Avis N. Chronic vulvar and other gynecologic pain: prevalence and characteristics in a self-reported survey. J Reprod Med. 2006 Jan;51(1):3-9. PMID: 16482769; PMCID: PMC1388073.
National Collaborating Centre for Mental Health (UK). Depression in Adults with a Chronic Physical Health Problem: Treatment and Management. Leicester (UK): British Psychological Society (UK); 2010. (NICE Clinical Guidelines, No. 91.) Appendix 12, The classification of depression and depression rating scales/questionnaires.
https://www.ncbi.nlm.nih.gov/books/NBK82926/
Chand SP, Arif H. Depression. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 28613597.
Q.
Are there any facial signs of depression?
A.
Facial signs of depression can manifest as reduced facial expressions, changes in eye contact, and overall appearance. These signs can reflect the emotional state of an individual and may be noticeable to others.
References:
Lacerda KCD, Souza FCO, Araújo CRV, Mota BEF, Muñoz PMG, Berger W, Vilete L, Bearzoti E, Guerra Leal Souza G. High depressive symptomatology reduces emotional reactions to pictures of social interaction. Sci Rep. 2024 Jan 13;14(1):1266. doi: 10.1038/s41598-024-51813-1. PMID: 38219004; PMCID: PMC10787838.
Gehricke J, Shapiro D. Reduced facial expression and social context in major depression: discrepancies between facial muscle activity and self-reported emotion. Psychiatry Res. 2000 Aug 21;95(2):157-67. doi: 10.1016/s0165-1781(00)00168-2. PMID: 10963801.
Q.
What are the signs and symptoms of “smiling depression”? What are risk factors?
A.
"Smiling depression" refers to individuals who appear outwardly happy and functional while privately struggling with depressive symptoms. Recognizing the subtle signs, such as loss of interest or pleasure, changes in sleep and appetite, and persistent fatigue, is crucial for seeking help.
References:
Bhattacharya S, Laura Hoedebeck K, Sharma N, Gokdemir O, Singh A. “Smiling depression” (an emerging threat): Let’s Talk. Indian J Community Health [Internet]. 2019 Dec. 31 [cited 2024 Oct. 10];31(4):433-6.
https://www.iapsmupuk.org/journal/index.php/IJCH/article/view/1255
Zullino DF, Bancila V. You don't believe in a patient's depression? Watch the watch! Arch Psychiatr Nurs. 2008 Feb;22(1):50-1. doi: 10.1016/j.apnu.2007.04.005. PMID: 18207056.
Q.
What are some noticeable behavior changes in people with depression and anxiety?
A.
Both depression and anxiety are characterized by changes in appetite, declines in energy and motivation, as well as changes in work performance.
References:
Simon GE, Moise N, Mohr DC. Management of Depression in Adults: A Review. JAMA. 2024 Jul 9;332(2):141-152. doi: 10.1001/jama.2024.5756. Erratum in: JAMA. 2024 Sep 16. doi: 10.1001/jama.2024.18427. PMID: 38856993.
Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec 27;328(24):2431-2445. doi: 10.1001/jama.2022.22744. PMID: 36573969.
Ubie is supervised by 50+ medical experts worldwide
Our symptom checker AI is continuously refined with input from experienced physicians, empowering them to make more accurate diagnoses.
Ubie is recognized by healthcare and tech leaders
“World’s Best Digital
Health Companies”
Newsweek 2024
“Best With AI”
Google Play Best of 2023
“Best in Class”
Digital Health Awards 2023 (Quarterfinalist)
Which is the best Symptom Checker?
Ubie’s symptom checker demonstrated a Top-10 hit accuracy of 71.6%, surpassing the performance of several leading symptom checkers in the market, which averaged around 60% accuracy in similar assessments.
Link to full study:
https://www.medrxiv.org/content/10.1101/2024.08.29.24312810v1References
Alexopoulos GS. Depression in the elderly. Lancet. 2005 Jun 4-10;365(9475):1961-70. doi: 10.1016/S0140-6736(05)66665-2. PMID: 15936426.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)66665-2/fulltextZhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: Current understanding. J Clin Neurosci. 2018 Jan;47:1-5. doi: 10.1016/j.jocn.2017.09.022. Epub 2017 Oct 21. PMID: 29066229.
https://www.jocn-journal.com/article/S0967-5868(16)30628-2/fulltextWang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry. 2013 Oct-Dec;35(4):416-31. doi: 10.1590/1516-4446-2012-1048. Epub 2013 Dec 23. PMID: 24402217.
https://www.scielo.br/j/rbp/a/84pk6g6z4FVyGtkncK4m6XR/?lang=enHammen C. Risk Factors for Depression: An Autobiographical Review. Annu Rev Clin Psychol. 2018 May 7;14:1-28. doi: 10.1146/annurev-clinpsy-050817-084811. Epub 2018 Jan 12. PMID: 29328780.
https://www.annualreviews.org/doi/10.1146/annurev-clinpsy-050817-084811Greenberg J, Tesfazion AA, Robinson CS. Screening, diagnosis, and treatment of depression. Mil Med. 2012 Aug;177(8 Suppl):60-6. doi: 10.7205/milmed-d-12-00102. PMID: 22953442.
https://academic.oup.com/milmed/article/177/suppl_8/60/4345395